0001628280-18-013693.txt : 20181106 0001628280-18-013693.hdr.sgml : 20181106 20181106084409 ACCESSION NUMBER: 0001628280-18-013693 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181106 DATE AS OF CHANGE: 20181106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioScrip, Inc. CENTRAL INDEX KEY: 0001014739 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 050489664 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11993 FILM NUMBER: 181161639 BUSINESS ADDRESS: STREET 1: 1600 BROADWAY STREET 2: SUITE 950 CITY: DENVER STATE: CO ZIP: 80202 BUSINESS PHONE: 720 697 5200 MAIL ADDRESS: STREET 1: 1600 BROADWAY STREET 2: SUITE 950 CITY: DENVER STATE: CO ZIP: 80202 FORMER COMPANY: FORMER CONFORMED NAME: MIM CORP DATE OF NAME CHANGE: 19960516 10-Q 1 bios-20180930x10q.htm 10-Q Document



 
 
 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-Q

(Mark One)
 
þ
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended September 30, 2018
 
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from     to             

Commission file number: 001-11993

logowithregisteredtm10.jpg
BioScrip, Inc.
(Exact name of registrant as specified in its charter)
Delaware
05-0489664
(State of incorporation)
(I.R.S. Employer Identification No.)
1600 Broadway, Suite 700, Denver, Colorado
80202
(Address of principal executive offices)
(Zip Code)

Registrant’s telephone number, including area code:
720-697-5200

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes þ     No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes þ No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o     Accelerated filer þ     Non-accelerated filer o      Smaller reporting company o Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes o     No þ

On November 6, 2018, there were 128,041,101 shares of the registrant’s Common Stock outstanding.



TABLE OF CONTENTS
 
 
Page
Number
PART I
 
 
 
 
 
 
 
 
 
 
PART II 
 
 
 
 
 
 
 
 
 
 
 
 
 


2

PART I
FINANCIAL INFORMATION
Item 1.
Financial Statements

3

BIOSCRIP, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share amounts)
 
(unaudited)
 
 
 
September 30,
2018
 
December 31,
2017
ASSETS
 
 
 
Current assets
 
 
 
Cash and cash equivalents
$
18,944

 
$
39,457

Restricted cash
4,320


4,950

Accounts receivable, net of allowance for doubtful accounts of $0 and $37,912 as of September 30, 2018 and December 31, 2017, respectively
113,628

 
85,522

Inventory
23,105

 
38,044

Prepaid expenses and other current assets
11,944

 
18,620

Total current assets
171,941

 
186,593

Property and equipment, net of accumulated depreciation of $97,788 and $88,298 as of September 30, 2018 and December 31, 2017, respectively
25,177

 
26,973

Goodwill
367,198

 
367,198

Intangible assets, net of accumulated amortization of $47,120 and $40,436 as of September 30, 2018 and December 31, 2017, respectively
12,030

 
19,114

Deferred taxes
990

 
1,098

Other non-current assets
1,836

 
2,116

Total assets
$
579,172

 
$
603,092

LIABILITIES AND STOCKHOLDERS’ DEFICIT
 

 
 

Current liabilities
 

 
 

Current portion of long-term debt
$
2,076

 
$
1,722

Accounts payable
63,901

 
65,963

Amounts due to plan sponsors
1,546

 
4,621

Accrued interest
2,268

 
6,706

Accrued expenses and other current liabilities
26,204

 
26,118

Total current liabilities
95,995

 
105,130

Long-term debt, net of current portion
496,770

 
478,866

Other non-current liabilities
22,744

 
21,769

Total liabilities
615,509

 
605,765

Series A convertible preferred stock, $.0001 par value; 825,000 shares authorized; 21,630 and 21,645 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively; and $3,172 and $2,916 liquidation preference as of September 30, 2018 and December 31, 2017, respectively
3,126

 
2,827

Series C convertible preferred stock, $.0001 par value; 625,000 shares authorized; 614,177 shares issued and outstanding as of September 30, 2018 and December 31, 2017; and $92,038 and $84,555 liquidation preference as of September 30, 2018 and December 31, 2017, respectively
87,225

 
79,252

Stockholders’ deficit
 

 
 

Preferred stock, $.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively
—

 
—

Common stock, $.0001 par value; 250,000,000 shares authorized; 128,064,145 and 127,634,012 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively
13

 
13

Treasury stock, 287,248 and 5,106 shares outstanding, at cost, as of September 30, 2018 and December 31, 2017, respectively
(849
)
 
(16
)
Additional paid-in capital
619,989

 
624,762

Accumulated deficit
(745,841
)
 
(709,511
)
Total stockholders’ deficit
(126,688
)
 
(84,752
)
Total liabilities and stockholders’ deficit
$
579,172

 
$
603,092


See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.

4

BIOSCRIP, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)

 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2018
 
2017
 
2018
 
2017
Net revenue
$
180,962

 
$
198,692

 
$
525,335

 
$
634,608

Cost of revenue (excluding depreciation expense)
115,051

 
132,129

 
344,419

 
435,560

Gross profit
65,911

 
66,563

 
180,916

 
199,048

 
 
 
 
 
 
 
 
Other operating expenses
38,216

 
38,143

 
116,378

 
124,755

Bad debt expense
—

 
6,488

 
—

 
19,648

General and administrative expenses
12,478

 
9,405

 
34,084

 
28,325

Restructuring, acquisition, integration, and other expenses
885

 
4,037

 
4,789

 
11,407

Change in fair value of equity linked liabilities
1,605

 
1,103

 
1,228

 
1,103

Depreciation and amortization expense
5,767

 
7,058

 
18,617

 
21,288

Interest expense
14,971

 
13,360

 
42,171

 
38,649

Loss on extinguishment of debt
—

 
—

 
—

 
13,453

Loss (gain) on dispositions
(10
)
 
(33
)
 
(330
)
 
652

Loss from continuing operations, before income taxes
(8,001
)
 
(12,998
)
 
(36,021
)
 
(60,232
)
Income tax expense
102

 
60

 
191

 
1,397

Loss from continuing operations, net of income taxes
(8,103
)
 
(13,058
)
 
(36,212
)
 
(61,629
)
Income (loss) from discontinued operations, net of income taxes
(71
)
 
66

 
(118
)
 
(606
)
Net loss
$
(8,174
)
 
$
(12,992
)
 
$
(36,330
)
 
$
(62,235
)
Accrued dividends on preferred stock
(2,861
)
 
(2,569
)
 
(8,272
)
 
(7,435
)
Loss attributable to common stockholders
$
(11,035
)
 
$
(15,561
)
 
$
(44,602
)
 
$
(69,670
)
 
 
 
 
 
 
 
 
Loss per common share:
 
 
 
 
 
 
 
Loss from continuing operations, basic and diluted
$
(0.09
)
 
$
(0.12
)
 
$
(0.35
)
 
$
(0.56
)
Loss from discontinued operations, basic and diluted
—

 
—

 
—

 
(0.01
)
Loss per common share, basic and diluted
$
(0.09
)
 
$
(0.12
)
 
$
(0.35
)
 
$
(0.57
)
 
 
 
 
 
 
 
 
Weighted average common shares outstanding, basic and diluted
127,528

 
127,488

 
127,893

 
122,519


See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.

5

BIOSCRIP, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
 
Nine Months Ended 
 September 30,
 
2018
 
2017
Cash flows from operating activities:
 
 
 
Net loss
$
(36,330
)
 
$
(62,235
)
Less: Loss from discontinued operations, net of income taxes
(118
)
 
(606
)
Loss from continuing operations, net of income taxes
(36,212
)
 
(61,629
)
Adjustments to reconcile loss from continuing operations, net of income taxes to net cash used in operating activities:
 
 
 
Depreciation and amortization
18,617

 
21,288

Amortization of deferred financing costs and debt discount
6,084

 
4,676

Change in fair value of equity linked liabilities
1,228

 
1,103

Change in deferred income taxes
108

 
1,868

Stock-based compensation
3,032

 
1,525

Paid-in-kind interest capitalized as principal on Second Lien Note Facility
3,800

 
—

Loss (gain) on dispositions
(330
)
 
652

Loss on extinguishment of debt
—

 
13,453

Changes in assets and liabilities:
 
 
 
Accounts receivable
(28,106
)
 
22,257

Inventory
14,939

 
8,391

Prepaid expenses and other assets
6,956

 
3,033

Accounts payable
(2,062
)
 
(14,716
)
Amounts due to plan sponsors
(3,075
)
 
1,091

Accrued interest
(4,438
)
 
(3,508
)
Accrued expenses and other liabilities
(667
)
 
(2,800
)
Net cash used in operating activities from continuing operations
(20,126
)
 
(3,316
)
Net cash used in operating activities from discontinued operations
(117
)
 
(6,106
)
Net cash used in operating activities
(20,243
)
 
(9,422
)
Cash flows from investing activities:
 
 
 
Purchases of property and equipment
(9,408
)
 
(6,570
)
Net cash used in investing activities
(9,408
)
 
(6,570
)
Cash flows from financing activities:
 
 
 
Proceeds from priming credit agreement, net of issuance costs
—

 
23,060

Fees attributable to extinguishment of debt
—

 
(980
)
Net proceeds from issuance of equity, net of issuance costs
—

 
20,822

Borrowings on long-term debt, net of expenses
10,000

 
294,446

Borrowings on revolving credit facility
—

 
563

Repayments on revolving credit facility
—

 
(55,863
)
Principal payments of long-term debt
—

 
(236,770
)
Repayments of capital leases
(1,623
)
 
(792
)
Net activity from exercises of employee stock awards
131

 
(100
)
Net cash provided by financing activities
8,508

 
44,386

Net change in cash, cash equivalents, and restricted cash
(21,143
)
 
28,394

Cash, cash equivalents and restricted cash - beginning of period
44,407

 
9,569

Cash, cash equivalents and restricted cash - end of period
$
23,264

 
$
37,963

DISCLOSURE OF CASH FLOW INFORMATION:
 
 
 
Cash paid during the period for interest
$
36,735

 
$
38,454

Cash paid during the period for income taxes
$
51

 
$
327

DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
 
 
 
Entry into capital lease
$
—

 
$
1,825

Paid-in-kind interest capitalized as principal on Second Lien Note Facility
$
3,800

 
$
—


See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.

6

BIOSCRIP, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 — BASIS OF PRESENTATION
We are a national provider of infusion solutions with nearly 70 service locations around the U.S. We partner with physicians, hospital systems, skilled nursing facilities, and healthcare payors to provide patients with access to post-acute care services. We are committed to bringing customer-focused healthcare infusion therapy services into the home or alternate site setting. By collaborating with the full spectrum of healthcare professionals and the patient, we aim to provide cost-effective care that is driven by clinical excellence, customer service and values that promote positive outcomes and an enhanced quality of life for those whom we serve.
We operate in one segment, Infusion Services, and accordingly, we do not present disaggregated segment information.
These Unaudited Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements, including the notes thereto, and other information included in the Annual Report on Form 10-K of BioScrip, Inc. and its wholly-owned subsidiaries (the “Company”) for the year ended December 31, 2017 (the “Annual Report”) filed with the U.S. Securities and Exchange Commission (“SEC”). These Unaudited Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information, and the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.
The information furnished in these Unaudited Consolidated Financial Statements reflects all adjustments, including normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. Operating results for the interim periods presented require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes and are not necessarily indicative of the results that may be expected for the full year.
The Unaudited Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Reclassifications
Prior period financial statement amounts have been reclassified to conform to current period presentation.
Immaterial Error Correction

During the fourth quarter of 2017, the Company determined that certain prior period balances contained errors, predominantly due to a failure to appropriately account for and resolve transactions specific to suspense and clearing accounts. Management evaluated the materiality of the errors quantitatively and qualitatively, and concluded that they were not material to the financial statements of any period presented, but has elected to correct them in the accompanying prior period consolidated financial statements.

The following tables set forth the effect these corrections had on the Company’s unaudited consolidated statements of operations for the three and nine months ended ended September 30, 2017:

7

 
Three Months Ended 
 September 30, 2017
 
Nine Months Ended 
 September 30, 2017
 
Previously Reported
 
Corrections
 
Revised
 
Previously Reported
 
Corrections
 
Revised
 Net revenue
$
198,692

 
$
—

 
$
198,692

 
$
634,608

 
$
—

 
$
634,608

 Gross profit
67,176

 
(613
)
 
66,563

 
201,070

 
(2,022
)
 
199,048

 Total Operating Expenses
66,345

 
(144
)
 
66,201

 
221,128

 
(497
)
 
220,631

 Interest expense
13,175

 
185

 
13,360

 
38,635

 
14

 
38,649

 Loss from continuing operations, net of income taxes
(12,404
)
 
(654
)
 
(13,058
)
 
(60,090
)
 
(1,538
)
 
(61,628
)
 Income (loss) from discontinued operations, net of income taxes
(113
)
 
179

 
66

 
(1,053
)
 
447

 
(606
)
 Net loss
$
(12,517
)
 
$
(475
)
 
$
(12,992
)
 
$
(61,143
)
 
$
(1,091
)
 
$
(62,234
)
Certain amounts disclosed in the accompanying notes to the financial statements have been revised to reflect the corrections.
NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Cash and Cash Equivalents and Restricted Cash

Highly liquid investments with a maturity of three months or less when purchased are classified as cash equivalents. Restricted cash consists of cash balances held by financial institutions as collateral for letters of credit. These balances are reclassified to cash and cash equivalents when the underlying obligation is satisfied, or in accordance with the governing agreement. Restricted cash balances expected to become unrestricted during the next twelve months are recorded as current assets. As of September 30, 2018, the Company had a restricted cash balance, in a money market account, of $4.3 million to cash collateralize outstanding letters of credit.

Collectability of Accounts Receivable

The following table sets forth the aging of our net accounts receivable (net of allowance for contractual adjustments, and prior to allowance for doubtful accounts), aged based on date of service and categorized based on the three primary overall types of accounts receivable characteristics (in thousands):
 
 
September 30, 2018
 
December 31, 2017
 
 
0 - 180 days
 
Over 180 days
 
Total
 
0 - 180 days
 
Over 180 days
 
Total
Government
 
$
12,555

 
$
3,028

 
$
15,583

 
$
20,602

 
$
10,082

 
$
30,684

Commercial
 
80,508

 
10,825

 
91,333

 
63,767

 
18,779

 
82,546

Patient
 
1,922

 
4,790

 
6,712

 
2,577

 
7,627

 
10,204

Gross accounts receivable
 
$
94,985

 
$
18,643

 
113,628

 
$
86,946

 
$
36,488

 
123,434

Allowance for doubtful accounts
 
 
 
 
 
—

 
 
 
 
 
(37,912
)
Net accounts receivable
 
 
 
 
 
$
113,628

 
 
 
 
 
$
85,522


Recent Accounting Pronouncements

In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-15 — Internal Use Software. ASU 2018-15 aligns the requirements for capitalization of implementation costs related to hosted software with the existing internal-use software guidance. The effective date for ASU 2018-15 is for annual and interim periods beginning after December 15, 2019. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.
In August 2018, the FASB issued ASU 2018-13— Fair Value Measurement (Topic 820): Disclosure Framework— Changes to the Disclosure Requirements for Fair Value Measurements. ASU 2018-13 modifies fair value measurement disclosure

8

requirements. The effective date for ASU 2018-13 is for annual and interim periods beginning after December 15, 2019. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s disclosures to the consolidated financial statements.
In May 2014, the FASB issued ASU 2014-09—Revenue from Contracts with Customers (Topic 606). The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The FASB delayed the effective date to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. The Company did not elect early adoption and applied the modified retrospective approach upon adoption which results in application of the new guidance only to contracts that are not completed at the adoption date and does not require adjustment of prior reporting periods. Assessment of the new guidance did not result in an opening retained earnings adjustment, but did result in the adjustment of accounts receivable as the allowance for doubtful accounts was eliminated upon implementation. Pursuant to the requirements of Topic 606, the transaction price to be recognized as revenue is estimated based upon the amount of cash ultimately expected to be collected. Therefore, amounts expected to be written off are reflected in the amount of revenue recognized upon fulfillment of the performance obligation. The new standard resulted in the recognition of amounts previously reported as bad debt expense as a reduction to revenue upon implementation; see Note 3 - Revenue.
In July 2017, the FASB issued ASU 2017-11—Earnings Per Share (Topic 260), Distinguishing Liabilities From Equity (Topic 480), and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 eliminates the requirement that a down round feature precludes equity classification when assessing whether an instrument is indexed to an entity’s own stock. A freestanding equity-linked financial instrument no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. The effective date for ASU 2017-11 is for annual or any interim periods beginning after December 15, 2018. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.
In May 2017, the FASB issued ASU 2017-09—Compensation–Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-09 modifies when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the same immediately before and after a change to the terms and conditions of the award. The effective date for ASU 2017-09 is for annual or any interim periods beginning after December 15, 2017. The Company adopted this ASU effective January 1, 2018. The adoption of this standard did not materially impact the Company’s consolidated financial statements.
In November 2016, the FASB issued ASU 2016-18—Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The effective date for ASU 2016-18 is for annual or any interim periods beginning after December 15, 2017. The Company adopted this ASU effective January 1, 2018. The adoption of this standard did not materially impact the Company’s consolidated financial statements.
In August 2016, the FASB issued ASU 2016-15—Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 provides guidance for eight specific cash flow issues with respect to how cash receipts and cash payments are classified in the statements of cash flows, with the objective of reducing diversity in practice. The effective date for ASU 2016-15 is for annual periods beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this ASU effective January 1, 2018. The adoption of this standard did not materially impact the Company’s consolidated financial statements.
In February 2016, the FASB issued ASU 2016-02—Leases (Topic 842), requiring lessees to recognize a right-of-use asset and a lease liability on the balance sheet for all leases with the exception of short-term leases. For lessees, leases will continue to be classified as either operating or finance leases in the income statement. The effective date of the new standard for public companies is for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. In January 2018, the FASB issued an additional amendment that provides a practical expedient giving companies the option to not evaluate existing or expired land easements that were not previously accounted for as leases under the current leases guidance. The amendment in the update is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. In July 2018, the FASB issued an additional amendment, ASU 2018-11, which provides a new, optional transition method and provides lessors a practical expedient for separating lease and non-lease components. In July 2018, the FASB additionally issued ASU 2018-1— Codification Improvements to Topic 842, Leases, which clarifies and correct errors in ASC 842. The effective date for the amendments issued is the same as the effective date of ASC 842. Although early adoption is permitted, the Company plans to

9

adopt the guidance on January 1, 2019. Topic 842 requires the recognition and measurement of leases at the beginning of the earliest comparative period presented in the financial statements, using a modified retrospective approach, with an option to apply the transition provisions of the new guidance at the adoption date without adjusting the comparative periods presented. The Company is evaluating the effect of adoption of the updated standard on its consolidated financial statements.

NOTE 3 — REVENUE

Adoption of ASC Topic 606, "Revenue from Contracts with Customers"

On January 1, 2018, the Company adopted Topic 606 using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under Topic 606, while prior period amounts are not restated and continue to be reported in accordance with accounting standards in effect for those periods.

Infusion Revenues

The Company generates revenue principally through the provision of infusion services to provide clinical management services and the delivery of cost effective prescription medications. Prescription drugs are dispensed either through a pharmacy participating in the Company’s pharmacy network or a pharmacy owned by the Company. Fee-for-service agreements include pharmacy agreements, under which we dispense prescription medications through the Company’s pharmacy facilities.

The Company provides a variety of therapies to patients. For infusion-related therapies, the Company frequently provides multiple deliverables of drugs and related nursing services. After applying the criteria from Topic 606, the Company concluded that multiple performance obligations exist in its contracts with its customers. Revenue is allocated to each performance obligation based on relative standalone price, determined based on reimbursement rates established in the third party payor contracts. Drug revenue is recognized at the time the drug is shipped, and nursing revenue is recognized on the date of service.

Revenue Recognition

Topic 606 requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to be entitled to in exchange for those goods or services. Topic 606 requires application of a five-step model to determine when to recognize revenue and at what amount. The revenue standard applies to all contracts with customers and revenues are to be recognized when control of the promised goods or services is transferred to the Company’s patients in an amount that reflects consideration expected to be received in exchange for those goods or services.

The following table presents our revenues at amounts initially recognized for each associated payor class for the three and nine months ended September 30, 2018 (in millions). Sales and usage-based taxes are excluded from revenues.
 
 
Three Months Ended September 30, 2018
 
Nine Months Ended September 30, 2018
 Commercial
 
$
139,077

 
$
431,869

 Government
 
39,498

 
88,437

 Patient
 
2,387

 
5,029

 Total Revenue
 
$
180,962

 
$
525,335


Absent implementation of Topic 606, the Company would have reported revenue of $186.7 million and $541.9 million, gross profit of $71.6 million and $197.5 million, and bad debt expense of $5.7 million and $16.5 million for the three and nine months ended September 30, 2018, respectively; and allowance for doubtful accounts of $42.9 million at September 30, 2018.

Contract Assets and Liabilities
    
In accordance with Topic 606, contract assets are to be recognized when an entity has the right to receive consideration in exchange for goods or services that have been transferred to a customer when that right is conditional on something other than the passage of time. The Company does not recognize contract assets as the right to receive consideration is unconditional in accordance with the passage of time criteria. Also in accordance with Topic 606, contract liabilities are to be recognized when an

10

entity is obligated to transfer goods or services for which consideration has already been received. The Company does not receive consideration prior to the transfer of goods or services and, therefore, does not recognize contract liabilities.

Significant Judgments

The Company determines implicit price concessions based on historical collection experience using a portfolio approach. The Company determines the transaction price based on gross charges for services provided, reduced by contractual adjustments based on contractual agreements and historical experience. Pursuant to the requirements of Topic 606, the transaction price to be recognized as revenue is estimated based upon the amount of cash ultimately expected to be collected. Therefore, amounts expected to be written off are reflected in the amount of revenue recognized upon fulfillment of the performance obligation as an implicit price concession.

The Company elected a practical expedient to expense sales commissions when incurred as the amortization period associated therewith is generally one year or less and the total paid is representative of less than 1.0% of total revenue. These costs are recorded in other operating expenses.

NOTE 4 — LOSS PER SHARE
The Company presents basic and diluted loss per share for its common stock, par value $0.0001 per share (“Common Stock”). Basic loss per share is calculated by dividing the net loss attributable to common stockholders of the Company by the weighted average number of shares of Common Stock outstanding during the period. Diluted loss per share is determined by adjusting the profit or loss attributable to stockholders and the weighted average number of shares of Common Stock outstanding adjusted for the effects of all dilutive potential common shares comprised of options granted, unvested restricted stock, stock appreciation rights, warrants and Series A and Series C Preferred Stock (as defined below). Potential Common Stock equivalents that have been issued by the Company related to outstanding stock options, unvested restricted stock and warrants are determined using the treasury stock method, while potential common shares related to Series A and Series C Preferred Stock are determined using the “if converted” method.
The Company's Series A Convertible Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), and Series C Convertible Preferred Stock, par value $0.0001 per share (the “Series C Preferred Stock” and, together with the Series A Preferred Stock, the “Preferred Stock”), is considered a participating security, which means the security may participate in undistributed earnings with Common Stock. The holders of the Preferred Stock would be entitled to share in dividends, on an as-converted basis, if the holders of Common Stock were to receive dividends. The Company is required to use the two-class method when computing loss per share when it has a security that qualifies as a participating security. The two-class method is an earnings allocation formula that determines loss per share for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. In determining the amount of net earnings to allocate to common stockholders, earnings are allocated to both common and participating securities based on their respective weighted-average shares outstanding during the period. Diluted loss per share for the Company’s Common Stock is computed using the more dilutive of the two-class method or the if-converted method.

11

The following table sets forth the computation of basic and diluted loss per common share (in thousands, except for per share amounts):
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2018
 
2017
 
2018
 
2017
Numerator:
 
 
 
 
 
 
 
Loss from continuing operations, net of income taxes
$
(8,103
)
 
$
(13,058
)
 
$
(36,212
)
 
$
(61,629
)
Income (Loss) from discontinued operations, net of income taxes
(71
)
 
66

 
(118
)
 
(606
)
Net loss
$
(8,174
)
 
$
(12,992
)
 
$
(36,330
)
 
$
(62,235
)
Dividends on preferred stock
(2,861
)
 
(2,569
)
 
(8,272
)
 
(7,435
)
Loss attributable to common stockholders
$
(11,035
)
 
$
(15,561
)
 
$
(44,602
)
 
$
(69,670
)
 
 
 
 
 
 
 
 
Denominator - Basic and Diluted:
 

 
 

 
 

 
 

Weighted average common shares outstanding
127,528

 
127,488

 
127,893

 
122,519

 
 
 
 
 
 
 
 
Loss per Common Share:
 
 
 
 
 
 
 
Loss from continuing operations, basic and diluted
$
(0.09
)
 
$
(0.12
)
 
$
(0.35
)
 
$
(0.56
)
Loss from discontinued operations, basic and diluted
—

 
—

 
—

 
(0.01
)
Loss per common share, basic and diluted
$
(0.09
)
 
$
(0.12
)
 
$
(0.35
)
 
$
(0.57
)
The loss attributable to common stockholders is used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. Accordingly, the computation of diluted shares for the three and nine months ended September 30, 2018 and 2017 excludes the effect of shares that would be issued in connection with the PIPE Transaction, the Rights Offering, 2017 Warrants (see Note 5 - Stockholders’ Deficit), stock options, and restricted stock awards, as their inclusion would be anti-dilutive to loss attributable to common stockholders.
NOTE 5 — STOCKHOLDERS’ DEFICIT
Carrying Value of Series A Preferred Stock
As of September 30, 2018, the carrying value of Series A Preferred Stock included accrued dividends at 11.5% and discount accretion from the date of issuance. Dividends and discount accretion totaled $0.2 million and $0.1 million, respectively, for the nine months ended September 30, 2018 and were recorded as a reduction to additional paid-in capital. The following table sets forth the activity recorded during the nine months ended September 30, 2018 related to the Series A Preferred Stock (in thousands):
Series A Preferred Stock carrying value at December 31, 2017
$
2,827

Dividends and discount accretion through September 30, 2018 1
299

Series A Preferred Stock carrying value September 30, 2018
$
3,126

1 Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.
Carrying Value of Series C Preferred Stock
As of September 30, 2018, the carrying value of Series C Preferred Stock included accrued dividends at 11.5% and discount accretion from the date of issuance. Dividends and discount accretion totaled $7.5 million and $0.5 million, respectively, for the nine months ended September 30, 2018 and were recorded as a reduction to additional paid-in capital. The following table sets forth the activity recorded during the nine months ended September 30, 2018 related to the Series C Preferred Stock (in thousands):
Series C Preferred Stock carrying value at December 31, 2017
$
79,252

Dividends and discount accretion through September 30, 2018 1
7,973

Series C Preferred Stock carrying value September 30, 2018
$
87,225


1 Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.

12

As of September 30, 2018, the Liquidation Preference of the Series A Preferred Stock and Series C Preferred Stock was $3.2 million and $92.0 million, respectively.
2017 Warrants
In connection with the Second Lien Note Facility (as defined below), the Company also issued warrants (the “2017 Warrants”) to the purchasers of the Second Lien Notes (as defined below) pursuant to a Warrant Purchase Agreement dated as of June 29, 2017 (the “Warrant Purchase Agreement”). The 2017 Warrants entitle the purchasers of the Warrants to purchase shares of Common Stock, representing at the time of any exercise of the 2017 Warrants an equivalent number of shares equal to 4.99% of the Common Stock of the Company on a fully diluted basis, subject to the terms of the Warrant Agreement governing the Warrants, dated as of June 29, 2017 (the “Warrant Agreement”); provided, however, the Warrants may not be converted to the extent that, after giving effect to such conversion, the holders of the 2017 Warrants would beneficially own, in the aggregate, in excess of (i) 19.99% of the shares of Common Stock outstanding as of June 29, 2017 (the “Closing Date”) minus (ii) the shares of Common Stock that were sold pursuant to the Second Quarter 2017 Private Placement (as defined below) (the “Conversion Cap”). The Conversion Cap will not apply to the 2017 Warrants if the Company obtains the approval of its stockholders for the removal of the Conversion Cap, which the Company is required to take certain steps to attempt to obtain, subject to the terms of the Warrant Agreement.
The 2017 Warrants have a 10-year term and an initial exercise price of $2.00 per share, and may be exercised by payment of the exercise price in cash or surrender of shares of Common Stock into which the Warrants are being converted in an aggregate amount sufficient to pay the exercise price.  The exercise price and the number of shares that may be acquired upon exercise of the 2017 Warrants is subject to adjustment in certain situations, including price based anti-dilution protection whereby, subject to certain exceptions, if the Company later issues Common Stock or certain Common Stock Equivalents (as defined in the Warrant Agreement) at a price less than either the then-current market price per share or exercise price of the 2017 Warrants, then the exercise price will be decreased and the percentage of shares of Common Stock issuable upon exercise of the Warrants will remain the same, giving effect to such issuance. Additionally, the 2017 Warrants have standard anti-dilution protections if the Company effects a stock split, subdivision, reclassification or combination of its Common Stock or fixes a record date for the making of a dividend or distribution to stockholders of cash or certain assets. Upon the occurrence of certain business combinations the 2017 Warrants will be converted into the right to acquire shares of stock or other securities or property (including cash) of the successor entity. The 2017 Warrants are reflected as a liability in other non-current liabilities on the balance sheet and are adjusted to fair value at the end of each reporting period through an adjustment to earnings. The fair value of the 2017 Warrants was $21.7 million as of September 30, 2018 and was included in other non-current liabilities on the accompanying Unaudited Consolidated Balance Sheets. Fair value increases of $1.6 million and $1.2 million for the three months and nine months ended September 30, 2018, respectively, are presented as changes in fair value of equity linked liabilities on the accompanying Unaudited Consolidated Statements of Operations.
NOTE 6 — RESTRUCTURING, ACQUISITION, INTEGRATION, AND OTHER EXPENSES
Restructuring, acquisition, integration and other expenses include non-operating costs associated with restructuring, acquisition, and integration initiatives such as employee severance costs, certain legal and professional fees, training costs, redundant wage costs, impacts recorded from the change in contingent consideration obligations, and other costs related to contract terminations and closed branches/offices.
Restructuring, acquisition, integration, and other expenses in the Unaudited Consolidated Statements of Operations for the three and nine months ended ended September 30, 2018 and 2017 consisted of the following (in thousands):
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2018
 
2017
 
2018
 
2017
Restructuring expense
$
833

 
$
3,791

 
$
4,666

 
$
10,881

Acquisition and integration expense
52

 
246

 
123

 
526

Total restructuring, acquisition, integration, and other expenses
$
885

 
$
4,037

 
$
4,789

 
$
11,407


13

NOTE 7 — DEBT
As of September 30, 2018 and December 31, 2017, the Company’s debt consisted of the following (in thousands):
 
September 30,
 2018
 
December 31,
2017
First Lien Note Facility, net of unamortized discount
198,801

 
198,324

Second Lien Note Facility, net of unamortized discount
103,571

 
85,694

2021 Notes, net of unamortized discount
197,927

 
197,363

Capital leases
1,239

 
2,863

Less: Deferred financing costs
(2,692
)
 
(3,656
)
Total Debt
498,846

 
480,588

Less: Current portion of long-term debt
(2,076
)
 
(1,722
)
Long-term debt, net of current portion
$
496,770

 
$
478,866

Debt Facilities
On June 29, 2017 (the “Closing Date”), the Company entered into (i) a first lien note purchase agreement (the “First Lien Note Facility”), among the Company, which is the issuer under the agreement, the financial institutions and note purchasers from time to time party to the agreement (the “First Lien Note Purchasers”), and Wells Fargo Bank, National Association, in its capacity as collateral agent for itself and the First Lien Note Purchasers (the “First Lien Collateral Agent”), pursuant to which the Company issued first lien senior secured notes in an aggregate principal amount of $200.0 million (the “First Lien Notes”); and (ii) a second lien note purchase agreement (the “Second Lien Note Facility” and, together with the First Lien Note Facility, the “Notes Facilities”) among the Company, which is the issuer under the agreement, the financial institutions and note purchasers from time to time party to the agreement (the “Second Lien Note Purchasers”), and Wells Fargo Bank, National Association, in its capacity as collateral agent for itself and the Second Lien Note Purchasers (the “Second Lien Collateral Agent” and, together with the First Lien Collateral Agent, the “Collateral Agent”), pursuant to which the Company (a) issued second lien senior secured notes in an aggregate initial principal amount of $100.0 million (the “Initial Second Lien Notes”) and (b) had the ability to draw upon the Second Lien Note Facility and issue second lien delayed draw senior secured notes, which was exercised on June 21, 2018, in an aggregate initial principal amount of $10.0 million, representing the maximum borrowings allowed on this facility (the “Second Lien Delayed Draw Notes” and, together with the Initial Second Lien Notes, the “Second Lien Notes”; the Second Lien Notes, together with the First Lien Notes, the “Notes”). Funds managed by Ares are acting as lead purchasers for the Notes Facilities.
The Company used the proceeds of the sale of the First Lien Notes and the Initial Second Lien Notes to repay in full all amounts outstanding under the Prior Credit Agreements and extinguished the liability. Each of the Prior Credit Agreements was terminated following such repayment. The Company used the remaining proceeds of $15.9 million, net of $0.2 million in issuance costs, from the Notes Facilities and the Second Quarter 2017 Private Placement for working capital and general corporate purposes.
The First Lien Notes accrue interest, payable monthly in arrears, at a floating rate or rates equal to, at the option of the Company, (i) the base rate (defined as the highest of the Federal Funds Rate plus 0.5% per annum, the Prime Rate as published by The Wall Street Journal and the one-month London Interbank Offered Rate (“LIBOR”) (subject to a 1.0% floor) plus 1.0%), or (ii) the one-month LIBOR rate (subject to a 1.0% floor), plus a margin of 6.0% if the base rate is selected or 7.0% if the LIBOR Option is selected. The First Lien Notes mature on August 15, 2020, provided that if the Company’s existing 8.875% Senior Notes due 2021 (the “2021 Notes”) are refinanced prior to August 15, 2020, then the scheduled maturity date of the First Lien Notes shall be June 30, 2022.
The First Lien Notes will amortize in equal quarterly installments equal to 0.625% of the aggregate principal amount of the First Lien Note Facility, commencing on September 30, 2019, and on the last day of each third month thereafter, with the balance payable at maturity. The First Lien Notes are pre-payable at the Company’s option at specified premiums to the principal amount that will decline over the term of the First Lien Note Facility. If the First Lien Notes are prepaid prior to the second anniversary of the Closing Date, the Company will be required to pay a make-whole premium based on the present value (using a discount rate based on the specified treasury rate plus 50 basis points) of all remaining interest payments on the First Lien Notes being prepaid prior to the second anniversary of the Closing Date, plus 4.0% of the principal amount of First Lien Notes being prepaid. On or after the second anniversary of the Closing Date, the prepayment premium is 4.0%, which declines to 2.0% on or after the third anniversary of the Closing Date, and declines to 0.0% on or after the fourth anniversary of the Closing Date. At any time, the Company may pre-pay up to $50.0 million in aggregate principal amount of the First Lien Notes from internally generated cash without incurring any make-whole or prepayment premium. The occurrence of certain events of default may increase the applicable rate of interest by 2.0% and could result in the acceleration of the Company’s obligations under the First Lien Note

14

Facility prior to stated maturity and an obligation of the Company to pay the full amount of its obligations under the First Lien Note Facility.
The First Lien Note Facility contains customary events of default that include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material indebtedness and events constituting a change of control. In addition, the obligations under the First Lien Note Facility will be guaranteed by joint and several guarantees from the Company’s subsidiaries.
In connection with the First Lien Note Facility, the Company, its subsidiaries and the First Lien Collateral Agent entered into a First Lien Guaranty and Security Agreement, dated as of June 29, 2017 (the “First Lien Guaranty and Security Agreement”). Pursuant to the First Lien Guaranty and Security Agreement, the obligations under the First Lien Notes will be secured by first priority liens on, and security interests in, substantially all of the assets of the Company and its subsidiaries.
The Second Lien Notes accrue interest, payable monthly in arrears, at a floating rate or rates equal to, at the option of the Company, (i) one-month LIBOR (subject to a 1.25% floor) plus 9.25% per annum in cash, (ii) one-month LIBOR (subject to a 1.25% floor) plus 11.25% per annum, which amount will be capitalized on each interest payment date, or (iii) one-month LIBOR (subject to a 1.25% floor) plus 10.25% per annum, of which one-half LIBOR plus 4.625% per annum will be payable in cash and one-half LIBOR plus 5.625% per annum will be capitalized on each interest payment date, provided that, in each case, if any permitted refinancing indebtedness with which the 2021 Notes are refinanced requires or permits the payment of cash interest, all of the interest on the Second Lien Notes shall be paid in cash. During the third quarter, $3.8 million of interest was capitalized to the Second Lien Notes, increasing the principal amount to $113.8 million as of September 30, 2018. The Second Lien Notes mature on August 15, 2020, provided that if the 2021 Notes are refinanced prior to August 15, 2020, then the scheduled maturity date of the Second Lien Notes shall be June 30, 2022.
In connection with the Second Lien Note Facility, the Company also issued warrants (the “2017 Warrants”) to the purchasers of the Second Lien Notes pursuant to a Warrant Purchase Agreement dated as of June 29, 2017 (the “Warrant Purchase Agreement”). The 2017 Warrants entitle the purchasers of the Warrants to purchase shares of Common Stock, representing at the time of any exercise of the 2017 Warrants an equivalent number of shares equal to 4.99% of the Common Stock of the Company on a fully diluted basis, subject to the terms of the Warrant Agreement governing the Warrants, dated as of June 29, 2017 (the “Warrant Agreement”). The 2017 Warrants, considered a derivative and subject to remeasurement at each reporting period, are reflected in other non-current liabilities at a fair value of $21.7 million.
The Second Lien Notes are not subject to scheduled amortization installments. The Second Lien Notes are pre-payable at the Company’s option at specified premiums to the principal amount that will decline over the term of the Second Lien Note Facility. If the Second Lien Notes are prepaid prior to the third anniversary of the Closing Date, the Company will need to pay a make-whole premium based on the present value (using a discount rate based on the specified treasury rate plus 50 basis points) of all remaining interest payments on the Second Lien Notes being prepaid prior to the third anniversary of the Closing Date, plus 4.0% of the principal amount of Second Lien Notes being prepaid. On or after the third anniversary of the Closing Date, the prepayment premium is 4.0%, which declines to 2.0% on or after the fourth anniversary of the Closing Date, and declines to 0.0% on or after the fifth anniversary of the Closing Date. The occurrence of certain events of default may increase the applicable rate of interest by 2.0% and could result in the acceleration of the Company’s obligations under the Second Lien Note Facility prior to stated maturity and an obligation of the Company to pay the full amount of its obligations under the Second Lien Note Facility.
The Second Lien Note Facility contains customary events of default that include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material indebtedness and events constituting a change of control. In addition, the obligations under the Second Lien Note Facility will be guaranteed by joint and several guarantees from the Company’s subsidiaries.
In connection with the Second Lien Note Facility, the Company, its subsidiaries and the Second Lien Collateral Agent entered into a Second Lien Guaranty and Security Agreement, dated as of June 29, 2017 (the “Second Lien Guaranty and Security Agreement”). Pursuant to the Second Lien Guaranty and Security Agreement, the obligations under the Second Lien Notes will be secured by second priority liens on, and security interests in, substantially all of the assets of the Company and its subsidies.
In connection with the First Lien Note Facility and the Second Lien Note Facility, the Company, the First Lien Collateral Agent and the Second Lien Collateral Agent, entered into an intercreditor agreement containing customary provisions to, among other things, subordinate the lien priority of the liens granted under the Second Lien Note Facility to the liens granted under the First Lien Note Facility.

15

2021 Notes
On February 11, 2014, the Company issued $200.0 million aggregate principal amount of the 2021 Notes. The 2021 Notes are senior unsecured obligations of the Company and are fully and unconditionally guaranteed by all existing and future subsidiaries of the Company.
Interest on the 2021 Notes accrues at a fixed rate of 8.875% per annum and is payable in cash semi-annually on February 15 and August 15 of each year. The debt discount of $5.0 million at issuance is being amortized as interest expense through maturity which will result in the accretion over time of the outstanding debt balance to the principal amount. The 2021 Notes are the Company’s senior unsecured obligations and rank equally in right of payment with all of its other existing and future senior unsecured indebtedness and senior in right of payment to all of its existing and future subordinated indebtedness.
The 2021 Notes are guaranteed on a full, joint and several basis by each of the Company’s existing and future domestic restricted subsidiaries that is a borrower under any of the Company’s credit facilities or that guarantees any of the Company’s debt or that of any of its restricted subsidiaries, in each case incurred under the Company’s credit facilities. As of September 30, 2018, the Company does not have any independent assets or operations, and as a result, its direct and indirect subsidiaries (other than minor subsidiaries), each being 100% owned by the Company, are fully and unconditionally, jointly and severally, providing guarantees on a senior unsecured basis to the 2021 Notes.
Fair Value of Financial Instruments
The following details our financial instruments where the carrying value and the fair value differ (in thousands):
Financial Instrument
 
Carrying Value as of September 30, 2018
 
Markets for Identical Item (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
First Lien Note Facility
 
$
198,801

 
$
—

 
$
—

 
$
202,512

Second Lien Note Facility
 
103,571

 
—

 
—

 
117,219

2017 Warrants
 
21,724

 
—

 
21,724

 
—

2021 Notes
 
197,927

 
—

 
189,500

 
—

Total
 
$
522,023

 
$
—

 
$
211,224

 
$
319,731

The fair value hierarchy for disclosure of fair value measurements is as follows:
Level 1:  Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2:  Quoted prices, other than quoted prices included in Level 1, which are observable for the assets or liabilities, either directly or indirectly.
Level 3:  Inputs that are unobservable for the assets or liabilities.
Financial assets with carrying values approximating fair value include cash and cash equivalents and accounts receivable. Financial liabilities with carrying values approximating fair value include accounts payable and capital leases. The carrying value of these financial assets and liabilities approximates fair value due to their short maturities.
NOTE 8 — COMMITMENTS AND CONTINGENCIES
Legal Proceedings
The Company is a party to various legal, regulatory and governmental proceedings incidental to its business. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental matters, including the matters described herein, will have a material adverse effect on the consolidated financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in pending legal, regulatory and governmental matters, some of which are beyond the Company’s control, and the indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could be material to the Company’s results of operations or cash flows for any particular reporting period. 
 
With respect to all legal, regulatory and governmental proceedings, the Company considers the likelihood of a negative outcome. If the Company determines the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, the Company records an accrual for the estimated loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and the Company is

16

able to determine an estimate of the possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, the Company discloses the estimate of the possible loss or range of loss. However, the Company is unable to estimate a possible loss or range of loss in some instances based on the significant uncertainties involved in, and/or the preliminary nature of, certain legal, regulatory and governmental matters.

On December 18, 2017, a commercial payor of the Company sent a letter that claimed an alleged breach of the Company’s obligation under its provider contracts.  No legal proceeding has been filed. The Company is not able to estimate the amount of any possible loss.  The Company believes this claim is without merit and intends to vigorously defend against this claim if any such legal proceeding is commenced.

Government Regulation

Various federal and state laws and regulations affecting the healthcare industry impact or may in the future impact the Company’s current and planned operations, including, without limitation, federal and state laws and regulations prohibiting kickbacks in connection with healthcare services, prohibiting certain conduct deemed to be anti-competitive (antitrust laws) and restricting drug distribution. Other laws and regulations that may affect our business include, but are not limited to, consumer protection, insurance, licensure, and privacy. There can be no assurance the Company will be able to obtain or maintain any of the regulatory approvals that may be required to operate its business, and the failure to do so could have a material effect on the Company’s financial statements.

From time to time, the Company responds to investigatory subpoenas and requests for information from governmental agencies and private parties. The Company cannot predict with certainty what the outcome of any of the foregoing might be. While the Company believes it is in substantial compliance with all existing laws and regulations material to the operation of its business, such laws and regulations are often uncertain in their application to our business practices as they evolve and are subject to rapid change. As controversies continue to arise in the healthcare industry, federal and state regulation and enforcement priorities in this area can be expected to increase, the impact of which cannot be predicted. There can be no assurance that the Company will not be subject to scrutiny or challenge under one or more regulations or that any such challenge would not be successful. Any such challenge, whether or not successful, could have a material effect upon the Company’s Consolidated Financial Statements. A violation of the federal Anti-Kickback Statute, for example, may result in substantial criminal and civil penalties, as well as suspension or exclusion from the Medicare and Medicaid programs. Moreover, the costs and expenses associated with defending these actions, even where successful, can be significant.
NOTE 9 — CONCENTRATION OF RISK
Customer and Credit Concentration Risk
The Company provides trade credit to its customers in the normal course of business. No single payor accounted for more than 10.0% of revenue during the three and nine months ended September 30, 2018. One commercial payor, United Healthcare, accounted for approximately 18.1% and 21.0% of revenue during the three and nine months ended September 30, 2017, respectively. 

17

NOTE 10 — INCOME TAXES
The Company’s federal and state income tax provision from continuing operations for the three months and nine months ended September 30, 2018 and 2017 is summarized in the following table (in thousands):
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2018
 
2017
 
2018
 
2017
Current
 
 
 
 
 
 
 
Federal
$
—

 
$
(925
)
 
$
—

 
$
(925
)
State
50

 
378

 
84

 
528

Total current
50

 
(547
)
 
84

 
(397
)
Deferred
 

 
 

 
 

 
 

Federal
—

 
515

 
—

 
1,523

State
52

 
92

 
107

 
271

Total deferred
52

 
607

 
107

 
1,794

Total income tax expense
$
102

 
$
60

 
$
191

 
$
1,397


The Company’s reconciliation of the statutory rate from continuing operations to the effective income tax rate for the three months and nine months ended September 30, 2018 and 2017 is summarized as follows (in thousands):
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2018
 
2017
 
2018
 
2017
Tax benefit at statutory rate
$
(1,680
)
 
$
(4,307
)
 
$
(7,564
)
 
$
(20,543
)
State tax expense, net of federal taxes
102

 
378

 
191

 
528

Alternative Minimum Tax receivable
—

 
(925
)
 
—

 
(925
)
Valuation allowance changes affecting income tax provision
1,261

 
4,876

 
7,163

 
22,194

Permanent items
419

 
38

 
401

 
143

Income tax expense
$
102

 
$
60

 
$
191

 
$
1,397

On December 22, 2017, the President of the United States signed into law the Tax Cuts and Jobs Act of 2017 or U.S. Federal Tax Reform (the “Reform”). The enactment included broad tax changes that are applicable to BioScrip, Inc. Most notably, the Reform decreased the U.S. corporate income tax rate from a high of 35% to a flat 21% rate effective January 1, 2018. As a result, the Company has revalued its ending net deferred tax assets as of December 31, 2017. At September 30, 2018, the Company had Federal net operating loss (“NOL”) carry forwards of approximately $427.0 million, of which $10.8 million is subject to an annual limitation, which will begin expiring in 2026 and later. The Company also has a carryforward of approximately $37.1 million related to the interest expense limitation, which is not subject to an expiration period. The Company has post-apportioned state NOL carry forwards of approximately $467.1 million, the majority of which will begin expiring in 2018 and later.
NOTE 11 — STOCK-BASED COMPENSATION
BioScrip Equity Incentive Plans
Under the Company’s 2018 Equity Incentive Plan (the “2018 Plan”), approved at the annual meeting by the stockholders on May 3, 2018, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights (“SARs”), restricted stock units, stock grants, and performance units to key employees and directors. The 2018 Plan is administered by the Company’s Management Development and Compensation Committee (the “Compensation Committee”), a standing committee of the Board of Directors.
A total of 16,406,939 shares of stock are authorized for issuance under the 2018 Plan, to include shares that remained available for grant under the 2008 Plan as of the effective date of the 2018 Plan. The authorized shares were reduced by all shares granted under the 2008 Plan after December 31, 2017 in accordance with the terms of the 2018 Plan. No key employee in any calendar year will be granted more than 3,000,000 shares of Stock with respect to (i) Options to purchase shares of Stock, (ii) Stock

18

Appreciation Rights (based on the appreciation with respect to shares of Stock); and (iii) Stock Grants and Restricted Stock Units that are intended to comply with the requirements of Section 162(m) of the Code.
As of September 30, 2018, 13,339,067 shares remain available for grant under the 2018 Plan.
Stock Options
The Company recognized compensation expense related to stock options of $0.3 million and $0.1 million during the three months ended September 30, 2018 and 2017, respectively, and $0.9 million and $0.8 million during the nine months ended September 30, 2018 and 2017, respectively.
Restricted Stock
The Company recognized $0.8 million and $0.4 million of compensation expense related to restricted stock awards during the three months ended September 30, 2018 and 2017, respectively, and $1.8 million and $0.6 million of compensation expense during the nine months ended September 30, 2018 and 2017, respectively.
Stock Appreciation Rights and Market Based Cash Awards
The Company recognized nominal amounts of compensation expense related to stock appreciation rights awards during the three months ended September 30, 2018 and 2017 and the nine months ended September 30, 2018 and 2017.
The Company recognized $0.1 million and a nominal amount of compensation expense related to market based cash awards during the three months ended September 30, 2018 and 2017, respectively, and $0.2 million and $0.1 million of compensation expense during nine months ended September 30, 2018 and 2017, respectively.
Employee Stock Purchase Plan
On May 3, 2018, the Company’s stockholders approved an amendment to the BioScrip, Inc. Employee Stock Purchase Plan (the “ESPP”). The ESPP provides all eligible employees, as defined under the ESPP, the opportunity to purchase up to a maximum number of shares of Common Stock of the Company as determined by the Compensation Committee. Participants in the ESPP may acquire the Common Stock at a cost of 85% of the lower of the fair market value on the first or last day of the quarterly offering period.
As of September 30, 2018, 1,422,842 shares remained available for grant under the ESPP. Since inception, the ESPP’s third-party service provider has purchased 827,158 shares on the open market and delivered these shares to the Company’s employees pursuant to the ESPP. During the three months ended September 30, 2018 and 2017, the Company incurred less than $0.1 million of expense. During the nine months ended September 30, 2018 and 2017, the company incurred $0.1 million of expense related to the ESPP.

19

Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion should be read in conjunction with the Audited Consolidated Financial Statements, including the notes thereto, and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2017 (the “Annual Report”) filed with the U.S. Securities and Exchange Commission (“SEC”), as well as our Unaudited Consolidated Financial Statements and the related notes thereto included elsewhere in this report.
This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains statements not purely historical and which may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including statements regarding our expectations, beliefs, future plans and strategies, anticipated events or trends concerning matters that are not historical facts or that necessarily depend upon future events. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “predict,” “potential,” and similar expressions. Specifically, this Quarterly Report contains, among others, forward-looking statements about:
•
our ability to make principal and interest payments on our debt and satisfy the other covenants contained in our debt agreements;
•
our high level of indebtedness;
•
our expectations regarding financial condition or results of operations in future periods;
•
our future sources of, and needs for, liquidity and capital resources;
•
our expectations regarding economic and business conditions;
•
our expectations regarding potential legislative and regulatory changes impacting the level of reimbursement received from the Medicare program and state Medicaid programs;
•
periodic reviews and billing audits from governmental and private payors;
•
our expectations regarding the size and growth of the market for our products and services;
•
our business strategies and our ability to grow our business;
•
the implementation or interpretation of current or future regulations and laws, particularly those affecting governmental oversight of our business;
•
our expectations regarding the outcome of litigation;
•
our ability to maintain contracts and relationships with our customers;
•
our ability to avoid delays in payment from our customers;
•
sales and marketing efforts;
•
the status of material contractual arrangements, including the negotiation or re-negotiation of such arrangements;
•
future capital expenditures;
•
our ability to hire and retain key employees;
•
our ability to execute our acquisition and growth strategy; and
•
our ability to successfully integrate other businesses we may acquire.
Investors are cautioned that any such forward-looking statements are not guarantees of future performance, involve risks and uncertainties and that actual results may differ materially from those possible results discussed in the forward-looking statements as a result of various factors. Important factors that could cause such differences include, among other things:
•
risks associated with increased or changing government regulation related to the health care and insurance industries in general, and more specifically, home infusion providers;
•
our ability to comply with debt covenants in our Notes Facility (as defined below) and unsecured notes indenture;
•
risks associated with our issuance of the 2017 Warrants (as defined below);
•
risks associated with the retention or transition of executive officers and key employees;
•
our expectation regarding the interim and ultimate outcome of commercial disputes, including litigation;
•
unfavorable economic and market conditions;
•
disruptions in supplies and services resulting from force majeure events such as war, strike, riot, crime, or “acts of God” such as hurricanes, flooding, blizzards or earthquakes;
•
reductions to and delays or suspensions of federal and state payments for services provided;
•
efforts to reduce healthcare costs and alter health care financing, which may involve reductions in reimbursement for our products and services and value based payment initiatives, including accountable care organizations;
•
the effect of health reform efforts, including the 21st Century Cures Act (the “Cures Act”) and the Patient Protections and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (together the “Affordable Care Act”);
•
existence of complex laws and regulations relating to our business;

20

•
availability of financing sources;
•
declines and other changes in revenue due to the expiration of short-term contracts;
•
network lockouts and decisions to in-source by health insurers including lockouts with respect to acquired entities;
•
unforeseen contract terminations;
•
difficulties in the implementation and ongoing evolution of our operating systems;
•
difficulties with the implementation of our growth strategy and integrating businesses we have acquired or will acquire;
•
increases or other changes in our acquisition cost for our products;
•
increased competition from competitors having greater financial, technical, reimbursement, marketing and other resources could have the effect of reducing prices and margins;
•
disruptions in our relationship with our primary supplier of prescription products;
•
the level of our indebtedness and its effect on our ability to execute our business strategy and increased risk of default under our debt obligations;
•
introduction of new drugs, which can cause prescribers to adopt therapies for existing patients that are less profitable to us;
•
changes in industry pricing benchmarks, which could have the effect of reducing prices and margins; and
•
other risks and uncertainties described from time to time in our filings with the SEC.
You should not place undue reliance on such forward-looking statements as they speak only as of the date they are made. Except as required by law, we assume no obligation to publicly update or revise any forward-looking statement even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized.
Business Overview
We are a national provider of infusion solutions with nearly 70 service locations around the U.S. We partner with physicians, hospital systems, skilled nursing facilities, and healthcare payors to provide patients with access to post-acute care services. We are committed to bringing customer-focused healthcare infusion therapy services into the home or alternate site setting. By collaborating with the full spectrum of healthcare professionals and the patient, we aim to provide cost-effective care that is driven by clinical excellence, customer service and values that promote positive outcomes and an enhanced quality of life for those whom we serve.
Our platform provides nationwide service capabilities and the ability to deliver clinical management services that offer patients a high-touch, community-based and home-based care environment. Our core services are provided in coordination with, and under the direction of, the patient’s physician. Our multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, works with the physician to develop a plan of care suited to our patient’s specific needs. Whether in the home, physician office, ambulatory infusion center, skilled nursing facility or other alternate sites of care, we provide products, services and condition-specific clinical management programs tailored to improve the care of individuals with complex health conditions such as gastrointestinal abnormalities, infectious diseases, cancer, multiple sclerosis, organ and blood cell transplants, bleeding disorders, immune deficiencies and heart failure.
We operate in one segment, Infusion Services, and accordingly, we do not present disaggregated segment information.
Regulatory Matters Update
Approximately 19.1% and 15.6% of revenue for the three months ended September 30, 2018 and 2017, respectively, and approximately 19.6% and 16.0% of revenue for the nine months ended September 30, 2018 and 2017, respectively, was derived directly from the Medicare program, state Medicaid programs and other government payors. We also provide services to beneficiaries of Medicare, Medicaid and other government-sponsored healthcare programs indirectly through managed care entities. Medicare Part D, for example, is administered through managed care entities. In the normal course of business, we and our customers are subject to legislative and regulatory changes impacting the level of reimbursement received from the Medicare program and state Medicaid programs.
State Medicaid Programs
Medicaid coverage of infusion therapy varies by state. We are sensitive to possible changes in state Medicaid programs. Budgetary concerns in many states have resulted in, and may continue to result in, reductions to Medicaid reimbursement and delays in payment of outstanding claims. In addition, many states have implemented or are considering strategies to reduce coverage, restrict eligibility, or enroll Medicaid recipients in managed care programs.
Each individual state Medicaid program represents less than 5% of our consolidated revenue for the three months and nine months ended September 30, 2018, and no individual state Medicaid reimbursement reduction is expected to have a material effect

21

on our Consolidated Financial Statements. We are continually assessing the impact of the state Medicaid reimbursement cuts as states propose, finalize and implement various cost-saving measures.
Given the reimbursement pressures, we strive to improve operational efficiencies and reduce costs to mitigate the impact on results of operations where possible. In some cases, reimbursement rate reductions may result in negative operating results, and we would likely exit some or all services where rate reductions result in unacceptable returns to our stockholders.
Medicare
We receive reimbursement for infusion therapy under the Medicare program. Coverage is limited based on the place of service, diagnosis, and method of drug delivery. In recent years, legislative and regulatory changes have resulted in limitations and reductions in reimbursement under the Medicare program. For example, the Cures Act, which Congress passed in December 2016, changed the payment methodology for certain infusion drugs under the Part B DME benefit. Significant reductions to the amount paid by Medicare for many infusion drugs took effect January 1, 2017. In addition, the Cures Act provides for the implementation of a clinical services payment under Part B for “qualified home infusion therapy suppliers.” Under this new payment system, Medicare will reimburse home infusion therapy suppliers based on a single, all-inclusive rate. The services payment provision does not take effect until January 1, 2021. However, the Bipartisan Budget Act of 2018 provides for temporary transitional benefit payments, starting January 1, 2019, for Medicare Part B home infusion services. This temporary benefit will continue until January 1, 2021, when the services payment in the Cures Act takes effect.

There are also more general efforts to reduce federal spending. For example, the Budget Control Act of 2011 (the “BCA”) requires automatic spending reductions to reduce the federal deficit, including Medicare spending reductions of up to 2% per fiscal year, with a uniform percentage reduction across all Medicare programs. Centers for Medicare and Medicaid Services (“CMS”) began imposing a 2% reduction on Medicare claims in 2013. These reductions have been extended through 2027.

Approximately 6.8% and 7.6% of revenue for the three and nine months ended ended September 30, 2018, respectively, and 6.3% and 6.8% of revenue for the three and nine months ended ended September 30, 2017, respectively, was derived from Medicare.
Critical Accounting Estimates
Our Unaudited Consolidated Financial Statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”). In preparing our financial statements, we are required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Accordingly, actual results could differ from these estimates.
We evaluate our estimates and judgments on an ongoing basis. We base our estimates and judgments on historical experience and on various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the period presented. Our actual results may differ from these estimates, and different assumptions or conditions may yield different estimates. Our critical accounting estimates have not changed from the description provided in our Annual Report, except for the changes related to the implementation of ASU 2014-09 as they relate to transaction price and implicit price concessions; see Note 3 - Revenue. For a full description of our accounting policies please refer to Management’s Discussion and Analysis of Financial Condition and Results of Operations in the Annual Report.

22

Collectability of Accounts Receivable
The following table sets forth the aging of our net accounts receivable (net of allowance for contractual adjustments, and prior to allowance for doubtful accounts), aged based on date of service and categorized based on the three primary overall types of accounts receivable characteristics (in thousands):
 
 
September 30, 2018
 
December 31, 2017
 
 
0 - 180 days
 
Over 180 days
 
Total
 
0 - 180 days
 
Over 180 days
 
Total
Government
 
$
12,555

 
$
3,028

 
$
15,583

 
$
20,602

 
$
10,082

 
$
30,684

Commercial
 
80,508

 
10,825

 
91,333

 
63,767

 
18,779

 
82,546

Patient
 
1,922

 
4,790

 
6,712

 
2,577

 
7,627

 
10,204

Gross accounts receivable
 
$
94,985

 
$
18,643

 
113,628

 
$
86,946

 
$
36,488

 
123,434

Allowance for doubtful accounts
 
 
 
 
 
—

 
 
 
 
 
(37,912
)
Net accounts receivable
 
 
 
 
 
$
113,628

 
 
 
 
 
$
85,522



23

Results of Operations
The following consolidated statements have been derived from our unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q. The discussion set forth below compares our results of operations for the three months and nine months ended September 30, 2018 with the results of operations for the corresponding periods in 2017.
Three months ended September 30, 2018 compared to three months ended September 30, 2017
 
Three Months Ended September 30,
 
As a Percentage of Revenue
 
(in thousands)
 
 
 
 
 
2018
 
2017
 
2018
 
2017
Net revenue
180,962

 
198,692

 
100.0
 %
 
100.0
 %
Gross profit
65,911

 
66,563

 
36.4
 %
 
33.5
 %
Other operating expenses
38,216

 
38,143

 
21.1
 %
 
19.2
 %
Bad debt expense
—

 
6,488

 
—
 %
 
3.3
 %
General and administrative expenses
12,478

 
9,405

 
6.9
 %
 
4.7
 %
Restructuring, acquisition, integration, and other expenses
885

 
4,037

 
0.5
 %
 
2.0
 %
Change in fair value of equity linked liabilities
1,605

 
1,103

 
0.9
 %
 
0.6
 %
Depreciation and amortization expense
5,767

 
7,058

 
3.2
 %
 
3.6
 %
Interest expense
14,971

 
13,360

 
8.3
 %
 
6.7
 %
Loss on extinguishment of debt
—

 
—

 
—
 %
 
—
 %
Loss on dispositions
(10
)
 
(33
)
 
—
 %
 
—
 %
Loss from continuing operations, before income taxes
(8,001
)
 
(12,998
)
 
(4.4
)%
 
(6.5
)%
Income tax expense
102

 
60

 
0.1
 %
 
—
 %
Loss from continuing operations, net of income taxes
(8,103
)
 
(13,058
)
 
(4.5
)%
 
(6.6
)%
Income (loss) from discontinued operations, net of income taxes
(71
)
 
66

 
—
 %
 
—
 %
Net loss
(8,174
)
 
(12,992
)
 
(4.5
)%
 
(6.5
)%
Net Revenue. Net revenue for the three months ended September 30, 2018 decreased $17.7 million, or 8.9%, to $181.0 million, compared to net revenue of $198.7 million for the same period in 2017. The decrease in net revenue primarily reflects the Company’s shift in strategy to focus on growing its core revenue mix, including the impact of the UnitedHealthcare contract transition effective September 30, 2017. Additionally, implementation of Topic 606 during the first quarter of 2018 resulted in the recognition of amounts previously recorded as bad debt expense as a reduction to revenue. The impact of the change in accounting principle during the three months ended September 30, 2018 was a $5.7 million, or 3.1%, reduction to revenue. Prior period amounts have not been reclassified, consistent with the modified retrospective implementation approach, as outlined in Topic 606.
Gross Profit. Gross profit consists of revenue less cost of revenue (excluding depreciation expense). The cost of revenue (excluding depreciation expense) primarily includes the costs of prescription medications, supplies, nursing services, shipping and other direct and indirect costs. Gross profit as a percentage of revenue improved by 2.9 percentage points for the three months ended September 30, 2018 as compared to the same period in 2017 due to an improved mix of higher margin core therapy revenues versus lower margin non-core therapy revenues, coupled with a decreased cost of prescription medicines as a result of improved supply chain management, offset partially by the impact of ASC Topic 606 implementation. The decrease in gross profit of $0.7 million or 1.0% was primarily driven by the decrease in revenue of $5.7 million associated with the impact of implementation of ASC Topic 606 (see Note 3 - Revenue) and lower revenues from the impact of the UnitedHealthcare contract transition effective September 30, 2017, partially offset by higher gross profit margins due to higher core mix and lower costs of prescription medications.
Other Operating Expenses. Other operating expenses consist primarily of wages and benefits, travel expenses, professional service and field office expenses for our healthcare professionals engaged in providing infusion services to our patients. Other operating expenses for the three months ended September 30, 2018 increased $0.1 million or 0.2% compared to the same period in 2017 due to a nominal increase in professional service and field office expenses.
Bad Debt Expense. Bad debt expense decreased $6.5 million during the three months ended September 30, 2018 as compared to the same period in 2017 consistent with the implementation of ASC Topic 606 (see Note 3 - Revenue) which resulted in the

24

recognition of all of the Company’s bad debt expense as a reduction to revenue for the three months ended September 30, 2018. Bad debt expense as a percentage of revenue was 3.3% during the same period in 2017.
General and Administrative Expenses. General and administrative expenses consist of wages and benefits for corporate overhead personnel, and certain corporate level professional service fees, including legal, accounting, and IT fees. The increase of $3.1 million or 32.7% in general and administrative expenses during the three months ended September 30, 2018 as compared to the same period in 2017, resulted primarily from increased stock based compensation, employee benefit and professional service fees including legal and accounting.
Restructuring, Acquisition, Integration, and Other Expenses. Restructuring, acquisition, integration, and other expenses decreased by $3.2 million or 78.1% during the three months ended September 30, 2018 as compared to the same period in 2017. The decrease was driven by a reduction of restructuring, acquisition and integration activity during the current quarter. Restructuring, acquisition, integration, and other expenses consist primarily of employee severance and other benefit-related costs, third-party consulting costs, redundant facility and personnel-related costs and certain other costs associated with our restructuring, acquisition, and integration activities.
Depreciation and Amortization Expense. Depreciation and amortization expense includes the depreciation of property and equipment and the amortization of intangible assets such as customer relationships, trademarks, and non-compete agreements with estimable lives. During the three months ended September 30, 2018 and 2017, depreciation expense was $3.6 million and $4.1 million, respectively, and amortization expense was $2.2 million and $3.0 million, respectively. The decrease in depreciation and amortization expense during the three months ended September 30, 2018 as compared to the same period in 2017 is attributable to full depreciation of certain property and equipment and full amortization of certain intangible assets.
Interest Expense. Interest expense consists of interest expense, amortization of deferred financing costs and debt discounts reduced by an immaterial amount of interest income. During the three months ended September 30, 2018 and 2017, interest expense was $15.0 million and $13.4 million, respectively, including $2.0 million and $1.7 million of amortization of deferred financing costs and debt discounts, respectively. The increase in interest expense during the three months ended September 30, 2018 as compared to the same period in 2017 is primarily the result of increasing variable interest rates on the First and Second Lien Note Facilities.
Change in Fair Value of Equity Linked Liabilities. The increase in the fair value of equity linked liabilities of $1.6 million during the three months ended September 30, 2018 represents the mark to market adjustment associated with the issuance of the 2017 Warrants in connection with the Second Lien Note Facility (see Note 7 - Debt). The increase is primarily driven by an increase in the Company’s stock price.
Income Tax Expense. Income tax expense for the three months ended September 30, 2018 of $0.1 million includes a $1.3 million increase in deferred tax asset valuation allowances and $0.1 million of state tax expense, partially offset by a federal tax benefit of $1.7 million and $0.4 million of permanent items. Income tax expense for the three months ended September 30, 2017 of $0.1 million includes a $4.9 million increase in deferred tax asset valuation allowances and $0.4 million of state tax expense, partially offset by a federal tax benefit of $4.3 million and alternative minimum taxes of $0.9 million.

25

Nine months ended September 30, 2018 compared to nine months ended September 30, 2017
 
Nine Months Ended September 30,
 
As a Percentage of Revenue
 
(in thousands)
 
 
 
 
 
2018
 
2017
 
2018
 
2017
Net revenue
$
525,335

 
$
634,608

 
100.0
 %
 
100.0
 %
Gross profit
180,916

 
199,048

 
34.4
 %
 
31.4
 %
Other operating expenses
116,378

 
124,755

 
22.2
 %
 
19.7
 %
Bad debt expense
—

 
19,648

 
—
 %
 
3.1
 %
General and administrative expenses
34,084

 
28,325

 
6.5
 %
 
4.5
 %
Restructuring, acquisition, integration, and other expenses
4,789

 
11,407

 
0.9
 %
 
1.8
 %
Change in fair value of equity linked liabilities
1,228

 
1,103

 
0.2
 %
 
0.2
 %
Depreciation and amortization expense
18,617

 
21,288

 
3.5
 %
 
3.4
 %
Interest expense
42,171

 
38,649

 
8.0
 %
 
6.1
 %
Loss on extinguishment of debt
—

 
13,453

 
—
 %
 
2.1
 %
Loss (gain) on dispositions
(330
)
 
652

 
(0.1
)%
 
0.1
 %
Loss from continuing operations, before income taxes
(36,021
)
 
(60,232
)
 
(6.9
)%
 
(9.5
)%
Income tax expense
191

 
1,397

 
—
 %
 
0.2
 %
Loss from continuing operations, net of income taxes
(36,212
)
 
(61,629
)
 
(6.9
)%
 
(9.7
)%
Income (loss) from discontinued operations, net of income taxes
(118
)
 
(606
)
 
—
 %
 
(0.1
)%
Net loss
$
(36,330
)
 
$
(62,235
)
 
(6.9
)%
 
(9.8
)%
Net Revenue. Net revenue for the nine months ended September 30, 2018 decreased $109.3 million, or 17.2%, to $525.3 million, compared to net revenue of $634.6 million for the same period in 2017. The decrease in net revenue primarily reflects the Company’s shift in strategy to focus on growing its core revenue mix, including the impact of the UnitedHealthcare contract transition effective September 30, 2017, and lower patient volumes in certain product lines, including the impact of temporary closures of Company branches due to inclement winter weather during the first quarter. Additionally, implementation of Topic 606 during the first quarter of 2018 resulted in the recognition of amounts previously recorded as bad debt expense as a reduction to revenue. The impact of the change in accounting principle during the nine months ended September 30, 2018 was a $16.5 million, or 3.1%, reduction to revenue. Prior period amounts have not been reclassified, consistent with the modified retrospective implementation approach, as outlined in Topic 606.
Gross Profit. Gross profit consists of revenue less cost of revenue (excluding depreciation expense). The cost of revenue (excluding depreciation expense) primarily includes the costs of prescription medications, supplies, nursing services, shipping and other direct and indirect costs. Gross profit as a percentage of revenue improved by 3.0 percentage points for the nine months ended September 30, 2018 as compared to the same period in 2017 due to an improved mix of higher margin core therapy revenues versus lower margin non-core therapy revenues, coupled with decreased cost of prescription medicines as a result of improved supply chain management, offset partially by the impact of ASC Topic 606 implementation. The decrease in gross profit of $18.1 million or 9.1% was primarily driven by the decrease in revenue of $16.5 million associated with the impact of implementation of ASC Topic 606 (see Note 3 - Revenue), lower revenues from the impact of the UnitedHealthcare contract transition effective September 30, 2017, and lower patient volumes in certain product lines, including the impact of temporary closures of Company branches due to inclement winter weather during the first quarter, partially offset by higher gross profit margins due to higher core mix and lower costs of prescription medications.
Other Operating Expenses. Other operating expenses consist primarily of wages and benefits, travel expenses, professional service and field office expenses for our healthcare professionals engaged in providing infusion services to our patients. Other operating expenses for the nine months ended September 30, 2018 decreased $8.4 million or 6.7% compared to the same period in 2017 due to decreased wage, benefit, and other employee costs as a result of integration, restructuring, and other workforce optimization efforts.
Bad Debt Expense. Bad debt expense decreased $19.6 million during the nine months ended September 30, 2018 as compared to the same period in 2017 consistent with the implementation of ASC Topic 606 (see Note 3 - Revenue) which resulted in the recognition of all of the Company’s bad debt expense as a reduction to revenue for the nine months ended September 30, 2018. Bad debt expense as a percentage of revenue was 3.1% during the same period in 2017.

26

General and Administrative Expenses. General and administrative expenses consist of wages and benefits for corporate overhead personnel and certain corporate level professional service fees, including legal, accounting, and IT fees. The increase in general and administrative expenses of $5.8 million or 20.3% resulted primarily from increased stock based compensation expense, investments in our field force including our National Meeting, sales force effectiveness tools and strategies, and additional professional service fees including legal and accounting.
Restructuring, Acquisition, Integration, and Other Expenses. Restructuring, acquisition, integration, and other expenses decreased by $6.6 million or 58.0% during the nine months ended September 30, 2018. The decrease was driven by a reduction of restructuring, acquisition and integration activity during the nine months ended September 30, 2018. Restructuring, acquisition, integration, and other expenses consist primarily of employee severance and other benefit-related costs, third-party consulting costs, redundant facility and personnel-related costs and certain other costs associated with our restructuring, acquisition, and integration activities.
Depreciation and Amortization Expense. Depreciation and amortization expense includes the depreciation of property and equipment and the amortization of intangible assets such as customer relationships, trademarks, and non-compete agreements with estimable lives. During the nine months ended September 30, 2018 and 2017, we recorded depreciation expense of $11.5 million and $11.9 million, respectively, and amortization expense of intangibles of $7.1 million and $9.4 million, respectively. The decrease in depreciation and amortization expense during the nine months ended September 30, 2018 as compared to the same period in 2017 is primarily attributable to full amortization of certain intangible assets.
Change in Fair Value of Equity Linked Liabilities. The increase in the fair value of equity linked liabilities of $1.2 million during the nine months ended September 30, 2018 represents the mark to market adjustment associated with the issuance of the 2017 Warrants in connection with the Second Lien Note Facility (see Note 7 - Debt). The increase is primarily driven by an increase in the Company’s stock price.
Interest Expense. Interest expense consists of interest expense, amortization of deferred financing costs and debt discounts, reduced by an immaterial amount of interest income. During the nine months ended September 30, 2018 and 2017, we recorded interest expense of $42.2 million and $38.6 million, respectively, including $6.1 million and $4.7 million of amortization of deferred financing costs and debt discounts, respectively. The increase in interest expense during the nine months ended September 30, 2018 as compared to the same period in 2017 is primarily the result of the changes in debt structure (see Note 7 - Debt), and increasing variable interest rates on the First and Second Lien Note Facilities.
Income Tax Expense. Income tax expense for the nine months ended September 30, 2018 of $0.2 million includes a $7.2 million increase in deferred tax asset valuation allowances and $0.2 million of state tax expense, offset by a federal tax benefit of $7.6 million and permanent items of $0.2 million. Income tax expense for the nine months ended September 30, 2017 of $1.4 million includes a $22.2 million increase in deferred tax asset valuation allowances, $0.5 million of state tax expense, $0.1 million of permanent items, offset by a federal tax benefit of $20.5 million and alternative minimum taxes of $0.9 million.

27

Non-GAAP Measures
The following table reconciles GAAP loss from continuing operations, net of income taxes to Consolidated Adjusted EBITDA. Consolidated Adjusted EBITDA is net loss adjusted for interest expense, income tax expense, depreciation and amortization, impairments, loss on extinguishment of debt, and stock-based compensation expense. Consolidated Adjusted EBITDA also excludes restructuring, acquisition, integration and other expenses including non-operating costs associated with restructuring, acquisition and integration initiatives, such as employee severance costs, certain legal and professional fees, training costs, redundant wage costs, impacts recorded from the change in contingent consideration obligations, and other costs related to contract terminations and closed branches/offices.
Consolidated Adjusted EBITDA is a measure of earnings that management monitors as an important indicator of financial performance, particularly future earnings potential and recurring cash flow. Consolidated Adjusted EBITDA is also a primary objective of the management bonus plan. Inclusion of Consolidated Adjusted EBITDA is intended to provide investors insight into the manner in which management views the performance of the Company.
Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for our financial results prepared in accordance with GAAP. Our calculation of Non-GAAP Consolidated Adjusted EBITDA, as presented, may differ from similarly titled measures reported by other companies. We encourage investors to review these reconciliations and we qualify our use of non-GAAP financial measures with cautionary statements as to their limitations.
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2018
 
2017
 
2018
 
2017
(in thousands)
 
 
 
Loss from continuing operations, net of income taxes
$
(8,103
)
 
$
(13,058
)
 
$
(36,212
)
 
$
(61,629
)
 
 
 
 
 
 
 
 
Interest expense
(14,971
)
 
(13,360
)
 
(42,171
)
 
(38,649
)
Change in fair value of equity linked liabilities
(1,605
)
 
(1,103
)
 
(1,228
)
 
(1,103
)
Gain (loss) on dispositions
10

 
33

 
330

 
(652
)
Loss on extinguishment of debt
—

 
—

 
—

 
(13,453
)
Income tax expense
(102
)
 
(60
)
 
(191
)
 
(1,397
)
Depreciation and amortization
(5,767
)
 
(7,058
)
 
(18,617
)
 
(21,288
)
Stock-based compensation
(1,224
)
 
(545
)
 
(3,032
)
 
(1,525
)
Restructuring, acquisition, integration, and other expenses
(885
)
 
(4,037
)
 
(4,789
)
 
(11,407
)
Consolidated Adjusted EBITDA
$
16,441

 
$
13,072

 
$
33,486

 
$
27,845

Consolidated Adjusted EBITDA increased during the three and nine months ended September 30, 2018 compared to the same period of the prior year primarily due to the overall impact of the Company’s shift in strategy to focus on growing its core revenue mix, including the UnitedHealthcare contract transition effective September 30, 2017, and restructuring and integration efforts which optimized operations.
Liquidity and Capital Resources
Off-Balance Sheet Arrangements
As of September 30, 2018, we did not have any material off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K.

Sources and Uses of Funds
Net cash used in operating activities from continuing operations totaled $20.1 million during the nine months ended September 30, 2018 compared to $3.3 million during the nine months ended September 30, 2017, an increase of $16.8 million. The increase primarily relates to lower cash collections of accounts receivable, partially offset by strategic inventory management initiatives.

28

Net cash used in investing activities from continuing operations during the nine months ended September 30, 2018 was $9.4 million compared to $6.6 million in cash used during the same period in 2017. The increase in cash used in investing was primarily due to increased renovation and expansion of certain company branch locations.
Net cash provided by financing activities from continuing operations during the nine months ended September 30, 2018 was $8.5 million compared to $44.4 million in cash provided by financing activities during the same period in 2017, which was driven primarily by the first quarter 2017 private placement (see Note 5) and first quarter 2017 Priming Credit Agreement (see Note 7).
At September 30, 2018, we had working capital of $75.9 million, including $18.9 million of cash on hand, compared to working capital of $81.5 million at December 31, 2017. The $5.6 million decrease in working capital results primarily from the decrease in our cash and cash equivalents and restricted cash of $21.1 million offset by an increase in our accounts receivable of$28.1 million. Accounts receivable balances have increased due to temporal slower cash collections. During the second quarter, the Company exercised the $10.0 million delayed draw provided for in our Second Lien Note Facility. At September 30, 2018, we had outstanding letters of credit totaling $4.3 million, collateralized by restricted cash of $4.3 million.
A summary of the Company’s debt is included in Note 7 to the Financial Statements.

Future Cash Requirements
Net cash used in operating activities from continuing operations totaled $20.1 million during the nine months ended September 30, 2018. Our working capital decreased $5.6 million as of September 30, 2018 compared to December 31, 2017, primarily as a result of a decrease in our cash and cash equivalents of $20.5 million due to lower operating cash flow driven by an increase in accounts receivable due to temporal slower collection rates. At September 30, 2018, we had $18.9 million of unrestricted cash on hand. We expect cash and cash equivalents during the fourth quarter of 2018 to remain consistent or increase compared to September 30, 2018 levels, driven by increasing profitability, lower levels of strategic inventory purchases, and improved cash collections of accounts receivable.
If we cannot successfully execute our strategic plans we will likely require additional or alternative sources of liquidity, including additional borrowings.
On June 29, 2017, we entered into the Notes Facilities pursuant to which we issued new senior secured notes and refinanced our existing senior secured credit facilities. Please refer to “Debt Facilities” in this section.
We regularly evaluate market conditions and financing options to improve our current liquidity profile and enhance our financial flexibility. These options may include opportunities to raise additional funds through the issuance of various forms of equity and/or debt securities or other instruments, the sale of assets or refinancing all or a portion of our indebtedness. However, there is no assurance that, if necessary, we would be able to raise capital to provide required liquidity.
Additionally, we will pursue our operational and strategic plan and will also review a range of strategic alternatives, which could include, among other things, transitioning chronic therapies to alliance partners, a potential sale or merger of our company, or continuing to pursue our operational and strategic plan. Additionally, we may pursue joint venture arrangements, additional business acquisitions and other transactions designed to expand our business.
As of the filing of this Quarterly Report, we expect that our cash on hand and cash from operations will be sufficient to fund our anticipated working capital, scheduled interest repayments and other cash needs for at least the next 12 months. Quarterly principal payments on the Notes Facilities of $1.25 million commence on September 30, 2019.
The accompanying unaudited consolidated financial statements have been prepared on a going concern basis, which contemplates realization of assets and satisfaction of liabilities in the ordinary course of business. As such, they do not include any adjustments to the recoverability and reclassification of recorded amounts that might be necessary should we be unable to continue as a going concern.
Item 3.
Quantitative and Qualitative Disclosures About Market Risks
There have been no material changes to our exposure to market risk since the Annual Report.

29

Item 4.
Controls and Procedures
Evaluation of Disclosure Controls and Procedures
The Company maintains disclosure controls and procedures (as such term is defined under Rule 13a-15(e) promulgated under the Exchange Act) that are designed to ensure that information required to be disclosed by the Company in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Under the supervision and with the participation of the Company’s management, including its Chief Executive Officer and Chief Financial Officer, management evaluated the effectiveness of the Company’s disclosure controls and procedures as of September 30, 2018. Based on that evaluation, the Company’s Chief Executive Officer and its Chief Financial Officer concluded that, as a result of not having completed the remediation of the material weakness in internal control over financial reporting identified and described in Item 9A of our Annual Report on Form 10-K for the year ended December 31, 2017, our disclosure controls and procedures were not effective as of September 30, 2018.
Remediation Plans
Management is actively remediating the identified material weakness, and has identified the following remediation steps:

•
Enhance risk assessment processes and monitoring activities to ensure the Company designs, implements, and operates effective controls that are responsive to identified risks.

•
Implementation of controls to validate key inputs and calculations used in spreadsheets used to determine financial statement amounts and disclosures.

•
Implementation of controls to identify and clear unmatched transactions in suspense accounts.

•
Implementation of monitoring controls to be operated by a centralized resource to ensure periodic counts of inventory and fixed assets are completed and differences are timely processed by our accounting systems.

•
Enhance controls surrounding the timely and accurate recognition of fixed asset disposals and abandonments.

Changes in Internal Control Over Financial Reporting
Aside from actions taken as described above in “Remediation Plans”, there have been no changes in our internal control over financial reporting that occurred during the three and nine months ended September 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II
OTHER INFORMATION
Item 1.
Legal Proceedings
 
For a summary of legal proceedings please refer to Note 8 within the financial statements section of this document.
Item 1A.
Risk Factors
The risk factors disclosed in “Item 1A. Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2017 are hereby incorporated by reference.
Item 5.
Other Information
None.

30

Item 6.
Exhibits
(a) Exhibits.
Exhibit Number 
Description
2.1+
2.2
2.3
2.4
3.1
3.2
3.3
3.4
3.5
3.6
3.7
3.8
4.1
4.2
31.1
31.2
32.1
32.2
101.INS
XBRL Instance Document
101.SCH
XBRL Taxonomy Extension Schema Document
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
XBRL Taxonomy Extension Labels Linkbase Document
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document
+
Certain schedules attached to the Home Solutions Agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company will furnish the omitted schedules to the Securities and Exchange Commission upon request by the Commission.

SIGNATURES


31

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on November 6, 2018.


                                                          BIOSCRIP INC.
 
                                                         /s/  Stephen Deitsch
                                                          Stephen Deitsch
Chief Financial Officer and Treasurer (Principal Financial Officer and Duly Authorized Officer)


32
 EX-31.1 2 bios-ex311x20180930x10q1.htm EXHIBIT 31.1 Exhibit


EXHIBIT 31.1 

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Daniel E. Greenleaf, certify that:
1.     I have reviewed this Quarterly Report on Form 10-Q of BioScrip, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))for the registrant and have:
(a) 
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) 
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) 
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) 
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) 
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) 
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: November 6, 2018


/s/ Daniel E. Greenleaf __________________________
Daniel E. Greenleaf, President, Chief Executive Officer
and Principal Executive Officer



 EX-31.2 3 bios-ex312x20180930x10q1.htm EXHIBIT 31.2 Exhibit


EXHIBIT 31.2

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Stephen M. Deitsch, certify that:
1.     I have reviewed this Quarterly Report on Form 10-Q of BioScrip, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))for the registrant and have:
(a) 
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) 
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) 
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) 
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) 
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) 
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 6, 2018


/s/ Stephen M. Deitsch
Stephen M. Deitsch, Chief Financial Officer,
Treasurer and Principal Financial Officer



 EX-32.1 4 bios-ex321x20180930x10q1.htm EXHIBIT 32.1 Exhibit


EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of BioScrip, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Daniel E. Greenleaf, Chief Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1)     The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 6, 2018



/s/ Daniel E. Greenleaf
Daniel E. Greenleaf, President, Chief Executive Officer
and Principal Executive Officer
    



 EX-32.2 5 bios-ex322x20180930x10q1.htm EXHIBIT 32.2 Exhibit


EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of BioScrip, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stephen M. Deitsch, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1)     The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 6, 2018



/s/ Stephen M. Deitsch _________________
Stephen M. Deitsch, Chief Financial Officer,
Treasurer and Principal Financial Officer
   





 EX-101.INS 6 bios-20180930.xml XBRL INSTANCE DOCUMENT 0001014739 2018-01-01 2018-09-30 0001014739 2018-11-06 0001014739 2017-12-31 0001014739 2018-09-30 0001014739 us-gaap:SeriesCPreferredStockMember 2018-09-30 0001014739 us-gaap:SeriesCPreferredStockMember 2017-12-31 0001014739 us-gaap:SeriesAPreferredStockMember 2018-09-30 0001014739 us-gaap:SeriesAPreferredStockMember 2017-12-31 0001014739 2018-07-01 2018-09-30 0001014739 2017-01-01 2017-09-30 0001014739 2017-07-01 2017-09-30 0001014739 2016-12-31 0001014739 2017-09-30 0001014739 bios:AccountingForSuspenseAndClearingAccountsMember 2017-07-01 2017-09-30 0001014739 srt:ScenarioPreviouslyReportedMember bios:AccountingForSuspenseAndClearingAccountsMember 2017-07-01 2017-09-30 0001014739 srt:ScenarioPreviouslyReportedMember bios:AccountingForSuspenseAndClearingAccountsMember 2017-01-01 2017-09-30 0001014739 srt:RestatementAdjustmentMember bios:AccountingForSuspenseAndClearingAccountsMember 2017-01-01 2017-09-30 0001014739 bios:AccountingForSuspenseAndClearingAccountsMember 2017-01-01 2017-09-30 0001014739 srt:RestatementAdjustmentMember bios:AccountingForSuspenseAndClearingAccountsMember 2017-07-01 2017-09-30 0001014739 us-gaap:GovernmentSectorMember bios:FinancingReceivables.Greaterthan180DaysPastDueMember 2018-09-30 0001014739 bios:PatientMember 2018-09-30 0001014739 us-gaap:CommercialAndIndustrialSectorMember bios:FinancingReceivables.1to180DaysPastDueMember 2018-09-30 0001014739 bios:PatientMember bios:FinancingReceivables.1to180DaysPastDueMember 2018-09-30 0001014739 us-gaap:CommercialAndIndustrialSectorMember bios:FinancingReceivables.Greaterthan180DaysPastDueMember 2017-12-31 0001014739 us-gaap:CommercialAndIndustrialSectorMember 2018-09-30 0001014739 us-gaap:CommercialAndIndustrialSectorMember 2017-12-31 0001014739 us-gaap:GovernmentSectorMember bios:FinancingReceivables.1to180DaysPastDueMember 2018-09-30 0001014739 bios:FinancingReceivables.1to180DaysPastDueMember 2017-12-31 0001014739 bios:PatientMember bios:FinancingReceivables.Greaterthan180DaysPastDueMember 2017-12-31 0001014739 bios:PatientMember 2017-12-31 0001014739 bios:FinancingReceivables.Greaterthan180DaysPastDueMember 2018-09-30 0001014739 us-gaap:GovernmentSectorMember bios:FinancingReceivables.1to180DaysPastDueMember 2017-12-31 0001014739 us-gaap:GovernmentSectorMember 2018-09-30 0001014739 us-gaap:GovernmentSectorMember 2017-12-31 0001014739 us-gaap:CommercialAndIndustrialSectorMember bios:FinancingReceivables.1to180DaysPastDueMember 2017-12-31 0001014739 us-gaap:GovernmentSectorMember bios:FinancingReceivables.Greaterthan180DaysPastDueMember 2017-12-31 0001014739 bios:FinancingReceivables.1to180DaysPastDueMember 2018-09-30 0001014739 bios:PatientMember bios:FinancingReceivables.1to180DaysPastDueMember 2017-12-31 0001014739 us-gaap:CommercialAndIndustrialSectorMember bios:FinancingReceivables.Greaterthan180DaysPastDueMember 2018-09-30 0001014739 bios:FinancingReceivables.Greaterthan180DaysPastDueMember 2017-12-31 0001014739 bios:PatientMember bios:FinancingReceivables.Greaterthan180DaysPastDueMember 2018-09-30 0001014739 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-07-01 2018-09-30 0001014739 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-09-30 0001014739 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-09-30 0001014739 us-gaap:SalesRevenueNetMember us-gaap:RevenueFromRightsConcentrationRiskMember 2018-01-01 2018-09-30 0001014739 bios:CommercialCustomerMember 2018-07-01 2018-09-30 0001014739 bios:GovernmentCustomerMember 2018-01-01 2018-09-30 0001014739 bios:CommercialCustomerMember 2018-01-01 2018-09-30 0001014739 bios:GovernmentCustomerMember 2018-07-01 2018-09-30 0001014739 bios:PatientCustomerMember 2018-07-01 2018-09-30 0001014739 bios:PatientCustomerMember 2018-01-01 2018-09-30 0001014739 us-gaap:SeriesAPreferredStockMember 2018-01-01 2018-09-30 0001014739 us-gaap:SeriesCPreferredStockMember 2018-01-01 2018-09-30 0001014739 bios:A2017WarrantsMember us-gaap:CommonStockMember 2017-06-29 0001014739 bios:A2017WarrantsMember us-gaap:CommonStockMember 2017-06-29 2017-06-29 0001014739 bios:A2017WarrantsMember us-gaap:CommonStockMember 2018-09-30 0001014739 us-gaap:CapitalLeaseObligationsMember 2017-12-31 0001014739 bios:SecondLienNoteMaturingAugust152020Member 2018-09-30 0001014739 bios:SecondLienNoteMaturingAugust152020Member 2017-12-31 0001014739 bios:FirstLienNoteMaturingJune302022Member 2017-12-31 0001014739 bios:SeniorUnsecured8.875NotesMember 2018-09-30 0001014739 bios:SeniorUnsecured8.875NotesMember 2017-12-31 0001014739 bios:FirstLienNoteMaturingJune302022Member 2018-09-30 0001014739 us-gaap:CapitalLeaseObligationsMember 2018-09-30 0001014739 bios:SeniorUnsecured8.875NotesMember us-gaap:FairValueInputsLevel1Member 2018-09-30 0001014739 us-gaap:FairValueInputsLevel3Member 2018-09-30 0001014739 bios:SecondLienNoteMaturingAugust152020Member us-gaap:FairValueInputsLevel2Member 2018-09-30 0001014739 us-gaap:FairValueInputsLevel2Member 2018-09-30 0001014739 bios:SeniorUnsecured8.875NotesMember us-gaap:FairValueInputsLevel2Member 2018-09-30 0001014739 bios:SecondLienNoteMaturingAugust152020Member us-gaap:FairValueInputsLevel3Member 2018-09-30 0001014739 us-gaap:FairValueInputsLevel1Member 2018-09-30 0001014739 bios:SecondLienNoteMaturingAugust152020Member us-gaap:FairValueInputsLevel1Member 2018-09-30 0001014739 bios:FirstLienNoteMaturingJune302022Member us-gaap:FairValueInputsLevel1Member 2018-09-30 0001014739 bios:SeniorUnsecured8.875NotesMember us-gaap:FairValueInputsLevel3Member 2018-09-30 0001014739 bios:FirstLienNoteMaturingJune302022Member us-gaap:FairValueInputsLevel2Member 2018-09-30 0001014739 bios:FirstLienNoteMaturingJune302022Member us-gaap:FairValueInputsLevel3Member 2018-09-30 0001014739 bios:SecondLienDelayedDrawNotesMember us-gaap:SeniorNotesMember 2018-06-21 0001014739 bios:FirstLienNoteMaturingJune302022Member us-gaap:SeniorNotesMember 2018-01-01 2018-09-30 0001014739 bios:FirstLienNoteMaturingJune302022Member us-gaap:SeniorNotesMember us-gaap:BaseRateMember 2018-01-01 2018-09-30 0001014739 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2017-06-29 2017-06-29 0001014739 bios:FirstLienNoteMaturingJune302022Member us-gaap:SeniorNotesMember us-gaap:PrimeRateMember 2018-01-01 2018-09-30 0001014739 srt:MinimumMember bios:FirstLienNoteMaturingJune302022Member us-gaap:SeniorNotesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01 2018-09-30 0001014739 bios:FirstLienNoteMaturingJune302022Member us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:SeniorNotesMember 2018-01-01 2018-09-30 0001014739 bios:OptionThreeHalfCapitalizedInterestMember bios:SecondLienNoteMaturingAugust152020Member us-gaap:SeniorNotesMember 2018-01-01 2018-09-30 0001014739 bios:SecondLienNoteMaturingAugust152020Member us-gaap:DebtInstrumentRedemptionPeriodThreeMember us-gaap:SeniorNotesMember 2018-01-01 2018-09-30 0001014739 bios:OptionThreeMember bios:SecondLienNoteMaturingAugust152020Member us-gaap:SeniorNotesMember 2018-01-01 2018-09-30 0001014739 bios:OptionTwoMember bios:SecondLienNoteMaturingAugust152020Member us-gaap:SeniorNotesMember 2018-01-01 2018-09-30 0001014739 bios:SecondLienNoteMaturingAugust152020Member us-gaap:SeniorNotesMember 2018-01-01 2018-09-30 0001014739 bios:OptionThreeHalfCashMember bios:SecondLienNoteMaturingAugust152020Member us-gaap:SeniorNotesMember 2018-01-01 2018-09-30 0001014739 bios:SecondLienNoteMaturingAugust152020Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:SeniorNotesMember 2018-01-01 2018-09-30 0001014739 bios:FirstLienNoteMaturingJune302022Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:SeniorNotesMember 2018-01-01 2018-09-30 0001014739 bios:SeniorUnsecured8.875NotesMember 2014-02-11 0001014739 bios:SecondLienNoteMaturingAugust152020Member us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:SeniorNotesMember 2018-01-01 2018-09-30 0001014739 bios:SecondLienNoteMaturingAugust152020Member us-gaap:SeniorNotesMember 2017-06-29 0001014739 bios:FirstLienNoteMaturingJune302022Member us-gaap:SeniorNotesMember 2017-06-29 0001014739 bios:FirstLienNoteMaturingJune302022Member us-gaap:DebtInstrumentRedemptionPeriodThreeMember us-gaap:SeniorNotesMember 2018-01-01 2018-09-30 0001014739 bios:OptionOneMember srt:MinimumMember bios:SecondLienNoteMaturingAugust152020Member us-gaap:SeniorNotesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01 2018-09-30 0001014739 bios:SecondLienNoteMaturingAugust152020Member us-gaap:SeniorNotesMember 2018-07-01 2018-09-30 0001014739 bios:SecondLienNoteMaturingAugust152020Member us-gaap:SeniorNotesMember 2018-09-30 0001014739 bios:OptionOneMember bios:SecondLienNoteMaturingAugust152020Member us-gaap:SeniorNotesMember 2018-01-01 2018-09-30 0001014739 srt:MinimumMember bios:FirstLienNoteMaturingJune302022Member us-gaap:SeniorNotesMember us-gaap:BaseRateMember 2018-01-01 2018-09-30 0001014739 bios:FirstLienNoteMaturingJune302022Member us-gaap:SeniorNotesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01 2018-09-30 0001014739 bios:UnitedHealthcareMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-09-30 0001014739 bios:UnitedHealthcareMember us-gaap:CustomerConcentrationRiskMember 2017-07-01 2017-09-30 0001014739 us-gaap:DomesticCountryMember 2018-09-30 0001014739 us-gaap:StateAndLocalJurisdictionMember 2018-09-30 0001014739 bios:EquityIncentivePlan2018Member 2018-09-30 0001014739 us-gaap:StockOptionMember 2017-07-01 2017-09-30 0001014739 us-gaap:EmployeeStockMember 2018-09-30 0001014739 us-gaap:RestrictedStockMember 2018-01-01 2018-09-30 0001014739 bios:EquityIncentivePlan2018Member 2018-05-03 0001014739 us-gaap:EmployeeStockMember 2018-05-03 2018-05-03 0001014739 us-gaap:RestrictedStockMember 2018-07-01 2018-09-30 0001014739 us-gaap:EmployeeStockMember 2018-01-01 2018-09-30 0001014739 us-gaap:StockOptionMember 2018-01-01 2018-09-30 0001014739 us-gaap:EmployeeStockMember 2018-07-01 2018-09-30 0001014739 bios:MarketBasedCashAwardsMember 2017-01-01 2017-09-30 0001014739 us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 0001014739 us-gaap:StockOptionMember 2018-07-01 2018-09-30 0001014739 bios:MarketBasedCashAwardsMember 2018-01-01 2018-09-30 0001014739 us-gaap:RestrictedStockMember 2017-07-01 2017-09-30 0001014739 bios:MarketBasedCashAwardsMember 2018-07-01 2018-09-30 0001014739 us-gaap:StockOptionMember 2017-01-01 2017-09-30 0001014739 us-gaap:EmployeeStockMember 2017-07-01 2017-09-30 0001014739 us-gaap:EmployeeStockMember 2017-01-01 2017-09-30 xbrli:shares bios:segment xbrli:pure bios:state iso4217:USD xbrli:shares iso4217:USD bios:location 26118000 26204000 4037000 11407000 885000 4789000 4621000 1546000 0.0499 P10Y 522023000 0.00625 0.02 0.02 0.05 0.05 0.04 0 0.02 0.04 0 0.02 50000000 925000 925000 0 0 -652000 330000 1091000 -3075000 70 10800000 299000 7973000 false --12-31 Q3 2018 2018-09-30 10-Q 0001014739 128041101 false Accelerated Filer BioScrip, Inc. false 65963000 63901000 123434000 10204000 2577000 7627000 82546000 63767000 18779000 30684000 20602000 10082000 86946000 36488000 113628000 6712000 1922000 4790000 91333000 80508000 10825000 15583000 12555000 3028000 94985000 18643000 85522000 113628000 88298000 97788000 624762000 619989000 200000 100000 400000 100000 100000 100000 600000 800000 100000 100000 800000 300000 200000 100000 1800000 900000 37912000 0 42900000 37912000 0 4676000 6084000 7058000 21288000 5767000 18617000 603092000 579172000 186593000 171941000 246000 526000 52000 123000 2863000 1239000 1825000 0 39457000 18944000 9569000 37963000 44407000 23264000 28394000 -21143000 -6106000 -117000 2.00 0.0001 0.0001 250000000 250000000 127634012 128064145 127634012 128064145 13000 13000 0.181 0.210 0.01 132129000 435560000 115051000 344419000 -925000 -925000 0 0 -547000 -397000 50000 84000 378000 528000 50000 84000 0.0125 0.0925 0.05625 0.04625 0.1025 0.1125 0.005 0.01 0.06 0.07 0.01 113800000.0 200000000.0 200000000 100000000 10000000 0.08875 0.08875 5000000 515000 1523000 0 0 3656000 2692000 607000 1794000 52000 107000 92000 271000 52000 107000 1098000 990000 37100000 21288000 18617000 -0.12 -0.57 -0.09 -0.35 0 211224000 319731000 40436000 47120000 19114000 12030000 33000 -652000 10000 330000 0 -13453000 0 0 9405000 28325000 12478000 34084000 367198000 367198000 66563000 -613000 67176000 66563000 199048000 -2022000 201070000 199048000 65911000 71600000 180916000 197500000 -13058000 -654000 -12404000 -13058000 -61629000 -1538000 -60090000 -61628000 -8103000 -36212000 -12998000 -60232000 -8001000 -36021000 -0.12 -0.56 -0.09 -0.35 66000 179000 -113000 66000 -606000 447000 -1053000 -606000 -71000 -118000 0.00 -0.01 0.00 0.00 60000 1397000 102000 191000 4876000 22194000 1261000 7163000 -4307000 -20543000 -1680000 -7564000 38000 143000 419000 401000 378000 528000 102000 191000 327000 51000 -14716000 -2062000 -1868000 -108000 -3508000 -4438000 -8391000 -14939000 -2800000 -667000 -3033000 -6956000 -22257000 28106000 0 3800000 3800000 185000 13175000 13360000 14000 38635000 38649000 -13360000 -38649000 -14971000 -42171000 38454000 36735000 6706000 2268000 38044000 23105000 605765000 615509000 603092000 579172000 105130000 95995000 -1103000 -1103000 -1605000 -1228000 198324000 85694000 197363000 198801000 103571000 197927000 478866000 496770000 1722000 2076000 480588000 498846000 0 0 202512000 0 0 117219000 0 189500000 0 0.1999 44386000 8508000 -6570000 -9408000 -9422000 -20243000 -3316000 -20126000 -12992000 -475000 -12517000 -12992000 -62235000 -1091000 -61143000 -62234000 -8174000 -36330000 -15561000 -69670000 -11035000 -44602000 1 27 -144000 66345000 66201000 -497000 221128000 220631000 427000000 467100000 2116000 1836000 21769000 22744000 38143000 124755000 38216000 116378000 0 3800000 980000 0 6570000 9408000 0.115 0.115 2569000 7435000 2861000 8272000 0.0001 0.0001 5000000 5000000 0 0 0 0 0 0 18620000 11944000 23060000 0 15900000 20822000 0 294446000 10000000 563000 0 -100000 131000 26973000 25177000 6488000 19648000 0 5700000 0 16500000 85522000 113628000 792000 1623000 55863000 0 236770000 0 4950000 4320000 3791000 10881000 833000 4666000 -709511000 -745841000 198692000 0 198692000 198692000 634608000 0 634608000 634608000 180962000 139077000 39498000 2387000 186700000 525335000 431869000 88437000 5029000 541900000 1525000 3032000 16406939 1422842 13339067 3000000 827158 0.85 -84752000 -126688000 200000 7500000 100000 500000 2827000 79252000 3126000 87225000 2569000 7435000 2861000 8272000 2916000 84555000 3200000 3172000 92000000 92038000 0.0001 0.0001 0.0001 0.0001 825000 625000 825000 625000 21645 614177 21630 614177 21645 614177 21630 614177 5106 287248 16000 849000 21724000 21700000 0 21724000 0 127488000 122519000 127528000 127893000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These Unaudited Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements, including the notes thereto, and other information included in the Annual Report on Form 10-K of BioScrip, Inc. and its wholly-owned subsidiaries (the &#8220;Company&#8221;) for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Annual Report&#8221;) filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). These Unaudited Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information, and the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information furnished in these Unaudited Consolidated Financial Statements reflects all adjustments, including normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. Operating results for the interim periods presented require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes and are not necessarily indicative of the results that may be expected for the full year.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RESTRUCTURING, ACQUISITION, INTEGRATION, AND OTHER EXPENSES</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restructuring, acquisition, integration and other expenses include non-operating costs associated with restructuring, acquisition, and integration initiatives such as employee severance costs, certain legal and professional fees, training costs, redundant wage costs, impacts recorded from the change in contingent consideration obligations, and other costs related to contract terminations and closed branches/offices.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restructuring, acquisition, integration, and other expenses in the Unaudited Consolidated Statements of Operations for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;September&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September&#160;30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,881</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Acquisition and integration expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52</font></div></td><td style="vertical-align:bottom;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">246</font></div></td><td style="vertical-align:bottom;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">123</font></div></td><td style="vertical-align:bottom;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">526</font></div></td><td style="vertical-align:bottom;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total restructuring, acquisition, integration, and other expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">885</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">4,037</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">4,789</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">11,407</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BASIS OF PRESENTATION</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a national provider of infusion solutions with nearly </font><font style="font-family:inherit;font-size:10pt;">70</font><font style="font-family:inherit;font-size:10pt;"> service locations around the U.S. We partner with physicians, hospital systems, skilled nursing facilities, and healthcare payors to provide patients with access to post-acute care services. We are committed to bringing customer-focused healthcare infusion therapy services into the home or alternate site setting. By collaborating with the full spectrum of healthcare professionals and the patient, we aim to provide cost-effective care that is driven by clinical excellence, customer service and values that promote positive outcomes and an enhanced quality of life for those whom we serve.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment, Infusion Services, and accordingly, we do not present disaggregated segment information.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These Unaudited Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements, including the notes thereto, and other information included in the Annual Report on Form 10-K of BioScrip, Inc. and its wholly-owned subsidiaries (the &#8220;Company&#8221;) for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Annual Report&#8221;) filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). These Unaudited Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information, and the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information furnished in these Unaudited Consolidated Financial Statements reflects all adjustments, including normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. Operating results for the interim periods presented require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes and are not necessarily indicative of the results that may be expected for the full year.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Unaudited Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior period financial statement amounts have been reclassified to conform to current period presentation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Immaterial Error Correction</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the fourth quarter of 2017, the Company determined that certain prior period balances contained errors, predominantly due to a failure to appropriately account for and resolve transactions specific to suspense and clearing accounts. Management evaluated the materiality of the errors quantitatively and qualitatively, and concluded that they were not material to the financial statements of any period presented, but has elected to correct them in the accompanying prior period consolidated financial statements. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables set forth the effect these corrections had on the Company&#8217;s unaudited consolidated statements of operations for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.703125%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Previously Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Corrections</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Previously Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Corrections</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revised</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Net revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">198,692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">198,692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">634,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">634,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Gross profit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,176</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(613</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,563</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,070</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,022</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,048</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Total Operating Expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221,128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(497</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220,631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,175</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,360</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,635</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,649</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Loss from continuing operations, net of income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,058</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60,090</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,538</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61,628</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Income (loss) from discontinued operations, net of income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(113</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">179</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,053</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">447</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(606</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(475</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,992</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(62,234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain amounts disclosed in the accompanying notes to the financial statements have been revised to reflect the corrections.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents and Restricted Cash</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Highly liquid investments with a maturity of three months or less when purchased are classified as cash equivalents. Restricted cash consists of cash balances held by financial institutions as collateral for letters of credit. These balances are reclassified to cash and cash equivalents when the underlying obligation is satisfied, or in accordance with the governing agreement. Restricted cash balances expected to become unrestricted during the next twelve months are recorded as current assets.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">COMMITMENTS AND CONTINGENCIES</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is a party to various legal, regulatory and governmental proceedings incidental to its business. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental matters, including the matters described herein, will have a material adverse effect on the consolidated financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in pending legal, regulatory and governmental matters, some of which are beyond the Company&#8217;s control, and the indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could be material to the Company&#8217;s results of operations or cash flows for any particular reporting period.&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to all legal, regulatory and governmental proceedings, the Company considers the likelihood of a negative outcome. If the Company determines the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, the Company records an accrual for the estimated loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and the Company is able to determine an estimate of the possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, the Company discloses the estimate of the possible loss or range of loss. However, the Company is unable to estimate a possible loss or range of loss in some instances based on the significant uncertainties involved in, and/or the preliminary nature of, certain legal, regulatory and governmental matters.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 18, 2017, a commercial payor of the Company sent a letter that claimed an alleged breach of the Company&#8217;s obligation under its provider contracts.&#160; No legal proceeding has been filed. The Company is not able to estimate the amount of any possible loss.&#160; The Company believes this claim is without merit and intends to vigorously defend against this claim if any such legal proceeding is commenced.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Government Regulation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various federal and state laws and regulations affecting the healthcare industry impact or may in the future impact the Company&#8217;s current and planned operations, including, without limitation, federal and state laws and regulations prohibiting kickbacks in connection with healthcare services, prohibiting certain conduct deemed to be anti-competitive (antitrust laws) and restricting drug distribution. Other laws and regulations that may affect our business include, but are not limited to, consumer protection, insurance, licensure, and privacy. There can be no assurance the Company will be able to obtain or maintain any of the regulatory approvals that may be required to operate its business, and the failure to do so could have a material effect on the Company&#8217;s financial statements. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, the Company responds to investigatory subpoenas and requests for information from governmental agencies and private parties. The Company cannot predict with certainty what the outcome of any of the foregoing might be. While the Company believes it is in substantial compliance with all existing laws and regulations material to the operation of its business, such laws and regulations are often uncertain in their application to our business practices as they evolve and are subject to rapid change. As controversies continue to arise in the healthcare industry, federal and state regulation and enforcement priorities in this area can be expected to increase, the impact of which cannot be predicted. There can be no assurance that the Company will not be subject to scrutiny or challenge under one or more regulations or that any such challenge would not be successful. Any such challenge, whether or not successful, could have a material effect upon the Company&#8217;s Consolidated Financial Statements. A violation of the federal Anti-Kickback Statute, for example, may result in substantial criminal and civil penalties, as well as suspension or exclusion from the Medicare and Medicaid programs. Moreover, the costs and expenses associated with defending these actions, even where successful, can be significant.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONCENTRATION OF RISK</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Customer and Credit Concentration Risk</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company provides trade credit to its customers in the normal course of business. No single payor accounted for more than 10.0% of revenue during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. One commercial payor, United Healthcare, accounted for approximately </font><font style="font-family:inherit;font-size:10pt;">18.1%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">21.0%</font><font style="font-family:inherit;font-size:10pt;"> of revenue during the </font><font style="font-family:inherit;font-size:10pt;">three and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Unaudited Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DEBT</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s debt consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.51219512195122%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September&#160;30,</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">First Lien Note Facility, net of unamortized discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">198,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">198,324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Second Lien Note Facility, net of unamortized discount</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">103,571</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85,694</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2021 Notes, net of unamortized discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">197,927</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">197,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Capital leases</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,239</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,863</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: Deferred financing costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,692</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,656</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total Debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">498,846</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">480,588</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: Current portion of long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,076</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,722</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Long-term debt, net of current portion</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">496,770</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">478,866</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Debt Facilities</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 29, 2017 (the &#8220;Closing Date&#8221;), the Company entered into (i) a first lien note purchase agreement (the &#8220;First Lien Note Facility&#8221;), among the Company, which is the issuer under the agreement, the financial institutions and note purchasers from time to time party to the agreement (the &#8220;First Lien Note Purchasers&#8221;), and Wells Fargo Bank, National Association, in its capacity as collateral agent for itself and the First Lien Note Purchasers (the &#8220;First Lien Collateral Agent&#8221;), pursuant to which the Company issued first lien senior secured notes in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$200.0 million</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;First Lien Notes&#8221;); and (ii) a second lien note purchase agreement (the &#8220;Second Lien Note Facility&#8221; and, together with the First Lien Note Facility, the &#8220;Notes Facilities&#8221;) among the Company, which is the issuer under the agreement, the financial institutions and note purchasers from time to time party to the agreement (the &#8220;Second Lien Note Purchasers&#8221;), and Wells Fargo Bank, National Association, in its capacity as collateral agent for itself and the Second Lien Note Purchasers (the &#8220;Second Lien Collateral Agent&#8221; and, together with the First Lien Collateral Agent, the &#8220;Collateral Agent&#8221;), pursuant to which the Company (a) issued second lien senior secured notes in an aggregate initial principal amount of </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Initial Second Lien Notes&#8221;) and (b) had the ability to draw upon the Second Lien Note Facility and issue second lien delayed draw senior secured notes, which was exercised on June 21, 2018, in an aggregate initial principal amount of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">, representing the maximum borrowings allowed on this facility (the &#8220;Second Lien Delayed Draw Notes&#8221; and, together with the Initial Second Lien Notes, the &#8220;Second Lien Notes&#8221;; the Second Lien Notes, together with the First Lien Notes, the &#8220;Notes&#8221;). Funds managed by Ares are acting as lead purchasers for the Notes Facilities.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company used the proceeds of the sale of the First Lien Notes and the Initial Second Lien Notes to repay in full all amounts outstanding under the Prior Credit Agreements and extinguished the liability. Each of the Prior Credit Agreements was terminated following such repayment. The Company used the remaining proceeds of </font><font style="font-family:inherit;font-size:10pt;">$15.9 million</font><font style="font-family:inherit;font-size:10pt;">, net of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> in issuance costs, from the Notes Facilities and the Second Quarter 2017 Private Placement for working capital and general corporate purposes.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The First Lien Notes accrue interest, payable monthly in arrears, at a floating rate or rates equal to, at the option of the Company, (i) the base rate (defined as the highest of the Federal Funds Rate plus </font><font style="font-family:inherit;font-size:10pt;">0.5%</font><font style="font-family:inherit;font-size:10pt;"> per annum, the Prime Rate as published by The Wall Street Journal and the one-month London Interbank Offered Rate (&#8220;LIBOR&#8221;) (subject to a </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;"> floor) plus </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;">), or (ii) the one-month LIBOR rate (subject to a </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;"> floor), plus a margin of </font><font style="font-family:inherit;font-size:10pt;">6.0%</font><font style="font-family:inherit;font-size:10pt;"> if the base rate is selected or </font><font style="font-family:inherit;font-size:10pt;">7.0%</font><font style="font-family:inherit;font-size:10pt;"> if the LIBOR Option is selected. The First Lien Notes mature on August 15, 2020, provided that if the Company&#8217;s existing </font><font style="font-family:inherit;font-size:10pt;">8.875%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes due 2021 (the &#8220;2021 Notes&#8221;) are refinanced prior to August 15, 2020, then the scheduled maturity date of the First Lien Notes shall be June 30, 2022.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The First Lien Notes will amortize in equal quarterly installments equal to </font><font style="font-family:inherit;font-size:10pt;">0.625%</font><font style="font-family:inherit;font-size:10pt;"> of the aggregate principal amount of the First Lien Note Facility, commencing on September 30, 2019, and on the last day of each third month thereafter, with the balance payable at maturity. The First Lien Notes are pre-payable at the Company&#8217;s option at specified premiums to the principal amount that will decline over the term of the First Lien Note Facility. If the First Lien Notes are prepaid prior to the second anniversary of the Closing Date, the Company will be required to pay a make-whole premium based on the present value (using a discount rate based on the specified treasury rate plus </font><font style="font-family:inherit;font-size:10pt;">50</font><font style="font-family:inherit;font-size:10pt;"> basis points) of all remaining interest payments on the First Lien Notes being prepaid prior to the second anniversary of the Closing Date, plus </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;"> of the principal amount of First Lien Notes being prepaid. On or after the second anniversary of the Closing Date, the prepayment premium is </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;">, which declines to </font><font style="font-family:inherit;font-size:10pt;">2.0%</font><font style="font-family:inherit;font-size:10pt;"> on or after the third anniversary of the Closing Date, and declines to </font><font style="font-family:inherit;font-size:10pt;">0.0%</font><font style="font-family:inherit;font-size:10pt;"> on or after the fourth anniversary of the Closing Date. At any time, the Company may pre-pay up to </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal amount of the First Lien Notes from internally generated cash without incurring any make-whole or prepayment premium. The occurrence of certain events of default may increase the applicable rate of interest by </font><font style="font-family:inherit;font-size:10pt;">2.0%</font><font style="font-family:inherit;font-size:10pt;"> and could result in the acceleration of the Company&#8217;s obligations under the First Lien Note Facility prior to stated maturity and an obligation of the Company to pay the full amount of its obligations under the First Lien Note Facility.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The First Lien Note Facility contains customary events of default that include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material indebtedness and events constituting a change of control. In addition, the obligations under the First Lien Note Facility will be guaranteed by joint and several guarantees from the Company&#8217;s subsidiaries.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the First Lien Note Facility, the Company, its subsidiaries and the First Lien Collateral Agent entered into a First Lien Guaranty and Security Agreement, dated as of June 29, 2017 (the &#8220;First Lien Guaranty and Security Agreement&#8221;). Pursuant to the First Lien Guaranty and Security Agreement, the obligations under the First Lien Notes will be secured by first priority liens on, and security interests in, substantially all of the assets of the Company and its subsidiaries.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Second Lien Notes accrue interest, payable monthly in arrears, at a floating rate or rates equal to, at the option of the Company, (i) one-month LIBOR (subject to a </font><font style="font-family:inherit;font-size:10pt;">1.25%</font><font style="font-family:inherit;font-size:10pt;"> floor) plus </font><font style="font-family:inherit;font-size:10pt;">9.25%</font><font style="font-family:inherit;font-size:10pt;"> per annum in cash, (ii) one-month LIBOR (subject to a </font><font style="font-family:inherit;font-size:10pt;">1.25%</font><font style="font-family:inherit;font-size:10pt;"> floor) plus </font><font style="font-family:inherit;font-size:10pt;">11.25%</font><font style="font-family:inherit;font-size:10pt;"> per annum, which amount will be capitalized on each interest payment date, or (iii) one-month LIBOR (subject to a </font><font style="font-family:inherit;font-size:10pt;">1.25%</font><font style="font-family:inherit;font-size:10pt;"> floor) plus </font><font style="font-family:inherit;font-size:10pt;">10.25%</font><font style="font-family:inherit;font-size:10pt;"> per annum, of which one-half LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">4.625%</font><font style="font-family:inherit;font-size:10pt;"> per annum will be payable in cash and one-half LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">5.625%</font><font style="font-family:inherit;font-size:10pt;"> per annum will be capitalized on each interest payment date, provided that, in each case, if any permitted refinancing indebtedness with which the 2021 Notes are refinanced requires or permits the payment of cash interest, all of the interest on the Second Lien Notes shall be paid in cash. During the third quarter, </font><font style="font-family:inherit;font-size:10pt;">$3.8 million</font><font style="font-family:inherit;font-size:10pt;"> of interest was capitalized to the Second Lien Notes, increasing the principal amount to </font><font style="font-family:inherit;font-size:10pt;">$113.8 million</font><font style="font-family:inherit;font-size:10pt;"> as of September 30, 2018. The Second Lien Notes mature on August 15, 2020, provided that if the 2021 Notes are refinanced prior to August 15, 2020, then the scheduled maturity date of the Second Lien Notes shall be June 30, 2022.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Second Lien Note Facility, the Company also issued warrants (the &#8220;2017 Warrants&#8221;) to the purchasers of the Second Lien Notes pursuant to a Warrant Purchase Agreement dated as of June 29, 2017 (the &#8220;Warrant Purchase Agreement&#8221;). The 2017 Warrants entitle the purchasers of the Warrants to purchase shares of Common Stock, representing at the time of any exercise of the 2017 Warrants an equivalent number of shares equal to </font><font style="font-family:inherit;font-size:10pt;">4.99%</font><font style="font-family:inherit;font-size:10pt;"> of the Common Stock of the Company on a fully diluted basis, subject to the terms of the Warrant Agreement governing the Warrants, dated as of June 29, 2017 (the &#8220;Warrant Agreement&#8221;). The 2017 Warrants, considered a derivative and subject to remeasurement at each reporting period, are reflected in other non-current liabilities at a fair value of </font><font style="font-family:inherit;font-size:10pt;">$21.7 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Second Lien Notes are not subject to scheduled amortization installments. The Second Lien Notes are pre-payable at the Company&#8217;s option at specified premiums to the principal amount that will decline over the term of the Second Lien Note Facility. If the Second Lien Notes are prepaid prior to the third anniversary of the Closing Date, the Company will need to pay a make-whole premium based on the present value (using a discount rate based on the specified treasury rate plus </font><font style="font-family:inherit;font-size:10pt;">50</font><font style="font-family:inherit;font-size:10pt;"> basis points) of all remaining interest payments on the Second Lien Notes being prepaid prior to the third anniversary of the Closing Date, plus </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;"> of the principal amount of Second Lien Notes being prepaid. On or after the third anniversary of the Closing Date, the prepayment premium is </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;">, which declines to </font><font style="font-family:inherit;font-size:10pt;">2.0%</font><font style="font-family:inherit;font-size:10pt;"> on or after the fourth anniversary of the Closing Date, and declines to </font><font style="font-family:inherit;font-size:10pt;">0.0%</font><font style="font-family:inherit;font-size:10pt;"> on or after the fifth anniversary of the Closing Date. The occurrence of certain events of default may increase the applicable rate of interest by </font><font style="font-family:inherit;font-size:10pt;">2.0%</font><font style="font-family:inherit;font-size:10pt;"> and could result in the acceleration of the Company&#8217;s obligations under the Second Lien Note Facility prior to stated maturity and an obligation of the Company to pay the full amount of its obligations under the Second Lien Note Facility.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Second Lien Note Facility contains customary events of default that include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material indebtedness and events constituting a change of control. In addition, the obligations under the Second Lien Note Facility will be guaranteed by joint and several guarantees from the Company&#8217;s subsidiaries.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Second Lien Note Facility, the Company, its subsidiaries and the Second Lien Collateral Agent entered into a Second Lien Guaranty and Security Agreement, dated as of June 29, 2017 (the &#8220;Second Lien Guaranty and Security Agreement&#8221;). Pursuant to the Second Lien Guaranty and Security Agreement, the obligations under the Second Lien Notes will be secured by second priority liens on, and security interests in, substantially all of the assets of the Company and its subsidies.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the First Lien Note Facility and the Second Lien Note Facility, the Company, the First Lien Collateral Agent and the Second Lien Collateral Agent, entered into an intercreditor agreement containing customary provisions to, among other things, subordinate the lien priority of the liens granted under the Second Lien Note Facility to the liens granted under the First Lien Note Facility.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2021 Notes</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 11, 2014, the Company issued </font><font style="font-family:inherit;font-size:10pt;">$200.0 million</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal amount of the 2021 Notes. The 2021 Notes are senior unsecured obligations of the Company and are fully and unconditionally guaranteed by all existing and future subsidiaries of the Company.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest on the 2021 Notes accrues at a fixed rate of </font><font style="font-family:inherit;font-size:10pt;">8.875%</font><font style="font-family:inherit;font-size:10pt;"> per annum and is payable in cash semi-annually on February 15 and August 15 of each year. The debt discount of </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> at issuance is being amortized as interest expense through maturity which will result in the accretion over time of the outstanding debt balance to the principal amount. The 2021 Notes are the Company&#8217;s senior unsecured obligations and rank equally in right of payment with all of its other existing and future senior unsecured indebtedness and senior in right of payment to all of its existing and future subordinated indebtedness.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2021 Notes are guaranteed on a full, joint and several basis by each of the Company&#8217;s existing and future domestic restricted subsidiaries that is a borrower under any of the Company&#8217;s credit facilities or that guarantees any of the Company&#8217;s debt or that of any of its restricted subsidiaries, in each case incurred under the Company&#8217;s credit facilities. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company does not have any independent assets or operations, and as a result, its direct and indirect subsidiaries (other than minor subsidiaries), each being 100% owned by the Company, are fully and unconditionally, jointly and severally, providing guarantees on a senior unsecured basis to the 2021 Notes.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following details our financial instruments where the carrying value and the fair value differ (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.95121951219512%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Financial Instrument</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Carrying Value as of September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Markets for Identical Item (Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Significant Other Observable Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Significant Unobservable Inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">First Lien Note Facility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">198,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">202,512</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Second Lien Note Facility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">103,571</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">117,219</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017 Warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2021 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">197,927</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">189,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">522,023</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">211,224</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">319,731</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value hierarchy for disclosure of fair value measurements is as follows:</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Level 1</font><font style="font-family:inherit;font-size:10pt;">:&#160; Quoted prices (unadjusted) in active markets for identical assets or liabilities.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Level 2</font><font style="font-family:inherit;font-size:10pt;">:&#160; Quoted prices, other than quoted prices included in Level 1, which are observable for the assets or liabilities, either directly or indirectly.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Level 3</font><font style="font-family:inherit;font-size:10pt;">:&#160; Inputs that are unobservable for the assets or liabilities. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets with carrying values approximating fair value include cash and cash equivalents and accounts receivable. Financial liabilities with carrying values approximating fair value include accounts payable and capital leases. The carrying value of these financial assets and liabilities approximates fair value due to their short maturities.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents our revenues at amounts initially recognized for each associated payor class for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> (in millions). Sales and usage-based taxes are excluded from revenues.</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:416px;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:184px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:98px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:98px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September&#160;30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;Commercial</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,077</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">431,869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Government</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,498</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;Patient</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Total Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180,962</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">525,335</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STOCK-BASED COMPENSATION</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">BioScrip Equity Incentive Plans</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;), approved at the annual meeting by the stockholders on May 3, 2018, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights (&#8220;SARs&#8221;), restricted stock units, stock grants, and performance units to key employees and directors. The 2018 Plan is administered by the Company&#8217;s Management Development and Compensation Committee (the &#8220;Compensation Committee&#8221;), a standing committee of the Board of Directors.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A total of </font><font style="font-family:inherit;font-size:10pt;">16,406,939</font><font style="font-family:inherit;font-size:10pt;"> shares of stock are authorized for issuance under the 2018 Plan, to include shares that remained available for grant under the 2008 Plan as of the effective date of the 2018 Plan. The authorized shares were reduced by all shares granted under the 2008 Plan after December 31, 2017 in accordance with the terms of the 2018 Plan. No key employee in any calendar year will be granted more than </font><font style="font-family:inherit;font-size:10pt;">3,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of Stock with respect to (i) Options to purchase shares of Stock, (ii) Stock Appreciation Rights (based on the appreciation with respect to shares of Stock); and (iii) Stock Grants and Restricted Stock Units that are intended to comply with the requirements of Section 162(m) of the Code.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">13,339,067</font><font style="font-family:inherit;font-size:10pt;"> shares remain available for grant under the 2018 Plan.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized compensation expense related to stock options of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">three months ended September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September&#160;30, 2018 and 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> of compensation expense related to restricted stock awards during the </font><font style="font-family:inherit;font-size:10pt;">three months ended September&#160;30, 2018 and 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> of compensation expense during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September&#160;30, 2018 and 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Appreciation Rights and Market Based Cash Awards</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized nominal amounts of compensation expense related to stock appreciation rights awards during the </font><font style="font-family:inherit;font-size:10pt;">three months ended September&#160;30, 2018 and 2017</font><font style="font-family:inherit;font-size:10pt;"> and the&#160;</font><font style="font-family:inherit;font-size:10pt;">nine months ended September&#160;30, 2018 and 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized&#160;</font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and a nominal amount of compensation expense related to market based cash awards during the </font><font style="font-family:inherit;font-size:10pt;">three months ended September&#160;30, 2018 and 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively, and&#160;</font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> of compensation expense during&#160;</font><font style="font-family:inherit;font-size:10pt;">nine months ended September&#160;30, 2018 and 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 3, 2018, the Company&#8217;s stockholders approved an amendment to the BioScrip, Inc. Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP provides all eligible employees, as defined under the ESPP, the opportunity to purchase up to a maximum number of shares of Common Stock of the Company as determined by the Compensation Committee. Participants in the ESPP may acquire the Common Stock at a cost of </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> of the lower of the fair market value on the first or last day of the quarterly offering period. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">1,422,842</font><font style="font-family:inherit;font-size:10pt;"> shares remained available for grant under the ESPP. Since inception, the ESPP&#8217;s third-party service provider has purchased </font><font style="font-family:inherit;font-size:10pt;">827,158</font><font style="font-family:inherit;font-size:10pt;"> shares on the open market and delivered these shares to the Company&#8217;s employees pursuant to the ESPP. During the </font><font style="font-family:inherit;font-size:10pt;">three months ended September&#160;30, 2018 and 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company incurred less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> of expense. During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September&#160;30, 2018 and 2017</font><font style="font-family:inherit;font-size:10pt;">, the company incurred </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> of expense related to the ESPP.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LOSS PER SHARE</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company presents basic and diluted loss per share for its common stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.0001</font><font style="font-family:inherit;font-size:10pt;"> per share (&#8220;Common Stock&#8221;). Basic loss per share is calculated by dividing the net loss attributable to common stockholders of the Company by the weighted average number of shares of Common Stock outstanding during the period. Diluted loss per share is determined by adjusting the profit or loss attributable to stockholders and the weighted average number of shares of Common Stock outstanding adjusted for the effects of all dilutive potential common shares comprised of options granted, unvested restricted stock, stock appreciation rights, warrants and Series A and Series C Preferred Stock (as defined below). Potential Common Stock equivalents that have been issued by the Company related to outstanding stock options, unvested restricted stock and warrants are determined using the treasury stock method, while potential common shares related to Series A and Series C Preferred Stock are determined using the &#8220;if converted&#8221; method.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's Series A Convertible Preferred Stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.0001</font><font style="font-family:inherit;font-size:10pt;"> per share (the &#8220;Series A Preferred Stock&#8221;), and Series C Convertible Preferred Stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.0001</font><font style="font-family:inherit;font-size:10pt;"> per share (the &#8220;Series C Preferred Stock&#8221; and, together with the Series A Preferred Stock, the &#8220;Preferred Stock&#8221;), is considered a participating security, which means the security may participate in undistributed earnings with Common Stock. The holders of the Preferred Stock would be entitled to share in dividends, on an as-converted basis, if the holders of Common Stock were to receive dividends. The Company is required to use the two-class method when computing loss per share when it has a security that qualifies as a participating security. The two-class method is an earnings allocation formula that determines loss per share for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. In determining the amount of net earnings to allocate to common stockholders, earnings are allocated to both common and participating securities based on their respective weighted-average shares outstanding during the period. Diluted loss per share for the Company&#8217;s Common Stock is computed using the more dilutive of the two-class method or the if-converted method.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted loss per common share (in thousands, except for per share amounts):</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;September&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September&#160;30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss from continuing operations, net of income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,103</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13,058</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(36,212</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(61,629</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Income (Loss) from discontinued operations, net of income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(71</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">66</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(118</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(606</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(8,174</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(12,992</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(36,330</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(62,235</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dividends on preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,569</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,272</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(11,035</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(15,561</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(44,602</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(69,670</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Denominator - Basic and Diluted: </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted average common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">127,528</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">127,488</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">127,893</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">122,519</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Loss per Common Share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss from continuing operations, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.09</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.56</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss from discontinued operations, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Loss per common share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(0.09</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(0.12</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(0.35</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(0.57</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The loss attributable to common stockholders is used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. Accordingly, the computation of diluted shares for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30,</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> excludes the effect of shares that would be issued in connection with the PIPE Transaction, the Rights Offering, 2017 Warrants (see Note 5 - Stockholders&#8217; Deficit), stock options, and restricted stock awards, as their inclusion would be anti-dilutive to loss attributable to common stockholders.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value hierarchy for disclosure of fair value measurements is as follows:</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Level 1</font><font style="font-family:inherit;font-size:10pt;">:&#160; Quoted prices (unadjusted) in active markets for identical assets or liabilities.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Level 2</font><font style="font-family:inherit;font-size:10pt;">:&#160; Quoted prices, other than quoted prices included in Level 1, which are observable for the assets or liabilities, either directly or indirectly.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Level 3</font><font style="font-family:inherit;font-size:10pt;">:&#160; Inputs that are unobservable for the assets or liabilities. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets with carrying values approximating fair value include cash and cash equivalents and accounts receivable. Financial liabilities with carrying values approximating fair value include accounts payable and capital leases. The carrying value of these financial assets and liabilities approximates fair value due to their short maturities.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INCOME TAXES</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s federal and state income tax provision from continuing operations for the </font><font style="font-family:inherit;font-size:10pt;">three months and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> is summarized in the following table (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;September&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September&#160;30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Current</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(925</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(925</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">528</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">50</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(547</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">84</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(397</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Deferred</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Federal</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">515</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,523</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">271</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total deferred</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">52</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">607</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">107</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">1,794</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">102</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">60</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">191</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">1,397</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s reconciliation of the statutory rate from continuing operations to the effective income tax rate for the </font><font style="font-family:inherit;font-size:10pt;">three months and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> is summarized as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;September&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September&#160;30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Tax benefit at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,680</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(20,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">State tax expense, net of federal taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">102</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">378</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">191</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">528</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Alternative Minimum Tax receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Valuation allowance changes affecting income tax provision</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,261</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,876</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,163</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22,194</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Permanent items</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">401</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">102</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">60</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">191</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">1,397</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the President of the United States signed into law the Tax Cuts and Jobs Act of 2017 or U.S. Federal Tax Reform (the &#8220;Reform&#8221;). The enactment included broad tax changes that are applicable to BioScrip, Inc. Most notably, the Reform decreased the U.S. corporate income tax rate from a high of 35% to a flat 21% rate effective January 1, 2018. As a result, the Company has revalued its ending net deferred tax assets as of December 31, 2017. At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had Federal net operating loss (&#8220;NOL&#8221;) carry forwards of approximately </font><font style="font-family:inherit;font-size:10pt;">$427.0 million</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">$10.8 million</font><font style="font-family:inherit;font-size:10pt;"> is subject to an annual limitation, which will begin expiring in 2026 and later. The Company also has a carryforward of approximately </font><font style="font-family:inherit;font-size:10pt;">$37.1 million</font><font style="font-family:inherit;font-size:10pt;"> related to the interest expense limitation, which is not subject to an expiration period. The Company has post-apportioned state NOL carry forwards of approximately </font><font style="font-family:inherit;font-size:10pt;">$467.1 million</font><font style="font-family:inherit;font-size:10pt;">, the majority of which will begin expiring in 2018 and later.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-15 &#8212; Internal Use Software. ASU 2018-15 aligns the requirements for capitalization of implementation costs related to hosted software with the existing internal-use software guidance. The effective date for ASU 2018-15 is for annual and interim periods beginning after December 15, 2019. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13&#8212; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework&#8212; Changes to the Disclosure Requirements for Fair Value Measurements</font><font style="font-family:inherit;font-size:10pt;">. ASU 2018-13 modifies fair value measurement disclosure requirements. The effective date for ASU 2018-13 is for annual and interim periods beginning after December 15, 2019. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s disclosures to the consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09&#8212;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:inherit;font-size:10pt;">. The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The FASB delayed the effective date to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. The Company did not elect early adoption and applied the modified retrospective approach upon adoption which results in application of the new guidance only to contracts that are not completed at the adoption date and does not require adjustment of prior reporting periods. Assessment of the new guidance did not result in an opening retained earnings adjustment, but did result in the adjustment of accounts receivable as the allowance for doubtful accounts was eliminated upon implementation. Pursuant to the requirements of Topic 606, the transaction price to be recognized as revenue is estimated based upon the amount of cash ultimately expected to be collected. Therefore, amounts expected to be written off are reflected in the amount of revenue recognized upon fulfillment of the performance obligation. The new standard resulted in the recognition of amounts previously reported as bad debt expense as a reduction to revenue upon implementation; see Note 3 - Revenue.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, the FASB issued ASU 2017-11&#8212;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Earnings Per Share (Topic 260), Distinguishing Liabilities From Equity (Topic 480)</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</font><font style="font-family:inherit;font-size:10pt;">. ASU 2017-11 eliminates the requirement that a down round feature precludes equity classification when assessing whether an instrument is indexed to an entity&#8217;s own stock. A freestanding equity-linked financial instrument no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. The effective date for ASU 2017-11 is for annual or any interim periods beginning after December 15, 2018. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU 2017-09&#8212;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#8211;Stock Compensation (Topic 718): Scope of Modification Accounting</font><font style="font-family:inherit;font-size:10pt;">. ASU 2017-09 modifies when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the same immediately before and after a change to the terms and conditions of the award. The effective date for ASU 2017-09 is for annual or any interim periods beginning after December 15, 2017. The Company adopted this ASU effective January 1, 2018. The adoption of this standard did not materially impact the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU 2016-18&#8212;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Restricted Cash</font><font style="font-family:inherit;font-size:10pt;">. ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The effective date for ASU 2016-18 is for annual or any interim periods beginning after December 15, 2017. The Company adopted this ASU effective January 1, 2018. The adoption of this standard did not materially impact the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU 2016-15&#8212;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:inherit;font-size:10pt;">. ASU 2016-15 provides guidance for eight specific cash flow issues with respect to how cash receipts and cash payments are classified in the statements of cash flows, with the objective of reducing diversity in practice.&#160;The effective date for ASU 2016-15 is for annual periods beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this ASU effective January 1, 2018. The adoption of this standard did not materially impact the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02&#8212;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">, requiring lessees to recognize a right-of-use asset and a lease liability on the balance sheet for all leases with the exception of short-term leases. For lessees, leases will continue to be classified as either operating or finance leases in the income statement. The effective date of the new standard for public companies is for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. In January 2018, the FASB issued an additional amendment that provides a practical expedient giving companies the option to not evaluate existing or expired land easements that were not previously accounted for as leases under the current leases guidance. The amendment in the update is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. In July 2018, the FASB issued an additional amendment, ASU 2018-11, which provides a new, optional transition method and provides lessors a practical expedient for separating lease and non-lease components. In July 2018, the FASB additionally issued ASU 2018-1&#8212; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</font><font style="font-family:inherit;font-size:10pt;">, which clarifies and correct errors in ASC 842. The effective date for the amendments issued is the same as the effective date of ASC 842. Although early adoption is permitted, the Company plans to adopt the guidance on January 1, 2019. Topic 842 requires the recognition and measurement of leases at the beginning of the earliest comparative period presented in the financial statements, using a modified retrospective approach, with an option to apply the transition provisions of the new guidance at the adoption date without adjusting the comparative periods presented. The Company is evaluating the effect of adoption of the updated standard on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Adoption of ASC Topic 606, "Revenue from Contracts with Customers"</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On&#160;January&#160;1, 2018, the Company adopted Topic 606 using the modified retrospective method applied to those contracts which were not completed as of&#160;January&#160;1, 2018. Results for reporting periods beginning after&#160;January&#160;1, 2018&#160;are presented under Topic 606, while prior period amounts are not restated and continue to be reported in accordance with accounting standards in effect for those periods. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Infusion Revenues</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company generates revenue principally through the provision of infusion services to provide clinical management services and the delivery of cost effective prescription medications. Prescription drugs are dispensed either through a pharmacy participating in the Company&#8217;s pharmacy network or a pharmacy owned by the Company. Fee-for-service agreements include pharmacy agreements, under which we dispense prescription medications through the Company&#8217;s pharmacy facilities.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company provides a variety of therapies to patients. For infusion-related therapies, the Company frequently provides multiple deliverables of drugs and related nursing services. After applying the criteria from Topic 606, the Company concluded that multiple performance obligations exist in its contracts with its customers. Revenue is allocated to each performance obligation based on relative standalone price, determined based on reimbursement rates established in the third party payor contracts. Drug revenue is recognized at the time the drug is shipped, and nursing revenue is recognized on the date of service. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Topic 606 requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to be entitled to in exchange for those goods or services. Topic 606 requires application of a five-step model to determine when to recognize revenue and at what amount. The revenue standard applies to all contracts with customers and revenues are to be recognized when control of the promised goods or services is transferred to the Company&#8217;s patients in an amount that reflects consideration expected to be received in exchange for those goods or services.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">REVENUE </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Adoption of ASC Topic 606, "Revenue from Contracts with Customers"</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On&#160;January&#160;1, 2018, the Company adopted Topic 606 using the modified retrospective method applied to those contracts which were not completed as of&#160;January&#160;1, 2018. Results for reporting periods beginning after&#160;January&#160;1, 2018&#160;are presented under Topic 606, while prior period amounts are not restated and continue to be reported in accordance with accounting standards in effect for those periods. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Infusion Revenues</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company generates revenue principally through the provision of infusion services to provide clinical management services and the delivery of cost effective prescription medications. Prescription drugs are dispensed either through a pharmacy participating in the Company&#8217;s pharmacy network or a pharmacy owned by the Company. Fee-for-service agreements include pharmacy agreements, under which we dispense prescription medications through the Company&#8217;s pharmacy facilities.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company provides a variety of therapies to patients. For infusion-related therapies, the Company frequently provides multiple deliverables of drugs and related nursing services. After applying the criteria from Topic 606, the Company concluded that multiple performance obligations exist in its contracts with its customers. Revenue is allocated to each performance obligation based on relative standalone price, determined based on reimbursement rates established in the third party payor contracts. Drug revenue is recognized at the time the drug is shipped, and nursing revenue is recognized on the date of service. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Topic 606 requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to be entitled to in exchange for those goods or services. Topic 606 requires application of a five-step model to determine when to recognize revenue and at what amount. The revenue standard applies to all contracts with customers and revenues are to be recognized when control of the promised goods or services is transferred to the Company&#8217;s patients in an amount that reflects consideration expected to be received in exchange for those goods or services.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents our revenues at amounts initially recognized for each associated payor class for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> (in millions). Sales and usage-based taxes are excluded from revenues.</font></div><div style="line-height:120%;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:416px;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:184px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:98px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:98px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September&#160;30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;Commercial</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,077</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">431,869</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Government</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,498</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;Patient</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Total Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">180,962</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">525,335</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Absent implementation of Topic 606, the Company would have reported revenue of </font><font style="font-family:inherit;font-size:10pt;">$186.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$541.9 million</font><font style="font-family:inherit;font-size:10pt;">, gross profit of </font><font style="font-family:inherit;font-size:10pt;">$71.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$197.5 million</font><font style="font-family:inherit;font-size:10pt;">, and bad debt expense of </font><font style="font-family:inherit;font-size:10pt;">$5.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$16.5 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively; and allowance for doubtful accounts of </font><font style="font-family:inherit;font-size:10pt;">$42.9 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract Assets and Liabilities</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with Topic 606, contract assets are to be recognized when an entity has the right to receive consideration in exchange for goods or services that have been transferred to a customer when that right is conditional on something other than the passage of time. The Company does not recognize contract assets as the right to receive consideration is unconditional in accordance with the passage of time criteria. Also in accordance with Topic 606, contract liabilities are to be recognized when an entity is obligated to transfer goods or services for which consideration has already been received. The Company does not receive consideration prior to the transfer of goods or services and, therefore, does not recognize contract liabilities. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Significant Judgments</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determines implicit price concessions based on historical collection experience using a portfolio approach. The Company determines the transaction price based on gross charges for services provided, reduced by contractual adjustments based on contractual agreements and historical experience. Pursuant to the requirements of Topic 606, the transaction price to be recognized as revenue is estimated based upon the amount of cash ultimately expected to be collected. Therefore, amounts expected to be written off are reflected in the amount of revenue recognized upon fulfillment of the performance obligation as an implicit price concession.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company elected a practical expedient to expense sales commissions when incurred as the amortization period associated therewith is generally one year or less and the total paid is representative of less than </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;"> of total revenue. These costs are recorded in other operating expenses.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the aging of our net accounts receivable (net of allowance for contractual adjustments, and prior to allowance for doubtful accounts), aged based on date of service and categorized based on the three primary overall types of accounts receivable characteristics (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">0 - 180 days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Over 180 days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">0 - 180 days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Over 180 days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,555</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,028</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20,602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">30,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">80,508</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,825</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">91,333</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63,767</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,779</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">82,546</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Patient</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,922</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,790</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,712</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,627</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,204</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">94,985</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">18,643</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">113,628</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">86,946</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">36,488</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">123,434</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(37,912</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">113,628</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">85,522</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following details our financial instruments where the carrying value and the fair value differ (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.95121951219512%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Financial Instrument</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Carrying Value as of September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Markets for Identical Item (Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Significant Other Observable Inputs (Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Significant Unobservable Inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">First Lien Note Facility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">198,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">202,512</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Second Lien Note Facility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">103,571</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">117,219</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017 Warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2021 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">197,927</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">189,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">522,023</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">211,224</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">319,731</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s federal and state income tax provision from continuing operations for the </font><font style="font-family:inherit;font-size:10pt;">three months and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> is summarized in the following table (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;September&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September&#160;30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Current</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(925</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(925</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">528</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">50</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(547</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">84</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(397</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Deferred</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Federal</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">515</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,523</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">271</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total deferred</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">52</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">607</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">107</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">1,794</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">102</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">60</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">191</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">1,397</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s debt consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.51219512195122%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September&#160;30,</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">First Lien Note Facility, net of unamortized discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">198,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">198,324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Second Lien Note Facility, net of unamortized discount</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">103,571</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85,694</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2021 Notes, net of unamortized discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">197,927</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">197,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Capital leases</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,239</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,863</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: Deferred financing costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,692</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,656</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total Debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">498,846</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">480,588</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: Current portion of long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,076</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,722</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Long-term debt, net of current portion</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">496,770</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">478,866</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted loss per common share (in thousands, except for per share amounts):</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;September&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September&#160;30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss from continuing operations, net of income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,103</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13,058</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(36,212</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(61,629</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Income (Loss) from discontinued operations, net of income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(71</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">66</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(118</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(606</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(8,174</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(12,992</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(36,330</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(62,235</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dividends on preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,861</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,569</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,272</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(11,035</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(15,561</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(44,602</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(69,670</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Denominator - Basic and Diluted: </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted average common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">127,528</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">127,488</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">127,893</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">122,519</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Loss per Common Share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss from continuing operations, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.09</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.56</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Loss from discontinued operations, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Loss per common share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(0.09</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(0.12</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(0.35</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(0.57</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s reconciliation of the statutory rate from continuing operations to the effective income tax rate for the </font><font style="font-family:inherit;font-size:10pt;">three months and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> is summarized as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;September&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September&#160;30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Tax benefit at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,680</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(20,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">State tax expense, net of federal taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">102</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">378</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">191</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">528</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Alternative Minimum Tax receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Valuation allowance changes affecting income tax provision</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,261</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,876</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,163</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22,194</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Permanent items</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">401</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">102</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">60</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">191</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">1,397</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables set forth the effect these corrections had on the Company&#8217;s unaudited consolidated statements of operations for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.703125%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Previously Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Corrections</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revised</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Previously Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Corrections</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revised</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Net revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">198,692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">198,692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">634,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">634,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Gross profit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,176</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(613</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,563</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,070</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,022</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,048</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Total Operating Expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221,128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(497</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220,631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,175</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,360</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,635</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,649</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Loss from continuing operations, net of income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,058</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60,090</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,538</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61,628</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Income (loss) from discontinued operations, net of income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(113</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">179</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,053</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">447</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(606</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(475</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,992</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(62,234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restructuring, acquisition, integration, and other expenses in the Unaudited Consolidated Statements of Operations for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended&#160;<br clear="none"/>&#160;September&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended&#160;<br clear="none"/>&#160;September&#160;30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Restructuring expense </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">833</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,881</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Acquisition and integration expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52</font></div></td><td style="vertical-align:bottom;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">246</font></div></td><td style="vertical-align:bottom;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">123</font></div></td><td style="vertical-align:bottom;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">526</font></div></td><td style="vertical-align:bottom;background-color:;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total restructuring, acquisition, integration, and other expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">885</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">4,037</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">4,789</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">11,407</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents and Restricted Cash</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Highly liquid investments with a maturity of three months or less when purchased are classified as cash equivalents. Restricted cash consists of cash balances held by financial institutions as collateral for letters of credit. These balances are reclassified to cash and cash equivalents when the underlying obligation is satisfied, or in accordance with the governing agreement. Restricted cash balances expected to become unrestricted during the next twelve months are recorded as current assets. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had a restricted cash balance, in a money market account, of $</font><font style="font-family:inherit;font-size:10pt;">4.3 million</font><font style="font-family:inherit;font-size:10pt;"> to cash collateralize outstanding letters of credit.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Collectability of Accounts Receivable</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the aging of our net accounts receivable (net of allowance for contractual adjustments, and prior to allowance for doubtful accounts), aged based on date of service and categorized based on the three primary overall types of accounts receivable characteristics (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">0 - 180 days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Over 180 days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">0 - 180 days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Over 180 days</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,555</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,028</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20,602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">30,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commercial</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">80,508</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,825</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">91,333</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">63,767</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,779</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">82,546</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Patient</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,922</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,790</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,712</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,627</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,204</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">94,985</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">18,643</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">113,628</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">86,946</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">36,488</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">123,434</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(37,912</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">113,628</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">85,522</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-15 &#8212; Internal Use Software. ASU 2018-15 aligns the requirements for capitalization of implementation costs related to hosted software with the existing internal-use software guidance. The effective date for ASU 2018-15 is for annual and interim periods beginning after December 15, 2019. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13&#8212; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework&#8212; Changes to the Disclosure Requirements for Fair Value Measurements</font><font style="font-family:inherit;font-size:10pt;">. ASU 2018-13 modifies fair value measurement disclosure requirements. The effective date for ASU 2018-13 is for annual and interim periods beginning after December 15, 2019. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s disclosures to the consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09&#8212;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:inherit;font-size:10pt;">. The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The FASB delayed the effective date to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. The Company did not elect early adoption and applied the modified retrospective approach upon adoption which results in application of the new guidance only to contracts that are not completed at the adoption date and does not require adjustment of prior reporting periods. Assessment of the new guidance did not result in an opening retained earnings adjustment, but did result in the adjustment of accounts receivable as the allowance for doubtful accounts was eliminated upon implementation. Pursuant to the requirements of Topic 606, the transaction price to be recognized as revenue is estimated based upon the amount of cash ultimately expected to be collected. Therefore, amounts expected to be written off are reflected in the amount of revenue recognized upon fulfillment of the performance obligation. The new standard resulted in the recognition of amounts previously reported as bad debt expense as a reduction to revenue upon implementation; see Note 3 - Revenue.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, the FASB issued ASU 2017-11&#8212;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Earnings Per Share (Topic 260), Distinguishing Liabilities From Equity (Topic 480)</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</font><font style="font-family:inherit;font-size:10pt;">. ASU 2017-11 eliminates the requirement that a down round feature precludes equity classification when assessing whether an instrument is indexed to an entity&#8217;s own stock. A freestanding equity-linked financial instrument no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. The effective date for ASU 2017-11 is for annual or any interim periods beginning after December 15, 2018. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU 2017-09&#8212;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#8211;Stock Compensation (Topic 718): Scope of Modification Accounting</font><font style="font-family:inherit;font-size:10pt;">. ASU 2017-09 modifies when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the same immediately before and after a change to the terms and conditions of the award. The effective date for ASU 2017-09 is for annual or any interim periods beginning after December 15, 2017. The Company adopted this ASU effective January 1, 2018. The adoption of this standard did not materially impact the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU 2016-18&#8212;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Restricted Cash</font><font style="font-family:inherit;font-size:10pt;">. ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The effective date for ASU 2016-18 is for annual or any interim periods beginning after December 15, 2017. The Company adopted this ASU effective January 1, 2018. The adoption of this standard did not materially impact the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU 2016-15&#8212;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:inherit;font-size:10pt;">. ASU 2016-15 provides guidance for eight specific cash flow issues with respect to how cash receipts and cash payments are classified in the statements of cash flows, with the objective of reducing diversity in practice.&#160;The effective date for ASU 2016-15 is for annual periods beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this ASU effective January 1, 2018. The adoption of this standard did not materially impact the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02&#8212;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">, requiring lessees to recognize a right-of-use asset and a lease liability on the balance sheet for all leases with the exception of short-term leases. For lessees, leases will continue to be classified as either operating or finance leases in the income statement. The effective date of the new standard for public companies is for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. In January 2018, the FASB issued an additional amendment that provides a practical expedient giving companies the option to not evaluate existing or expired land easements that were not previously accounted for as leases under the current leases guidance. The amendment in the update is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. In July 2018, the FASB issued an additional amendment, ASU 2018-11, which provides a new, optional transition method and provides lessors a practical expedient for separating lease and non-lease components. In July 2018, the FASB additionally issued ASU 2018-1&#8212; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</font><font style="font-family:inherit;font-size:10pt;">, which clarifies and correct errors in ASC 842. The effective date for the amendments issued is the same as the effective date of ASC 842. Although early adoption is permitted, the Company plans to adopt the guidance on January 1, 2019. Topic 842 requires the recognition and measurement of leases at the beginning of the earliest comparative period presented in the financial statements, using a modified retrospective approach, with an option to apply the transition provisions of the new guidance at the adoption date without adjusting the comparative periods presented. The Company is evaluating the effect of adoption of the updated standard on its consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STOCKHOLDERS&#8217; DEFICIT</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Carrying Value of Series A Preferred Stock</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the carrying value of Series A Preferred Stock included accrued dividends at </font><font style="font-family:inherit;font-size:10pt;">11.5%</font><font style="font-family:inherit;font-size:10pt;"> and discount accretion from the date of issuance. Dividends and discount accretion totaled </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, for the nine months ended September 30, 2018 and were recorded as a reduction to additional paid-in capital. The following table sets forth the activity recorded during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> related to the Series A Preferred Stock (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.4765625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Series A Preferred Stock carrying value at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2,827</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dividends and discount accretion through September 30, 2018</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#160;1</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">299</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Series A Preferred Stock carrying value September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">3,126</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1 </sup></font><font style="font-family:inherit;font-size:10pt;">Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Carrying Value of Series C Preferred Stock</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the carrying value of Series C Preferred Stock included accrued dividends at </font><font style="font-family:inherit;font-size:10pt;">11.5%</font><font style="font-family:inherit;font-size:10pt;"> and discount accretion from the date of issuance. Dividends and discount accretion totaled </font><font style="font-family:inherit;font-size:10pt;">$7.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, for the nine months ended September 30, 2018 and were recorded as a reduction to additional paid-in capital. The following table sets forth the activity recorded during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> related to the Series C Preferred Stock (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.4765625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Series C Preferred Stock carrying value at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">79,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dividends and discount accretion through September 30, 2018</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#160;1</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,973</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;background-color:#cceeff;font-weight:bold;">Series C Preferred Stock carrying value September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">87,225</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1 </sup></font><font style="font-family:inherit;font-size:10pt;">Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Liquidation Preference of the Series A Preferred Stock and Series C Preferred Stock was </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$92.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2017 Warrants</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Second Lien Note Facility (as defined below), the Company also issued warrants (the &#8220;2017 Warrants&#8221;) to the purchasers of the Second Lien Notes (as defined below) pursuant to a Warrant Purchase Agreement dated as of June 29, 2017 (the &#8220;Warrant Purchase Agreement&#8221;). The 2017 Warrants entitle the purchasers of the Warrants to purchase shares of Common Stock, representing at the time of any exercise of the 2017 Warrants an equivalent number of shares equal to </font><font style="font-family:inherit;font-size:10pt;">4.99%</font><font style="font-family:inherit;font-size:10pt;"> of the Common Stock of the Company on a fully diluted basis, subject to the terms of the Warrant Agreement governing the Warrants, dated as of June 29, 2017 (the &#8220;Warrant Agreement&#8221;); provided, however, the Warrants may not be converted to the extent that, after giving effect to such conversion, the holders of the 2017 Warrants would beneficially own, in the aggregate, in excess of (i) </font><font style="font-family:inherit;font-size:10pt;">19.99%</font><font style="font-family:inherit;font-size:10pt;"> of the shares of Common Stock outstanding as of June 29, 2017 (the &#8220;Closing Date&#8221;) minus (ii) the shares of Common Stock that were sold pursuant to the Second Quarter 2017 Private Placement (as defined below) (the &#8220;Conversion Cap&#8221;). The Conversion Cap will not apply to the 2017 Warrants if the Company obtains the approval of its stockholders for the removal of the Conversion Cap, which the Company is required to take certain steps to attempt to obtain, subject to the terms of the Warrant Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2017 Warrants have a </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;">-year term and an initial exercise price of </font><font style="font-family:inherit;font-size:10pt;">$2.00</font><font style="font-family:inherit;font-size:10pt;"> per share, and may be exercised by payment of the exercise price in cash or surrender of shares of Common Stock into which the Warrants are being converted in an aggregate amount sufficient to pay the exercise price.&#160; The exercise price and the number of shares that may be acquired upon exercise of the 2017 Warrants is subject to adjustment in certain situations, including price based anti-dilution protection whereby, subject to certain exceptions, if the Company later issues Common Stock or certain Common Stock Equivalents (as defined in the Warrant Agreement) at a price less than either the then-current market price per share or exercise price of the 2017 Warrants, then the exercise price will be decreased and the percentage of shares of Common Stock issuable upon exercise of the Warrants will remain the same, giving effect to such issuance. Additionally, the 2017 Warrants have standard anti-dilution protections if the Company effects a stock split, subdivision, reclassification or combination of its Common Stock or fixes a record date for the making of a dividend or distribution to stockholders of cash or certain assets. Upon the occurrence of certain business combinations the 2017 Warrants will be converted into the right to acquire shares of stock or other securities or property (including cash) of the successor entity. The 2017 Warrants are reflected as a liability in other non-current liabilities on the balance sheet and are adjusted to fair value at the end of each reporting period through an adjustment to earnings. The fair value of the 2017 Warrants was </font><font style="font-family:inherit;font-size:10pt;">$21.7 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and was included in other non-current liabilities on the accompanying Unaudited Consolidated Balance Sheets. Fair value increases of </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months and nine months</font><font style="font-family:inherit;font-size:10pt;"> ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, are presented as changes in fair value of equity linked liabilities on the accompanying Unaudited Consolidated Statements of Operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the activity recorded during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> related to the Series C Preferred Stock (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.4765625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Series C Preferred Stock carrying value at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">79,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dividends and discount accretion through September 30, 2018</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#160;1</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,973</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;background-color:#cceeff;font-weight:bold;">Series C Preferred Stock carrying value September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">87,225</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1 </sup></font><font style="font-family:inherit;font-size:10pt;">Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the activity recorded during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> related to the Series A Preferred Stock (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.4765625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Series A Preferred Stock carrying value at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2,827</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dividends and discount accretion through September 30, 2018</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#160;1</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">299</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Series A Preferred Stock carrying value September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">3,126</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1 </sup></font><font style="font-family:inherit;font-size:10pt;">Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.</font></div></div> EX-101.SCH 7 bios-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2101100 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - BASIS OF PRESENTATION (Details) link:presentationLink link:calculationLink link:definitionLink 2301301 - Disclosure - BASIS OF PRESENTATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - CONCENTRATION OF RISK link:presentationLink link:calculationLink link:definitionLink 2409401 - Disclosure - CONCENTRATION OF RISK (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - DEBT - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - DEBT - Carrying and Estimated Fair Values of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - DEBT - Summary of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - DEBT - Summary of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - INCOME TAXES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - INCOME TAXES - Reconciliation of the Income Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - INCOME TAXES - Schedule of Federal and State Income Tax Provision (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - LOSS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - REVENUE link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 2415401 - Disclosure - STOCK-BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - STOCKHOLDERS' DEFICIT link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - STOCKHOLDERS' DEFICIT - 2017 Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - STOCKHOLDERS' DEFICIT - Activity Related to Series A and C Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - STOCKHOLDERS' DEFICIT - Carrying Value of Preferred Stock Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - STOCKHOLDERS' DEFICIT (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounts Receivable Aging (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2302302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 bios-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 bios-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 bios-20180930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Equity [Abstract] Carrying value and activity of Preferred Shares Temporary Equity [Table Text Block] Temporary Equity, by Class of Stock [Table] Temporary Equity, by Class of Stock [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Series A Preferred Stock Series A Preferred Stock [Member] Series C Preferred Stock Series C Preferred Stock [Member] Temporary Equity [Line Items] Temporary Equity [Line Items] Increase (Decrease) in Temporary Equity [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Beginning Balance Temporary Equity, Carrying Amount, Attributable to Parent Dividends and discount accretion through September 30, 2018 Temporary Equity, Accretion Of Dividends And Discount Temporary Equity, Accretion Of Dividends And Discount Ending Balance Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] First Lien Note Facility, net of unamortized discount First Lien Note, Maturing June 30, 2022 [Member] First Lien Note, Maturing June 30, 2022 [Member] Second Lien Note Facility, net of unamortized discount Second Lien Note, Maturing August 15, 2020 [Member] Second Lien Note, Maturing August 15, 2020 [Member] 2021 Notes Senior Unsecured 8.875% Notes [Member] Senior Unsecured 8.875% Notes [Member] Capital leases Capital Lease Obligations [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Long-term debt Long-term Debt Capital leases Capital Lease Obligations Less: Deferred financing costs Debt Issuance Costs, Net Total Debt Long-term Debt and Capital Lease Obligations, Including Current Maturities Less: Current portion of long-term debt Long-term Debt and Capital Lease Obligations, Current Long-term debt, net of current portion Long-term Debt and Capital Lease Obligations Accounting Policies [Abstract] Restricted cash Restricted Cash and Cash Equivalents, Current Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Revenue from Contract with Customer [Abstract] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Revenue from Rights Concentration Risk Revenue from Rights Concentration Risk [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Sales Revenue, Net Sales Revenue, Net [Member] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Calculated under Revenue Guidance in Effect before Topic 606 Calculated under Revenue Guidance in Effect before Topic 606 [Member] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] Commercial Commercial Customer [Member] Commercial Customer [Member] Government Government Customer [Member] Government Customer [Member] Patient Patient Customer [Member] Patient Customer [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Total Revenue Revenue from Contract with Customer, Excluding Assessed Tax Gross profit Gross Profit Bad debt expense Provision for Doubtful Accounts Allowance for doubtful accounts Allowance for Doubtful Accounts Receivable Percentage of concentration risk Concentration Risk, Percentage Class of Warrant or Right [Table] Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Dividend accrual rate Preferred Stock, Dividend Rate, Percentage Accretion of dividends on preferred stock Temporary Equity, Accretion of Dividends Discount accretion on preferred stock Temporary Equity, Accretion to Redemption Value Convertible preferred stock series, liquidation preference Temporary Equity, Liquidation Preference Document Entity Information [Abstract] Document Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Emerging Growth Company Entity Emerging Growth Company Entity Small Business Entity Small Business Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Series A convertible preferred stock, $.0001 par value; 825,000 shares authorized; 21,630 and 21,645 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively; and $3,172 and $2,916 liquidation preference as of September 30, 2018 and December 31, 2017, respectively Series C convertible preferred stock, $.0001 par value; 625,000 shares authorized; 614,177 shares issued and outstanding as of September 30, 2018 and December 31, 2017; and $92,038 and $84,555 liquidation preference as of September 30, 2018 and December 31, 2017, respectively Statement [Line Items] Statement [Line Items] ASSETS Assets [Abstract] Current assets Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Accounts receivable, net of allowance for doubtful accounts of $0 and $37,912 as of September 30, 2018 and December 31, 2017, respectively Receivables, Net, Current Inventory Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net of accumulated depreciation of $97,788 and $88,298 as of September 30, 2018 and December 31, 2017, respectively Property, Plant and Equipment, Net Goodwill Goodwill Intangible assets, net of accumulated amortization of $47,120 and $40,436 as of September 30, 2018 and December 31, 2017, respectively Finite-Lived Intangible Assets, Net Deferred taxes Deferred Tax Assets, Net, Noncurrent Other non-current assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS’ DEFICIT Liabilities and Equity [Abstract] Current liabilities Liabilities, Current [Abstract] Current portion of long-term debt Accounts payable Accounts Payable, Current Amounts due to plan sponsors Amounts due to plan sponsors Carrying value as of the balance sheet date of obligations incurred through that date which are related to rebates due from third party vendors and payable to customers, combined with reclassified credits in accounts receivable (amounts due to customers), and amounts that may arise and be deemed due on third party vendor audit. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued interest Interest Payable, Current Accrued expenses and other current liabilities Accrued expenses and other current liabilities Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of the liabilities, combined with the aggregate carrying amount, as of the balance sheet date, of current obligations not separately disclosed in the balance sheet due to materiality considerations. Total current liabilities Liabilities, Current Other non-current liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Convertible preferred stock Stockholders’ deficit Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Preferred stock, $.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively Preferred Stock, Value, Issued Common stock, $.0001 par value; 250,000,000 shares authorized; 128,064,145 and 127,634,012 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively Common Stock, Value, Issued Treasury stock, 287,248 and 5,106 shares outstanding, at cost, as of September 30, 2018 and December 31, 2017, respectively Treasury Stock, Value Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders’ deficit Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ deficit Liabilities and Equity Earnings Per Share [Abstract] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Class of Stock [Line Items] Class of Stock [Line Items] Convertible preferred stock series, par value (in dollars per share) Temporary Equity, Par or Stated Value Per Share Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Loss from continuing operations, net of income taxes Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Income (loss) from discontinued operations, net of income taxes Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Net loss Net Income (Loss) Attributable to Parent Dividends on preferred stock Preferred Stock Dividends, Income Statement Impact Loss attributable to common stockholders Net Income (Loss) Available to Common Stockholders, Basic Denominator - Basic and Diluted: Earnings Per Share, Basic, Other Disclosures [Abstract] Weighted average number of common shares outstanding, basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Loss per Common Share: Earnings Per Share, Basic and Diluted [Abstract] Loss from continuing operations, basic and diluted (in dollars per share) Income (Loss) from Continuing Operations, Per Basic and Diluted Share Loss from discontinued operations, basic and diluted (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share Loss per common share, basic and diluted (in dollars per share) Earnings Per Share, Basic and Diluted Summary of Long-term Debt Schedule of Debt [Table Text Block] Schedule of Carrying and Estimated Fair Values of Financial Instruments Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] 2017 Warrants 2017 Warrants [Member] 2017 Warrants [Member] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Markets for Identical Item (Level 1) Fair Value, Inputs, Level 1 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Long-term debt, carrying value Long-term debt, fair value Long-term Debt, Fair Value Warrants, carrying value Warrants and Rights Outstanding Warrants, fair value Warrants Not Settleable in Cash, Fair Value Disclosure Total, carrying value Debt And Warrants Outstanding Debt And Warrants Outstanding Total, fair value Financial Liabilities Fair Value Disclosure Income Tax Disclosure [Abstract] Tax benefit at statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount State tax expense, net of federal taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Alternative Minimum Tax receivable Effective Income Tax Rate Reconciliation, Alternative Minimum Tax Receivable, Amount Effective Income Tax Rate Reconciliation, Alternative Minimum Tax Receivable, Amount Valuation allowance changes affecting income tax provision Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Permanent items Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Total income tax expense Income Tax Expense (Benefit) Loss Per Share Earnings Per Share [Text Block] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] First Lien Notes Second Lien Notes Second Lien Delayed Draw Notes Second Lien Delayed Draw Notes [Member] Second Lien Delayed Draw Notes [Member] Senior Unsecured 8.875% Notes Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Senior Secured Debt Senior Notes [Member] Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock [Domain] Sale of Stock [Domain] Private Placement Private Placement [Member] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Redemption Period One Debt Instrument, Redemption, Period One [Member] Redemption Period Two Debt Instrument, Redemption, Period Two [Member] Redemption Period Three Debt Instrument, Redemption, Period Three [Member] Debt Instrument, Accrued Interest Option [Axis] Debt Instrument, Accrued Interest Option [Axis] Debt Instrument, Accrued Interest Option [Axis] Debt Instrument, Accrued Interest Option [Domain] Debt Instrument, Accrued Interest Option [Domain] [Domain] for Debt Instrument, Accrued Interest Option [Axis] Option One Option One [Member] Option One [Member] Option Two Option Two [Member] Option Two [Member] Option Three Option Three [Member] Option Three [Member] Option Three, Half Cash Option Three, Half Cash [Member] Option Three, Half Cash [Member] Option Three, Half Capitalized Interest Option Three, Half Capitalized Interest [Member] Option Three, Half Capitalized Interest [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Base Rate Base Rate [Member] LIBOR London Interbank Offered Rate (LIBOR) [Member] Prime Rate Prime Rate [Member] Face amount of debt instruments Debt Instrument, Face Amount Net proceeds from issuance of equity, net of issuance costs Proceeds from Issuance of Common Stock Associated costs with private placement Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Stated rate on debt Debt Instrument, Interest Rate, Stated Percentage Amortization installment percentage of principal Debt Instrument, Amortization Installments, Percentage Of Principle Debt Instrument, Amortization Installments, Percentage Of Principle Early repayment premium base rate Debt Instrument, Early Repayment Premium, Base Rate Debt Instrument, Early Repayment Premium, Base Rate Early repayment premium rate Debt Instrument, Early Repayment Premium Rate Debt Instrument, Early Repayment Premium Rate Principal prepayment limit Debt Instrument, Principal Prepayment Limit Debt Instrument, Principal Prepayment Limit Default penalty interest rate increase Debt Instrument, Debt Default, Interest Rate, Penalty Increase Debt Instrument, Debt Default, Interest Rate, Penalty Increase Paid-in-kind interest capitalized as principal on Second Lien Note Facility Interest Costs Capitalized Warrant exercise threshold Class Of Warrant Or Right, Exercise Threshold Class Of Warrant Or Right, Exercise Threshold Warrants classified within equity at fair value Debt discount Debt Instrument, Unamortized Discount Federal Current Federal Tax Expense (Benefit) State Current State and Local Tax Expense (Benefit) Total current Current Income Tax Expense (Benefit) Federal Deferred Federal Income Tax Expense (Benefit) State Deferred State and Local Income Tax Expense (Benefit) Total deferred Deferred Income Tax Expense (Benefit) Restructuring and Related Activities [Abstract] Restructuring, Acquisition, Integration, and Other Expenses Business Acquisition, Integration, Restructuring and Other Related Costs [Text Block] Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table] Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table] Plan Name [Axis] Plan Name [Axis] Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain] Plan Name [Domain] The 2018 Plan Equity Incentive Plan, 2018 [Member] Equity Incentive Plan, 2018 [Member] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Stock Options Equity Option [Member] Restricted Stock Restricted Stock [Member] Market Based Cash Awards Market Based Cash Awards [Member] Market Based Cash Awards [Member] Employee Stock Purchase Plan Employee Stock [Member] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number of shares available for grant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Share-based compensation expense (less than for ESPP) Allocated Share-based Compensation Expense Purchase price of common stock, percent Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Shares purchased on the open market for award (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award Income Statement [Abstract] Net revenue Cost of revenue (excluding depreciation expense) Cost of Revenue Gross profit Other operating expenses Other Selling, General and Administrative Expense General and administrative expenses General and Administrative Expense Restructuring, acquisition, integration, and other expenses Acquisition, Integration, Restructuring and Other Expenses Acquisition, Integration, Restructuring and Other Expenses Change in fair value of equity linked liabilities Liabilities, Fair Value Adjustment Depreciation and amortization expense Amortization of Intangible Assets Interest expense Interest Income (Expense), Net Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Loss (gain) on dispositions Gain (Loss) on Disposition of Property Plant Equipment Loss from continuing operations, before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Income tax expense Loss from continuing operations, net of income taxes Accrued dividends on preferred stock Temporary Equity, Dividends, Adjustment Loss per common share: Weighted average common shares outstanding, basic and diluted (in shares) Revenue Revenue from Contract with Customer [Text Block] Allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Current Property and equipment, accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Intangible assets, accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Convertible preferred stock series, shares authorized (in shares) Temporary Equity, Shares Authorized Convertible preferred stock series, shares issued (in shares) Temporary Equity, Shares Issued Convertible preferred stock series, shares outstanding (in shares) Temporary Equity, Shares Outstanding Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares, issued (in shares) Common Stock, Shares, Issued Common stock, shares, outstanding (in shares) Common Stock, Shares, Outstanding Treasury stock, at cost (in shares) Treasury Stock, Shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Less: Loss from discontinued operations, net of income taxes Adjustments to reconcile loss from continuing operations, net of income taxes to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation Amortization of deferred financing costs and debt discount Amortization of Debt Issuance Costs and Discounts Change in deferred income taxes Increase (Decrease) in Deferred Income Taxes Stock-based compensation Share-based Compensation Paid-in-kind interest capitalized as principal on Second Lien Note Facility Paid-in-Kind Interest Loss (gain) on dispositions Gain (Loss) on Disposition of Property Plant Equipment1 Gain (Loss) on Disposition of Property Plant Equipment1 Loss on extinguishment of debt Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Receivables Inventory Increase (Decrease) in Inventories Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable Increase (Decrease) in Accounts Payable, Trade Amounts due to plan sponsors Increase (Decrease) in Amounts Due To Plan Sponsor The net change during the reporting period in the carrying value as of the balance sheet date of obligations incurred through that date which are related to rebates due from third party vendors and payable to customers, combined with reclassified credits in accounts receivable (amounts due to customers), and amounts that may arise and be deemed due on third party vendor audit. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued interest Increase (Decrease) in Interest Payable, Net Accrued expenses and other liabilities Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Net cash used in operating activities from continuing operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities from discontinued operations Cash Provided by (Used in) Operating Activities, Discontinued Operations Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from priming credit agreement, net of issuance costs Proceeds from Debt, Net of Issuance Costs Fees attributable to extinguishment of debt Payment for Debt Extinguishment or Debt Prepayment Cost Borrowings on long-term debt, net of expenses Proceeds from Issuance of Secured Debt Borrowings on revolving credit facility Proceeds from Long-term Lines of Credit Repayments on revolving credit facility Repayments of Long-term Lines of Credit Principal payments of long-term debt Repayments of Secured Debt Repayments of capital leases Repayments of Long-term Capital Lease Obligations Net activity from exercises of employee stock awards Proceeds from (Payments for) Other Financing Activities Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Net change in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, cash equivalents and restricted cash - beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash - end of period DISCLOSURE OF CASH FLOW INFORMATION: Supplemental Cash Flow Information [Abstract] Cash paid during the period for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid during the period for income taxes Income Taxes Paid, Net DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Noncash Investing and Financing Items [Abstract] Entry into capital lease Capital Lease Obligations Incurred Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Financing Receivables, Period Past Due [Axis] Financing Receivables, Period Past Due [Axis] Financing Receivables, Period Past Due [Domain] Financing Receivables, Period Past Due [Domain] Receivables 0 to 180 Days Past Due Financing Receivables. 1 to 180 Days Past Due [Member] Financing Receivables. 1 to 180 Days Past Due [Member] Receivables Over 180 Days Past Due Financing Receivables. Greater than 180 Days Past Due [Member] Financing Receivables. Greater than 180 Days Past Due [Member] Industry Sector [Axis] Industry Sector [Axis] Industry Sector [Domain] Industry Sector [Domain] Government Government Sector [Member] Commercial Commercial and Industrial Sector [Member] Patient Patient [Member] Patient [Member] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Gross accounts receivable Accounts Receivable, Gross Allowance for doubtful accounts Net accounts receivable Accounts Receivable, Net Stockholders' Deficit Stockholders' Equity Note Disclosure [Text Block] Restructuring expense Restructuring Charges Acquisition and integration expense Business Combination, Integration Related Costs Total restructuring, acquisition, integration, and other expenses Schedule of Restructuring, Acquisition, Integration, and Other Expenses, Net Restructuring and Related Costs [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Number of service locations Number Of Service Locations Number Of Service Locations Number of states in which the entity does business Number of States in which Entity Operates Number of operating segments Number of Operating Segments Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Restatement [Axis] Restatement [Axis] Restatement [Domain] Restatement [Domain] Previously Reported Previously Reported [Member] Corrections Restatement Adjustment [Member] Adjustments for Error Corrections [Axis] Adjustments for Error Corrections [Axis] Adjustments for Error Correction [Domain] Adjustments for Error Correction [Domain] Accounting For Suspense and Clearing Accounts Accounting For Suspense And Clearing Accounts [Member] Accounting For Suspense And Clearing Accounts [Member] Error Corrections and Prior Period Adjustments Restatement [Line Items] Error Corrections and Prior Period Adjustments Restatement [Line Items] Total Operating Expenses Operating Expenses Interest expense Interest Expense Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Federal Domestic Tax Authority [Member] State State and Local Jurisdiction [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Net operating loss carryforwards Operating Loss Carryforwards Net operating loss carryforwards subject to annual limitation Operating Loss Carryforwards, Limitations on Use, Amount Operating Loss Carryforwards, Limitations on Use, Amount Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration Debt Debt Disclosure [Text Block] Basis of Presentation Business Description and Basis of Presentation [Text Block] Schedule of Basic and Diluted Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Federal and State Income Tax Provision (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Reconciliation of the Income Tax Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of Effect of Error Corrections Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] Warrant holder outstanding common stock ownership limitation Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Term of warrants Class Of Warrant Or Right, Term Class Of Warrant Or Right, Term Exercise price of warrants (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Fair value adjustment Significant Accounting Policies Significant Accounting Policies [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Consolidation Consolidation, Policy [Policy Text Block] Cash and Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Fair Value Measurement Fair Value Measurement, Policy [Policy Text Block] Schedule of Accounts Receivable Aging Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Disaggregation of Revenue by Payor Disaggregation of Revenue [Table Text Block] Risks and Uncertainties [Abstract] Concentration of Risk Concentration Risk Disclosure [Text Block] Income Taxes Income Tax Disclosure [Text Block] Concentration Risk [Table] Concentration Risk [Table] Customer Concentration Risk Customer Concentration Risk [Member] United Healthcare UnitedHealthcare [Member] UnitedHealthcare [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] EX-101.PRE 11 bios-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 logowithregisteredtm10.jpg begin 644 logowithregisteredtm10.jpg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end XML 13 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2018
Nov. 06, 2018
Document Entity Information [Abstract]    
Entity Registrant Name BioScrip, Inc.  
Entity Central Index Key 0001014739  
Current Fiscal Year End Date --12-31  
Entity Filer Category Accelerated Filer  
Document Type 10-Q  
Document Period End Date Sep. 30, 2018  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Entity Common Stock, Shares Outstanding   128,041,101
Entity Emerging Growth Company false  
Entity Small Business false  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Current assets    
Cash and cash equivalents $ 18,944 $ 39,457
Restricted cash 4,320 4,950
Accounts receivable, net of allowance for doubtful accounts of $0 and $37,912 as of September 30, 2018 and December 31, 2017, respectively 113,628 85,522
Inventory 23,105 38,044
Prepaid expenses and other current assets 11,944 18,620
Total current assets 171,941 186,593
Property and equipment, net of accumulated depreciation of $97,788 and $88,298 as of September 30, 2018 and December 31, 2017, respectively 25,177 26,973
Goodwill 367,198 367,198
Intangible assets, net of accumulated amortization of $47,120 and $40,436 as of September 30, 2018 and December 31, 2017, respectively 12,030 19,114
Deferred taxes 990 1,098
Other non-current assets 1,836 2,116
Total assets 579,172 603,092
Current liabilities    
Current portion of long-term debt 2,076 1,722
Accounts payable 63,901 65,963
Amounts due to plan sponsors 1,546 4,621
Accrued interest 2,268 6,706
Accrued expenses and other current liabilities 26,204 26,118
Total current liabilities 95,995 105,130
Long-term debt, net of current portion 496,770 478,866
Other non-current liabilities 22,744 21,769
Total liabilities 615,509 605,765
Stockholders’ deficit    
Preferred stock, $.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively 0 0
Common stock, $.0001 par value; 250,000,000 shares authorized; 128,064,145 and 127,634,012 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively 13 13
Treasury stock, 287,248 and 5,106 shares outstanding, at cost, as of September 30, 2018 and December 31, 2017, respectively (849) (16)
Additional paid-in capital 619,989 624,762
Accumulated deficit (745,841) (709,511)
Total stockholders’ deficit (126,688) (84,752)
Total liabilities and stockholders’ deficit 579,172 603,092
Series A convertible preferred stock, $.0001 par value; 825,000 shares authorized; 21,630 and 21,645 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively; and $3,172 and $2,916 liquidation preference as of September 30, 2018 and December 31, 2017, respectively    
Current liabilities    
Convertible preferred stock 3,126 2,827
Series C convertible preferred stock, $.0001 par value; 625,000 shares authorized; 614,177 shares issued and outstanding as of September 30, 2018 and December 31, 2017; and $92,038 and $84,555 liquidation preference as of September 30, 2018 and December 31, 2017, respectively    
Current liabilities    
Convertible preferred stock $ 87,225 $ 79,252
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Allowance for doubtful accounts $ 0 $ 37,912,000
Property and equipment, accumulated depreciation 97,788,000 88,298,000
Intangible assets, accumulated amortization $ 47,120,000 $ 40,436,000
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 250,000,000 250,000,000
Common stock, shares, issued (in shares) 128,064,145 127,634,012
Common stock, shares, outstanding (in shares) 128,064,145 127,634,012
Treasury stock, at cost (in shares) 287,248 5,106
Series A Preferred Stock    
Convertible preferred stock series, par value (in dollars per share) $ 0.0001 $ 0.0001
Convertible preferred stock series, shares authorized (in shares) 825,000 825,000
Convertible preferred stock series, shares issued (in shares) 21,630 21,645
Convertible preferred stock series, shares outstanding (in shares) 21,630 21,645
Convertible preferred stock series, liquidation preference $ 3,172,000 $ 2,916,000
Series C Preferred Stock    
Convertible preferred stock series, par value (in dollars per share) $ 0.0001 $ 0.0001
Convertible preferred stock series, shares authorized (in shares) 625,000 625,000
Convertible preferred stock series, shares issued (in shares) 614,177 614,177
Convertible preferred stock series, shares outstanding (in shares) 614,177 614,177
Convertible preferred stock series, liquidation preference $ 92,038,000 $ 84,555,000
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Income Statement [Abstract]        
Net revenue $ 180,962 $ 198,692 $ 525,335 $ 634,608
Cost of revenue (excluding depreciation expense) 115,051 132,129 344,419 435,560
Gross profit 65,911 66,563 180,916 199,048
Other operating expenses 38,216 38,143 116,378 124,755
Bad debt expense 0 6,488 0 19,648
General and administrative expenses 12,478 9,405 34,084 28,325
Restructuring, acquisition, integration, and other expenses 885 4,037 4,789 11,407
Change in fair value of equity linked liabilities 1,605 1,103 1,228 1,103
Depreciation and amortization expense 5,767 7,058 18,617 21,288
Interest expense 14,971 13,360 42,171 38,649
Loss on extinguishment of debt 0 0 0 13,453
Loss (gain) on dispositions (10) (33) (330) 652
Loss from continuing operations, before income taxes (8,001) (12,998) (36,021) (60,232)
Income tax expense 102 60 191 1,397
Loss from continuing operations, net of income taxes (8,103) (13,058) (36,212) (61,629)
Income (loss) from discontinued operations, net of income taxes (71) 66 (118) (606)
Net loss (8,174) (12,992) (36,330) (62,235)
Accrued dividends on preferred stock (2,861) (2,569) (8,272) (7,435)
Loss attributable to common stockholders $ (11,035) $ (15,561) $ (44,602) $ (69,670)
Loss per common share:        
Loss from continuing operations, basic and diluted (in dollars per share) $ (0.09) $ (0.12) $ (0.35) $ (0.56)
Loss from discontinued operations, basic and diluted (in dollars per share) 0.00 0.00 0.00 (0.01)
Loss per common share, basic and diluted (in dollars per share) $ (0.09) $ (0.12) $ (0.35) $ (0.57)
Weighted average common shares outstanding, basic and diluted (in shares) 127,528 127,488 127,893 122,519
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Cash flows from operating activities:    
Net loss $ (36,330) $ (62,235)
Less: Loss from discontinued operations, net of income taxes (118) (606)
Loss from continuing operations, net of income taxes (36,212) (61,629)
Adjustments to reconcile loss from continuing operations, net of income taxes to net cash used in operating activities:    
Depreciation and amortization 18,617 21,288
Amortization of deferred financing costs and debt discount 6,084 4,676
Change in fair value of equity linked liabilities 1,228 1,103
Change in deferred income taxes 108 1,868
Stock-based compensation 3,032 1,525
Paid-in-kind interest capitalized as principal on Second Lien Note Facility 3,800 0
Loss (gain) on dispositions (330) 652
Loss on extinguishment of debt 0 13,453
Changes in assets and liabilities:    
Accounts receivable (28,106) 22,257
Inventory 14,939 8,391
Prepaid expenses and other assets 6,956 3,033
Accounts payable (2,062) (14,716)
Amounts due to plan sponsors (3,075) 1,091
Accrued interest (4,438) (3,508)
Accrued expenses and other liabilities (667) (2,800)
Net cash used in operating activities from continuing operations (20,126) (3,316)
Net cash used in operating activities from discontinued operations (117) (6,106)
Net cash used in operating activities (20,243) (9,422)
Cash flows from investing activities:    
Purchases of property and equipment (9,408) (6,570)
Net cash used in investing activities (9,408) (6,570)
Cash flows from financing activities:    
Proceeds from priming credit agreement, net of issuance costs 0 23,060
Fees attributable to extinguishment of debt 0 (980)
Net proceeds from issuance of equity, net of issuance costs 0 20,822
Borrowings on long-term debt, net of expenses 10,000 294,446
Borrowings on revolving credit facility 0 563
Repayments on revolving credit facility 0 (55,863)
Principal payments of long-term debt 0 (236,770)
Repayments of capital leases (1,623) (792)
Net activity from exercises of employee stock awards 131 (100)
Net cash provided by financing activities 8,508 44,386
Net change in cash, cash equivalents, and restricted cash (21,143) 28,394
Cash, cash equivalents and restricted cash - beginning of period 44,407 9,569
Cash, cash equivalents and restricted cash - end of period 23,264 37,963
DISCLOSURE OF CASH FLOW INFORMATION:    
Cash paid during the period for interest 36,735 38,454
Cash paid during the period for income taxes 51 327
DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Entry into capital lease 0 1,825
Paid-in-kind interest capitalized as principal on Second Lien Note Facility $ 3,800 $ 0
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
BASIS OF PRESENTATION
 9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
BASIS OF PRESENTATION
We are a national provider of infusion solutions with nearly 70 service locations around the U.S. We partner with physicians, hospital systems, skilled nursing facilities, and healthcare payors to provide patients with access to post-acute care services. We are committed to bringing customer-focused healthcare infusion therapy services into the home or alternate site setting. By collaborating with the full spectrum of healthcare professionals and the patient, we aim to provide cost-effective care that is driven by clinical excellence, customer service and values that promote positive outcomes and an enhanced quality of life for those whom we serve.
We operate in one segment, Infusion Services, and accordingly, we do not present disaggregated segment information.
These Unaudited Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements, including the notes thereto, and other information included in the Annual Report on Form 10-K of BioScrip, Inc. and its wholly-owned subsidiaries (the “Company”) for the year ended December 31, 2017 (the “Annual Report”) filed with the U.S. Securities and Exchange Commission (“SEC”). These Unaudited Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information, and the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.
The information furnished in these Unaudited Consolidated Financial Statements reflects all adjustments, including normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. Operating results for the interim periods presented require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes and are not necessarily indicative of the results that may be expected for the full year.
The Unaudited Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Reclassifications
Prior period financial statement amounts have been reclassified to conform to current period presentation.
Immaterial Error Correction

During the fourth quarter of 2017, the Company determined that certain prior period balances contained errors, predominantly due to a failure to appropriately account for and resolve transactions specific to suspense and clearing accounts. Management evaluated the materiality of the errors quantitatively and qualitatively, and concluded that they were not material to the financial statements of any period presented, but has elected to correct them in the accompanying prior period consolidated financial statements.

The following tables set forth the effect these corrections had on the Company’s unaudited consolidated statements of operations for the three and nine months ended ended September 30, 2017:
 
Three Months Ended 
 September 30, 2017
 
Nine Months Ended 
 September 30, 2017
 
Previously Reported
 
Corrections
 
Revised
 
Previously Reported
 
Corrections
 
Revised
 Net revenue
$
198,692

 
$
—

 
$
198,692

 
$
634,608

 
$
—

 
$
634,608

 Gross profit
67,176

 
(613
)
 
66,563

 
201,070

 
(2,022
)
 
199,048

 Total Operating Expenses
66,345

 
(144
)
 
66,201

 
221,128

 
(497
)
 
220,631

 Interest expense
13,175

 
185

 
13,360

 
38,635

 
14

 
38,649

 Loss from continuing operations, net of income taxes
(12,404
)
 
(654
)
 
(13,058
)
 
(60,090
)
 
(1,538
)
 
(61,628
)
 Income (loss) from discontinued operations, net of income taxes
(113
)
 
179

 
66

 
(1,053
)
 
447

 
(606
)
 Net loss
$
(12,517
)
 
$
(475
)
 
$
(12,992
)
 
$
(61,143
)
 
$
(1,091
)
 
$
(62,234
)

Certain amounts disclosed in the accompanying notes to the financial statements have been revised to reflect the corrections.
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Significant Accounting Policies
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Cash and Cash Equivalents and Restricted Cash

Highly liquid investments with a maturity of three months or less when purchased are classified as cash equivalents. Restricted cash consists of cash balances held by financial institutions as collateral for letters of credit. These balances are reclassified to cash and cash equivalents when the underlying obligation is satisfied, or in accordance with the governing agreement. Restricted cash balances expected to become unrestricted during the next twelve months are recorded as current assets. As of September 30, 2018, the Company had a restricted cash balance, in a money market account, of $4.3 million to cash collateralize outstanding letters of credit.

Collectability of Accounts Receivable

The following table sets forth the aging of our net accounts receivable (net of allowance for contractual adjustments, and prior to allowance for doubtful accounts), aged based on date of service and categorized based on the three primary overall types of accounts receivable characteristics (in thousands):
 
 
September 30, 2018
 
December 31, 2017
 
 
0 - 180 days
 
Over 180 days
 
Total
 
0 - 180 days
 
Over 180 days
 
Total
Government
 
$
12,555

 
$
3,028

 
$
15,583

 
$
20,602

 
$
10,082

 
$
30,684

Commercial
 
80,508

 
10,825

 
91,333

 
63,767

 
18,779

 
82,546

Patient
 
1,922

 
4,790

 
6,712

 
2,577

 
7,627

 
10,204

Gross accounts receivable
 
$
94,985

 
$
18,643

 
113,628

 
$
86,946

 
$
36,488

 
123,434

Allowance for doubtful accounts
 
 
 
 
 
—

 
 
 
 
 
(37,912
)
Net accounts receivable
 
 
 
 
 
$
113,628

 
 
 
 
 
$
85,522



Recent Accounting Pronouncements

In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-15 — Internal Use Software. ASU 2018-15 aligns the requirements for capitalization of implementation costs related to hosted software with the existing internal-use software guidance. The effective date for ASU 2018-15 is for annual and interim periods beginning after December 15, 2019. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.
In August 2018, the FASB issued ASU 2018-13— Fair Value Measurement (Topic 820): Disclosure Framework— Changes to the Disclosure Requirements for Fair Value Measurements. ASU 2018-13 modifies fair value measurement disclosure requirements. The effective date for ASU 2018-13 is for annual and interim periods beginning after December 15, 2019. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s disclosures to the consolidated financial statements.
In May 2014, the FASB issued ASU 2014-09—Revenue from Contracts with Customers (Topic 606). The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The FASB delayed the effective date to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. The Company did not elect early adoption and applied the modified retrospective approach upon adoption which results in application of the new guidance only to contracts that are not completed at the adoption date and does not require adjustment of prior reporting periods. Assessment of the new guidance did not result in an opening retained earnings adjustment, but did result in the adjustment of accounts receivable as the allowance for doubtful accounts was eliminated upon implementation. Pursuant to the requirements of Topic 606, the transaction price to be recognized as revenue is estimated based upon the amount of cash ultimately expected to be collected. Therefore, amounts expected to be written off are reflected in the amount of revenue recognized upon fulfillment of the performance obligation. The new standard resulted in the recognition of amounts previously reported as bad debt expense as a reduction to revenue upon implementation; see Note 3 - Revenue.
In July 2017, the FASB issued ASU 2017-11—Earnings Per Share (Topic 260), Distinguishing Liabilities From Equity (Topic 480), and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 eliminates the requirement that a down round feature precludes equity classification when assessing whether an instrument is indexed to an entity’s own stock. A freestanding equity-linked financial instrument no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. The effective date for ASU 2017-11 is for annual or any interim periods beginning after December 15, 2018. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.
In May 2017, the FASB issued ASU 2017-09—Compensation–Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-09 modifies when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the same immediately before and after a change to the terms and conditions of the award. The effective date for ASU 2017-09 is for annual or any interim periods beginning after December 15, 2017. The Company adopted this ASU effective January 1, 2018. The adoption of this standard did not materially impact the Company’s consolidated financial statements.
In November 2016, the FASB issued ASU 2016-18—Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The effective date for ASU 2016-18 is for annual or any interim periods beginning after December 15, 2017. The Company adopted this ASU effective January 1, 2018. The adoption of this standard did not materially impact the Company’s consolidated financial statements.
In August 2016, the FASB issued ASU 2016-15—Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 provides guidance for eight specific cash flow issues with respect to how cash receipts and cash payments are classified in the statements of cash flows, with the objective of reducing diversity in practice. The effective date for ASU 2016-15 is for annual periods beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this ASU effective January 1, 2018. The adoption of this standard did not materially impact the Company’s consolidated financial statements.
In February 2016, the FASB issued ASU 2016-02—Leases (Topic 842), requiring lessees to recognize a right-of-use asset and a lease liability on the balance sheet for all leases with the exception of short-term leases. For lessees, leases will continue to be classified as either operating or finance leases in the income statement. The effective date of the new standard for public companies is for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. In January 2018, the FASB issued an additional amendment that provides a practical expedient giving companies the option to not evaluate existing or expired land easements that were not previously accounted for as leases under the current leases guidance. The amendment in the update is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. In July 2018, the FASB issued an additional amendment, ASU 2018-11, which provides a new, optional transition method and provides lessors a practical expedient for separating lease and non-lease components. In July 2018, the FASB additionally issued ASU 2018-1— Codification Improvements to Topic 842, Leases, which clarifies and correct errors in ASC 842. The effective date for the amendments issued is the same as the effective date of ASC 842. Although early adoption is permitted, the Company plans to adopt the guidance on January 1, 2019. Topic 842 requires the recognition and measurement of leases at the beginning of the earliest comparative period presented in the financial statements, using a modified retrospective approach, with an option to apply the transition provisions of the new guidance at the adoption date without adjusting the comparative periods presented. The Company is evaluating the effect of adoption of the updated standard on its consolidated financial statements.
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
REVENUE
 9 Months Ended
Sep. 30, 2018
Revenue from Contract with Customer [Abstract]  
Revenue
REVENUE

Adoption of ASC Topic 606, "Revenue from Contracts with Customers"

On January 1, 2018, the Company adopted Topic 606 using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under Topic 606, while prior period amounts are not restated and continue to be reported in accordance with accounting standards in effect for those periods.

Infusion Revenues

The Company generates revenue principally through the provision of infusion services to provide clinical management services and the delivery of cost effective prescription medications. Prescription drugs are dispensed either through a pharmacy participating in the Company’s pharmacy network or a pharmacy owned by the Company. Fee-for-service agreements include pharmacy agreements, under which we dispense prescription medications through the Company’s pharmacy facilities.

The Company provides a variety of therapies to patients. For infusion-related therapies, the Company frequently provides multiple deliverables of drugs and related nursing services. After applying the criteria from Topic 606, the Company concluded that multiple performance obligations exist in its contracts with its customers. Revenue is allocated to each performance obligation based on relative standalone price, determined based on reimbursement rates established in the third party payor contracts. Drug revenue is recognized at the time the drug is shipped, and nursing revenue is recognized on the date of service.

Revenue Recognition

Topic 606 requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to be entitled to in exchange for those goods or services. Topic 606 requires application of a five-step model to determine when to recognize revenue and at what amount. The revenue standard applies to all contracts with customers and revenues are to be recognized when control of the promised goods or services is transferred to the Company’s patients in an amount that reflects consideration expected to be received in exchange for those goods or services.

The following table presents our revenues at amounts initially recognized for each associated payor class for the three and nine months ended September 30, 2018 (in millions). Sales and usage-based taxes are excluded from revenues.
 
 
Three Months Ended September 30, 2018
 
Nine Months Ended September 30, 2018
 Commercial
 
$
139,077

 
$
431,869

 Government
 
39,498

 
88,437

 Patient
 
2,387

 
5,029

 Total Revenue
 
$
180,962

 
$
525,335



Absent implementation of Topic 606, the Company would have reported revenue of $186.7 million and $541.9 million, gross profit of $71.6 million and $197.5 million, and bad debt expense of $5.7 million and $16.5 million for the three and nine months ended September 30, 2018, respectively; and allowance for doubtful accounts of $42.9 million at September 30, 2018.

Contract Assets and Liabilities
    
In accordance with Topic 606, contract assets are to be recognized when an entity has the right to receive consideration in exchange for goods or services that have been transferred to a customer when that right is conditional on something other than the passage of time. The Company does not recognize contract assets as the right to receive consideration is unconditional in accordance with the passage of time criteria. Also in accordance with Topic 606, contract liabilities are to be recognized when an entity is obligated to transfer goods or services for which consideration has already been received. The Company does not receive consideration prior to the transfer of goods or services and, therefore, does not recognize contract liabilities.

Significant Judgments

The Company determines implicit price concessions based on historical collection experience using a portfolio approach. The Company determines the transaction price based on gross charges for services provided, reduced by contractual adjustments based on contractual agreements and historical experience. Pursuant to the requirements of Topic 606, the transaction price to be recognized as revenue is estimated based upon the amount of cash ultimately expected to be collected. Therefore, amounts expected to be written off are reflected in the amount of revenue recognized upon fulfillment of the performance obligation as an implicit price concession.

The Company elected a practical expedient to expense sales commissions when incurred as the amortization period associated therewith is generally one year or less and the total paid is representative of less than 1.0% of total revenue. These costs are recorded in other operating expenses.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
LOSS PER SHARE
 9 Months Ended
Sep. 30, 2018
Earnings Per Share [Abstract]  
Loss Per Share
LOSS PER SHARE
The Company presents basic and diluted loss per share for its common stock, par value $0.0001 per share (“Common Stock”). Basic loss per share is calculated by dividing the net loss attributable to common stockholders of the Company by the weighted average number of shares of Common Stock outstanding during the period. Diluted loss per share is determined by adjusting the profit or loss attributable to stockholders and the weighted average number of shares of Common Stock outstanding adjusted for the effects of all dilutive potential common shares comprised of options granted, unvested restricted stock, stock appreciation rights, warrants and Series A and Series C Preferred Stock (as defined below). Potential Common Stock equivalents that have been issued by the Company related to outstanding stock options, unvested restricted stock and warrants are determined using the treasury stock method, while potential common shares related to Series A and Series C Preferred Stock are determined using the “if converted” method.
The Company's Series A Convertible Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), and Series C Convertible Preferred Stock, par value $0.0001 per share (the “Series C Preferred Stock” and, together with the Series A Preferred Stock, the “Preferred Stock”), is considered a participating security, which means the security may participate in undistributed earnings with Common Stock. The holders of the Preferred Stock would be entitled to share in dividends, on an as-converted basis, if the holders of Common Stock were to receive dividends. The Company is required to use the two-class method when computing loss per share when it has a security that qualifies as a participating security. The two-class method is an earnings allocation formula that determines loss per share for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. In determining the amount of net earnings to allocate to common stockholders, earnings are allocated to both common and participating securities based on their respective weighted-average shares outstanding during the period. Diluted loss per share for the Company’s Common Stock is computed using the more dilutive of the two-class method or the if-converted method.
The following table sets forth the computation of basic and diluted loss per common share (in thousands, except for per share amounts):
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2018
 
2017
 
2018
 
2017
Numerator:
 
 
 
 
 
 
 
Loss from continuing operations, net of income taxes
$
(8,103
)
 
$
(13,058
)
 
$
(36,212
)
 
$
(61,629
)
Income (Loss) from discontinued operations, net of income taxes
(71
)
 
66

 
(118
)
 
(606
)
Net loss
$
(8,174
)
 
$
(12,992
)
 
$
(36,330
)
 
$
(62,235
)
Dividends on preferred stock
(2,861
)
 
(2,569
)
 
(8,272
)
 
(7,435
)
Loss attributable to common stockholders
$
(11,035
)
 
$
(15,561
)
 
$
(44,602
)
 
$
(69,670
)
 
 
 
 
 
 
 
 
Denominator - Basic and Diluted:
 

 
 

 
 

 
 

Weighted average common shares outstanding
127,528

 
127,488

 
127,893

 
122,519

 
 
 
 
 
 
 
 
Loss per Common Share:
 
 
 
 
 
 
 
Loss from continuing operations, basic and diluted
$
(0.09
)
 
$
(0.12
)
 
$
(0.35
)
 
$
(0.56
)
Loss from discontinued operations, basic and diluted
—

 
—

 
—

 
(0.01
)
Loss per common share, basic and diluted
$
(0.09
)
 
$
(0.12
)
 
$
(0.35
)
 
$
(0.57
)

The loss attributable to common stockholders is used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. Accordingly, the computation of diluted shares for the three and nine months ended September 30, 2018 and 2017 excludes the effect of shares that would be issued in connection with the PIPE Transaction, the Rights Offering, 2017 Warrants (see Note 5 - Stockholders’ Deficit), stock options, and restricted stock awards, as their inclusion would be anti-dilutive to loss attributable to common stockholders.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCKHOLDERS' DEFICIT
 9 Months Ended
Sep. 30, 2018
Equity [Abstract]  
Stockholders' Deficit
STOCKHOLDERS’ DEFICIT
Carrying Value of Series A Preferred Stock
As of September 30, 2018, the carrying value of Series A Preferred Stock included accrued dividends at 11.5% and discount accretion from the date of issuance. Dividends and discount accretion totaled $0.2 million and $0.1 million, respectively, for the nine months ended September 30, 2018 and were recorded as a reduction to additional paid-in capital. The following table sets forth the activity recorded during the nine months ended September 30, 2018 related to the Series A Preferred Stock (in thousands):
Series A Preferred Stock carrying value at December 31, 2017
$
2,827

Dividends and discount accretion through September 30, 2018 1
299

Series A Preferred Stock carrying value September 30, 2018
$
3,126

1 Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.
Carrying Value of Series C Preferred Stock
As of September 30, 2018, the carrying value of Series C Preferred Stock included accrued dividends at 11.5% and discount accretion from the date of issuance. Dividends and discount accretion totaled $7.5 million and $0.5 million, respectively, for the nine months ended September 30, 2018 and were recorded as a reduction to additional paid-in capital. The following table sets forth the activity recorded during the nine months ended September 30, 2018 related to the Series C Preferred Stock (in thousands):
Series C Preferred Stock carrying value at December 31, 2017
$
79,252

Dividends and discount accretion through September 30, 2018 1
7,973

Series C Preferred Stock carrying value September 30, 2018
$
87,225


1 Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.
As of September 30, 2018, the Liquidation Preference of the Series A Preferred Stock and Series C Preferred Stock was $3.2 million and $92.0 million, respectively.
2017 Warrants
In connection with the Second Lien Note Facility (as defined below), the Company also issued warrants (the “2017 Warrants”) to the purchasers of the Second Lien Notes (as defined below) pursuant to a Warrant Purchase Agreement dated as of June 29, 2017 (the “Warrant Purchase Agreement”). The 2017 Warrants entitle the purchasers of the Warrants to purchase shares of Common Stock, representing at the time of any exercise of the 2017 Warrants an equivalent number of shares equal to 4.99% of the Common Stock of the Company on a fully diluted basis, subject to the terms of the Warrant Agreement governing the Warrants, dated as of June 29, 2017 (the “Warrant Agreement”); provided, however, the Warrants may not be converted to the extent that, after giving effect to such conversion, the holders of the 2017 Warrants would beneficially own, in the aggregate, in excess of (i) 19.99% of the shares of Common Stock outstanding as of June 29, 2017 (the “Closing Date”) minus (ii) the shares of Common Stock that were sold pursuant to the Second Quarter 2017 Private Placement (as defined below) (the “Conversion Cap”). The Conversion Cap will not apply to the 2017 Warrants if the Company obtains the approval of its stockholders for the removal of the Conversion Cap, which the Company is required to take certain steps to attempt to obtain, subject to the terms of the Warrant Agreement.
The 2017 Warrants have a 10-year term and an initial exercise price of $2.00 per share, and may be exercised by payment of the exercise price in cash or surrender of shares of Common Stock into which the Warrants are being converted in an aggregate amount sufficient to pay the exercise price.  The exercise price and the number of shares that may be acquired upon exercise of the 2017 Warrants is subject to adjustment in certain situations, including price based anti-dilution protection whereby, subject to certain exceptions, if the Company later issues Common Stock or certain Common Stock Equivalents (as defined in the Warrant Agreement) at a price less than either the then-current market price per share or exercise price of the 2017 Warrants, then the exercise price will be decreased and the percentage of shares of Common Stock issuable upon exercise of the Warrants will remain the same, giving effect to such issuance. Additionally, the 2017 Warrants have standard anti-dilution protections if the Company effects a stock split, subdivision, reclassification or combination of its Common Stock or fixes a record date for the making of a dividend or distribution to stockholders of cash or certain assets. Upon the occurrence of certain business combinations the 2017 Warrants will be converted into the right to acquire shares of stock or other securities or property (including cash) of the successor entity. The 2017 Warrants are reflected as a liability in other non-current liabilities on the balance sheet and are adjusted to fair value at the end of each reporting period through an adjustment to earnings. The fair value of the 2017 Warrants was $21.7 million as of September 30, 2018 and was included in other non-current liabilities on the accompanying Unaudited Consolidated Balance Sheets. Fair value increases of $1.6 million and $1.2 million for the three months and nine months ended September 30, 2018, respectively, are presented as changes in fair value of equity linked liabilities on the accompanying Unaudited Consolidated Statements of Operations.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES
 9 Months Ended
Sep. 30, 2018
Restructuring and Related Activities [Abstract]  
Restructuring, Acquisition, Integration, and Other Expenses
RESTRUCTURING, ACQUISITION, INTEGRATION, AND OTHER EXPENSES
Restructuring, acquisition, integration and other expenses include non-operating costs associated with restructuring, acquisition, and integration initiatives such as employee severance costs, certain legal and professional fees, training costs, redundant wage costs, impacts recorded from the change in contingent consideration obligations, and other costs related to contract terminations and closed branches/offices.
Restructuring, acquisition, integration, and other expenses in the Unaudited Consolidated Statements of Operations for the three and nine months ended ended September 30, 2018 and 2017 consisted of the following (in thousands):
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2018
 
2017
 
2018
 
2017
Restructuring expense
$
833

 
$
3,791

 
$
4,666

 
$
10,881

Acquisition and integration expense
52

 
246

 
123

 
526

Total restructuring, acquisition, integration, and other expenses
$
885

 
$
4,037

 
$
4,789

 
$
11,407
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
DEBT
 9 Months Ended
Sep. 30, 2018
Debt Disclosure [Abstract]  
Debt
DEBT
As of September 30, 2018 and December 31, 2017, the Company’s debt consisted of the following (in thousands):
 
September 30,
 2018
 
December 31,
2017
First Lien Note Facility, net of unamortized discount
198,801

 
198,324

Second Lien Note Facility, net of unamortized discount
103,571

 
85,694

2021 Notes, net of unamortized discount
197,927

 
197,363

Capital leases
1,239

 
2,863

Less: Deferred financing costs
(2,692
)
 
(3,656
)
Total Debt
498,846

 
480,588

Less: Current portion of long-term debt
(2,076
)
 
(1,722
)
Long-term debt, net of current portion
$
496,770

 
$
478,866


Debt Facilities
On June 29, 2017 (the “Closing Date”), the Company entered into (i) a first lien note purchase agreement (the “First Lien Note Facility”), among the Company, which is the issuer under the agreement, the financial institutions and note purchasers from time to time party to the agreement (the “First Lien Note Purchasers”), and Wells Fargo Bank, National Association, in its capacity as collateral agent for itself and the First Lien Note Purchasers (the “First Lien Collateral Agent”), pursuant to which the Company issued first lien senior secured notes in an aggregate principal amount of $200.0 million (the “First Lien Notes”); and (ii) a second lien note purchase agreement (the “Second Lien Note Facility” and, together with the First Lien Note Facility, the “Notes Facilities”) among the Company, which is the issuer under the agreement, the financial institutions and note purchasers from time to time party to the agreement (the “Second Lien Note Purchasers”), and Wells Fargo Bank, National Association, in its capacity as collateral agent for itself and the Second Lien Note Purchasers (the “Second Lien Collateral Agent” and, together with the First Lien Collateral Agent, the “Collateral Agent”), pursuant to which the Company (a) issued second lien senior secured notes in an aggregate initial principal amount of $100.0 million (the “Initial Second Lien Notes”) and (b) had the ability to draw upon the Second Lien Note Facility and issue second lien delayed draw senior secured notes, which was exercised on June 21, 2018, in an aggregate initial principal amount of $10.0 million, representing the maximum borrowings allowed on this facility (the “Second Lien Delayed Draw Notes” and, together with the Initial Second Lien Notes, the “Second Lien Notes”; the Second Lien Notes, together with the First Lien Notes, the “Notes”). Funds managed by Ares are acting as lead purchasers for the Notes Facilities.
The Company used the proceeds of the sale of the First Lien Notes and the Initial Second Lien Notes to repay in full all amounts outstanding under the Prior Credit Agreements and extinguished the liability. Each of the Prior Credit Agreements was terminated following such repayment. The Company used the remaining proceeds of $15.9 million, net of $0.2 million in issuance costs, from the Notes Facilities and the Second Quarter 2017 Private Placement for working capital and general corporate purposes.
The First Lien Notes accrue interest, payable monthly in arrears, at a floating rate or rates equal to, at the option of the Company, (i) the base rate (defined as the highest of the Federal Funds Rate plus 0.5% per annum, the Prime Rate as published by The Wall Street Journal and the one-month London Interbank Offered Rate (“LIBOR”) (subject to a 1.0% floor) plus 1.0%), or (ii) the one-month LIBOR rate (subject to a 1.0% floor), plus a margin of 6.0% if the base rate is selected or 7.0% if the LIBOR Option is selected. The First Lien Notes mature on August 15, 2020, provided that if the Company’s existing 8.875% Senior Notes due 2021 (the “2021 Notes”) are refinanced prior to August 15, 2020, then the scheduled maturity date of the First Lien Notes shall be June 30, 2022.
The First Lien Notes will amortize in equal quarterly installments equal to 0.625% of the aggregate principal amount of the First Lien Note Facility, commencing on September 30, 2019, and on the last day of each third month thereafter, with the balance payable at maturity. The First Lien Notes are pre-payable at the Company’s option at specified premiums to the principal amount that will decline over the term of the First Lien Note Facility. If the First Lien Notes are prepaid prior to the second anniversary of the Closing Date, the Company will be required to pay a make-whole premium based on the present value (using a discount rate based on the specified treasury rate plus 50 basis points) of all remaining interest payments on the First Lien Notes being prepaid prior to the second anniversary of the Closing Date, plus 4.0% of the principal amount of First Lien Notes being prepaid. On or after the second anniversary of the Closing Date, the prepayment premium is 4.0%, which declines to 2.0% on or after the third anniversary of the Closing Date, and declines to 0.0% on or after the fourth anniversary of the Closing Date. At any time, the Company may pre-pay up to $50.0 million in aggregate principal amount of the First Lien Notes from internally generated cash without incurring any make-whole or prepayment premium. The occurrence of certain events of default may increase the applicable rate of interest by 2.0% and could result in the acceleration of the Company’s obligations under the First Lien Note Facility prior to stated maturity and an obligation of the Company to pay the full amount of its obligations under the First Lien Note Facility.
The First Lien Note Facility contains customary events of default that include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material indebtedness and events constituting a change of control. In addition, the obligations under the First Lien Note Facility will be guaranteed by joint and several guarantees from the Company’s subsidiaries.
In connection with the First Lien Note Facility, the Company, its subsidiaries and the First Lien Collateral Agent entered into a First Lien Guaranty and Security Agreement, dated as of June 29, 2017 (the “First Lien Guaranty and Security Agreement”). Pursuant to the First Lien Guaranty and Security Agreement, the obligations under the First Lien Notes will be secured by first priority liens on, and security interests in, substantially all of the assets of the Company and its subsidiaries.
The Second Lien Notes accrue interest, payable monthly in arrears, at a floating rate or rates equal to, at the option of the Company, (i) one-month LIBOR (subject to a 1.25% floor) plus 9.25% per annum in cash, (ii) one-month LIBOR (subject to a 1.25% floor) plus 11.25% per annum, which amount will be capitalized on each interest payment date, or (iii) one-month LIBOR (subject to a 1.25% floor) plus 10.25% per annum, of which one-half LIBOR plus 4.625% per annum will be payable in cash and one-half LIBOR plus 5.625% per annum will be capitalized on each interest payment date, provided that, in each case, if any permitted refinancing indebtedness with which the 2021 Notes are refinanced requires or permits the payment of cash interest, all of the interest on the Second Lien Notes shall be paid in cash. During the third quarter, $3.8 million of interest was capitalized to the Second Lien Notes, increasing the principal amount to $113.8 million as of September 30, 2018. The Second Lien Notes mature on August 15, 2020, provided that if the 2021 Notes are refinanced prior to August 15, 2020, then the scheduled maturity date of the Second Lien Notes shall be June 30, 2022.
In connection with the Second Lien Note Facility, the Company also issued warrants (the “2017 Warrants”) to the purchasers of the Second Lien Notes pursuant to a Warrant Purchase Agreement dated as of June 29, 2017 (the “Warrant Purchase Agreement”). The 2017 Warrants entitle the purchasers of the Warrants to purchase shares of Common Stock, representing at the time of any exercise of the 2017 Warrants an equivalent number of shares equal to 4.99% of the Common Stock of the Company on a fully diluted basis, subject to the terms of the Warrant Agreement governing the Warrants, dated as of June 29, 2017 (the “Warrant Agreement”). The 2017 Warrants, considered a derivative and subject to remeasurement at each reporting period, are reflected in other non-current liabilities at a fair value of $21.7 million.
The Second Lien Notes are not subject to scheduled amortization installments. The Second Lien Notes are pre-payable at the Company’s option at specified premiums to the principal amount that will decline over the term of the Second Lien Note Facility. If the Second Lien Notes are prepaid prior to the third anniversary of the Closing Date, the Company will need to pay a make-whole premium based on the present value (using a discount rate based on the specified treasury rate plus 50 basis points) of all remaining interest payments on the Second Lien Notes being prepaid prior to the third anniversary of the Closing Date, plus 4.0% of the principal amount of Second Lien Notes being prepaid. On or after the third anniversary of the Closing Date, the prepayment premium is 4.0%, which declines to 2.0% on or after the fourth anniversary of the Closing Date, and declines to 0.0% on or after the fifth anniversary of the Closing Date. The occurrence of certain events of default may increase the applicable rate of interest by 2.0% and could result in the acceleration of the Company’s obligations under the Second Lien Note Facility prior to stated maturity and an obligation of the Company to pay the full amount of its obligations under the Second Lien Note Facility.
The Second Lien Note Facility contains customary events of default that include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material indebtedness and events constituting a change of control. In addition, the obligations under the Second Lien Note Facility will be guaranteed by joint and several guarantees from the Company’s subsidiaries.
In connection with the Second Lien Note Facility, the Company, its subsidiaries and the Second Lien Collateral Agent entered into a Second Lien Guaranty and Security Agreement, dated as of June 29, 2017 (the “Second Lien Guaranty and Security Agreement”). Pursuant to the Second Lien Guaranty and Security Agreement, the obligations under the Second Lien Notes will be secured by second priority liens on, and security interests in, substantially all of the assets of the Company and its subsidies.
In connection with the First Lien Note Facility and the Second Lien Note Facility, the Company, the First Lien Collateral Agent and the Second Lien Collateral Agent, entered into an intercreditor agreement containing customary provisions to, among other things, subordinate the lien priority of the liens granted under the Second Lien Note Facility to the liens granted under the First Lien Note Facility.
2021 Notes
On February 11, 2014, the Company issued $200.0 million aggregate principal amount of the 2021 Notes. The 2021 Notes are senior unsecured obligations of the Company and are fully and unconditionally guaranteed by all existing and future subsidiaries of the Company.
Interest on the 2021 Notes accrues at a fixed rate of 8.875% per annum and is payable in cash semi-annually on February 15 and August 15 of each year. The debt discount of $5.0 million at issuance is being amortized as interest expense through maturity which will result in the accretion over time of the outstanding debt balance to the principal amount. The 2021 Notes are the Company’s senior unsecured obligations and rank equally in right of payment with all of its other existing and future senior unsecured indebtedness and senior in right of payment to all of its existing and future subordinated indebtedness.
The 2021 Notes are guaranteed on a full, joint and several basis by each of the Company’s existing and future domestic restricted subsidiaries that is a borrower under any of the Company’s credit facilities or that guarantees any of the Company’s debt or that of any of its restricted subsidiaries, in each case incurred under the Company’s credit facilities. As of September 30, 2018, the Company does not have any independent assets or operations, and as a result, its direct and indirect subsidiaries (other than minor subsidiaries), each being 100% owned by the Company, are fully and unconditionally, jointly and severally, providing guarantees on a senior unsecured basis to the 2021 Notes.
Fair Value of Financial Instruments
The following details our financial instruments where the carrying value and the fair value differ (in thousands):
Financial Instrument
 
Carrying Value as of September 30, 2018
 
Markets for Identical Item (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
First Lien Note Facility
 
$
198,801

 
$
—

 
$
—

 
$
202,512

Second Lien Note Facility
 
103,571

 
—

 
—

 
117,219

2017 Warrants
 
21,724

 
—

 
21,724

 
—

2021 Notes
 
197,927

 
—

 
189,500

 
—

Total
 
$
522,023

 
$
—

 
$
211,224

 
$
319,731


The fair value hierarchy for disclosure of fair value measurements is as follows:
Level 1:  Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2:  Quoted prices, other than quoted prices included in Level 1, which are observable for the assets or liabilities, either directly or indirectly.
Level 3:  Inputs that are unobservable for the assets or liabilities.
Financial assets with carrying values approximating fair value include cash and cash equivalents and accounts receivable. Financial liabilities with carrying values approximating fair value include accounts payable and capital leases. The carrying value of these financial assets and liabilities approximates fair value due to their short maturities.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
COMMITMENTS AND CONTINGENCIES
 9 Months Ended
Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
COMMITMENTS AND CONTINGENCIES
Legal Proceedings
The Company is a party to various legal, regulatory and governmental proceedings incidental to its business. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental matters, including the matters described herein, will have a material adverse effect on the consolidated financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in pending legal, regulatory and governmental matters, some of which are beyond the Company’s control, and the indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could be material to the Company’s results of operations or cash flows for any particular reporting period. 
 
With respect to all legal, regulatory and governmental proceedings, the Company considers the likelihood of a negative outcome. If the Company determines the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, the Company records an accrual for the estimated loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and the Company is able to determine an estimate of the possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, the Company discloses the estimate of the possible loss or range of loss. However, the Company is unable to estimate a possible loss or range of loss in some instances based on the significant uncertainties involved in, and/or the preliminary nature of, certain legal, regulatory and governmental matters.

On December 18, 2017, a commercial payor of the Company sent a letter that claimed an alleged breach of the Company’s obligation under its provider contracts.  No legal proceeding has been filed. The Company is not able to estimate the amount of any possible loss.  The Company believes this claim is without merit and intends to vigorously defend against this claim if any such legal proceeding is commenced.

Government Regulation

Various federal and state laws and regulations affecting the healthcare industry impact or may in the future impact the Company’s current and planned operations, including, without limitation, federal and state laws and regulations prohibiting kickbacks in connection with healthcare services, prohibiting certain conduct deemed to be anti-competitive (antitrust laws) and restricting drug distribution. Other laws and regulations that may affect our business include, but are not limited to, consumer protection, insurance, licensure, and privacy. There can be no assurance the Company will be able to obtain or maintain any of the regulatory approvals that may be required to operate its business, and the failure to do so could have a material effect on the Company’s financial statements.

From time to time, the Company responds to investigatory subpoenas and requests for information from governmental agencies and private parties. The Company cannot predict with certainty what the outcome of any of the foregoing might be. While the Company believes it is in substantial compliance with all existing laws and regulations material to the operation of its business, such laws and regulations are often uncertain in their application to our business practices as they evolve and are subject to rapid change. As controversies continue to arise in the healthcare industry, federal and state regulation and enforcement priorities in this area can be expected to increase, the impact of which cannot be predicted. There can be no assurance that the Company will not be subject to scrutiny or challenge under one or more regulations or that any such challenge would not be successful. Any such challenge, whether or not successful, could have a material effect upon the Company’s Consolidated Financial Statements. A violation of the federal Anti-Kickback Statute, for example, may result in substantial criminal and civil penalties, as well as suspension or exclusion from the Medicare and Medicaid programs. Moreover, the costs and expenses associated with defending these actions, even where successful, can be significant.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONCENTRATION OF RISK
 9 Months Ended
Sep. 30, 2018
Risks and Uncertainties [Abstract]  
Concentration of Risk
CONCENTRATION OF RISK
Customer and Credit Concentration Risk
The Company provides trade credit to its customers in the normal course of business. No single payor accounted for more than 10.0% of revenue during the three and nine months ended September 30, 2018. One commercial payor, United Healthcare, accounted for approximately 18.1% and 21.0% of revenue during the three and nine months ended September 30, 2017, respectively.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
INCOME TAXES
 9 Months Ended
Sep. 30, 2018
Income Tax Disclosure [Abstract]  
Income Taxes
INCOME TAXES
The Company’s federal and state income tax provision from continuing operations for the three months and nine months ended September 30, 2018 and 2017 is summarized in the following table (in thousands):
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2018
 
2017
 
2018
 
2017
Current
 
 
 
 
 
 
 
Federal
$
—

 
$
(925
)
 
$
—

 
$
(925
)
State
50

 
378

 
84

 
528

Total current
50

 
(547
)
 
84

 
(397
)
Deferred
 

 
 

 
 

 
 

Federal
—

 
515

 
—

 
1,523

State
52

 
92

 
107

 
271

Total deferred
52

 
607

 
107

 
1,794

Total income tax expense
$
102

 
$
60

 
$
191

 
$
1,397



The Company’s reconciliation of the statutory rate from continuing operations to the effective income tax rate for the three months and nine months ended September 30, 2018 and 2017 is summarized as follows (in thousands):
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2018
 
2017
 
2018
 
2017
Tax benefit at statutory rate
$
(1,680
)
 
$
(4,307
)
 
$
(7,564
)
 
$
(20,543
)
State tax expense, net of federal taxes
102

 
378

 
191

 
528

Alternative Minimum Tax receivable
—

 
(925
)
 
—

 
(925
)
Valuation allowance changes affecting income tax provision
1,261

 
4,876

 
7,163

 
22,194

Permanent items
419

 
38

 
401

 
143

Income tax expense
$
102

 
$
60

 
$
191

 
$
1,397


On December 22, 2017, the President of the United States signed into law the Tax Cuts and Jobs Act of 2017 or U.S. Federal Tax Reform (the “Reform”). The enactment included broad tax changes that are applicable to BioScrip, Inc. Most notably, the Reform decreased the U.S. corporate income tax rate from a high of 35% to a flat 21% rate effective January 1, 2018. As a result, the Company has revalued its ending net deferred tax assets as of December 31, 2017. At September 30, 2018, the Company had Federal net operating loss (“NOL”) carry forwards of approximately $427.0 million, of which $10.8 million is subject to an annual limitation, which will begin expiring in 2026 and later. The Company also has a carryforward of approximately $37.1 million related to the interest expense limitation, which is not subject to an expiration period. The Company has post-apportioned state NOL carry forwards of approximately $467.1 million, the majority of which will begin expiring in 2018 and later.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCK-BASED COMPENSATION
 9 Months Ended
Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation
STOCK-BASED COMPENSATION
BioScrip Equity Incentive Plans
Under the Company’s 2018 Equity Incentive Plan (the “2018 Plan”), approved at the annual meeting by the stockholders on May 3, 2018, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights (“SARs”), restricted stock units, stock grants, and performance units to key employees and directors. The 2018 Plan is administered by the Company’s Management Development and Compensation Committee (the “Compensation Committee”), a standing committee of the Board of Directors.
A total of 16,406,939 shares of stock are authorized for issuance under the 2018 Plan, to include shares that remained available for grant under the 2008 Plan as of the effective date of the 2018 Plan. The authorized shares were reduced by all shares granted under the 2008 Plan after December 31, 2017 in accordance with the terms of the 2018 Plan. No key employee in any calendar year will be granted more than 3,000,000 shares of Stock with respect to (i) Options to purchase shares of Stock, (ii) Stock Appreciation Rights (based on the appreciation with respect to shares of Stock); and (iii) Stock Grants and Restricted Stock Units that are intended to comply with the requirements of Section 162(m) of the Code.
As of September 30, 2018, 13,339,067 shares remain available for grant under the 2018 Plan.
Stock Options
The Company recognized compensation expense related to stock options of $0.3 million and $0.1 million during the three months ended September 30, 2018 and 2017, respectively, and $0.9 million and $0.8 million during the nine months ended September 30, 2018 and 2017, respectively.
Restricted Stock
The Company recognized $0.8 million and $0.4 million of compensation expense related to restricted stock awards during the three months ended September 30, 2018 and 2017, respectively, and $1.8 million and $0.6 million of compensation expense during the nine months ended September 30, 2018 and 2017, respectively.
Stock Appreciation Rights and Market Based Cash Awards
The Company recognized nominal amounts of compensation expense related to stock appreciation rights awards during the three months ended September 30, 2018 and 2017 and the nine months ended September 30, 2018 and 2017.
The Company recognized $0.1 million and a nominal amount of compensation expense related to market based cash awards during the three months ended September 30, 2018 and 2017, respectively, and $0.2 million and $0.1 million of compensation expense during nine months ended September 30, 2018 and 2017, respectively.
Employee Stock Purchase Plan
On May 3, 2018, the Company’s stockholders approved an amendment to the BioScrip, Inc. Employee Stock Purchase Plan (the “ESPP”). The ESPP provides all eligible employees, as defined under the ESPP, the opportunity to purchase up to a maximum number of shares of Common Stock of the Company as determined by the Compensation Committee. Participants in the ESPP may acquire the Common Stock at a cost of 85% of the lower of the fair market value on the first or last day of the quarterly offering period.
As of September 30, 2018, 1,422,842 shares remained available for grant under the ESPP. Since inception, the ESPP’s third-party service provider has purchased 827,158 shares on the open market and delivered these shares to the Company’s employees pursuant to the ESPP. During the three months ended September 30, 2018 and 2017, the Company incurred less than $0.1 million of expense. During the nine months ended September 30, 2018 and 2017, the company incurred $0.1 million of expense related to the ESPP.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Basis of Presentation
These Unaudited Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements, including the notes thereto, and other information included in the Annual Report on Form 10-K of BioScrip, Inc. and its wholly-owned subsidiaries (the “Company”) for the year ended December 31, 2017 (the “Annual Report”) filed with the U.S. Securities and Exchange Commission (“SEC”). These Unaudited Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information, and the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.
The information furnished in these Unaudited Consolidated Financial Statements reflects all adjustments, including normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. Operating results for the interim periods presented require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes and are not necessarily indicative of the results that may be expected for the full year.
Consolidation
The Unaudited Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Cash and Cash Equivalents and Restricted Cash
Cash and Cash Equivalents and Restricted Cash

Highly liquid investments with a maturity of three months or less when purchased are classified as cash equivalents. Restricted cash consists of cash balances held by financial institutions as collateral for letters of credit. These balances are reclassified to cash and cash equivalents when the underlying obligation is satisfied, or in accordance with the governing agreement. Restricted cash balances expected to become unrestricted during the next twelve months are recorded as current assets.
Recent Accounting Pronouncements
Recent Accounting Pronouncements

In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-15 — Internal Use Software. ASU 2018-15 aligns the requirements for capitalization of implementation costs related to hosted software with the existing internal-use software guidance. The effective date for ASU 2018-15 is for annual and interim periods beginning after December 15, 2019. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.
In August 2018, the FASB issued ASU 2018-13— Fair Value Measurement (Topic 820): Disclosure Framework— Changes to the Disclosure Requirements for Fair Value Measurements. ASU 2018-13 modifies fair value measurement disclosure requirements. The effective date for ASU 2018-13 is for annual and interim periods beginning after December 15, 2019. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s disclosures to the consolidated financial statements.
In May 2014, the FASB issued ASU 2014-09—Revenue from Contracts with Customers (Topic 606). The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The FASB delayed the effective date to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. The Company did not elect early adoption and applied the modified retrospective approach upon adoption which results in application of the new guidance only to contracts that are not completed at the adoption date and does not require adjustment of prior reporting periods. Assessment of the new guidance did not result in an opening retained earnings adjustment, but did result in the adjustment of accounts receivable as the allowance for doubtful accounts was eliminated upon implementation. Pursuant to the requirements of Topic 606, the transaction price to be recognized as revenue is estimated based upon the amount of cash ultimately expected to be collected. Therefore, amounts expected to be written off are reflected in the amount of revenue recognized upon fulfillment of the performance obligation. The new standard resulted in the recognition of amounts previously reported as bad debt expense as a reduction to revenue upon implementation; see Note 3 - Revenue.
In July 2017, the FASB issued ASU 2017-11—Earnings Per Share (Topic 260), Distinguishing Liabilities From Equity (Topic 480), and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 eliminates the requirement that a down round feature precludes equity classification when assessing whether an instrument is indexed to an entity’s own stock. A freestanding equity-linked financial instrument no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. The effective date for ASU 2017-11 is for annual or any interim periods beginning after December 15, 2018. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.
In May 2017, the FASB issued ASU 2017-09—Compensation–Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-09 modifies when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the same immediately before and after a change to the terms and conditions of the award. The effective date for ASU 2017-09 is for annual or any interim periods beginning after December 15, 2017. The Company adopted this ASU effective January 1, 2018. The adoption of this standard did not materially impact the Company’s consolidated financial statements.
In November 2016, the FASB issued ASU 2016-18—Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The effective date for ASU 2016-18 is for annual or any interim periods beginning after December 15, 2017. The Company adopted this ASU effective January 1, 2018. The adoption of this standard did not materially impact the Company’s consolidated financial statements.
In August 2016, the FASB issued ASU 2016-15—Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 provides guidance for eight specific cash flow issues with respect to how cash receipts and cash payments are classified in the statements of cash flows, with the objective of reducing diversity in practice. The effective date for ASU 2016-15 is for annual periods beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this ASU effective January 1, 2018. The adoption of this standard did not materially impact the Company’s consolidated financial statements.
In February 2016, the FASB issued ASU 2016-02—Leases (Topic 842), requiring lessees to recognize a right-of-use asset and a lease liability on the balance sheet for all leases with the exception of short-term leases. For lessees, leases will continue to be classified as either operating or finance leases in the income statement. The effective date of the new standard for public companies is for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. In January 2018, the FASB issued an additional amendment that provides a practical expedient giving companies the option to not evaluate existing or expired land easements that were not previously accounted for as leases under the current leases guidance. The amendment in the update is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. In July 2018, the FASB issued an additional amendment, ASU 2018-11, which provides a new, optional transition method and provides lessors a practical expedient for separating lease and non-lease components. In July 2018, the FASB additionally issued ASU 2018-1— Codification Improvements to Topic 842, Leases, which clarifies and correct errors in ASC 842. The effective date for the amendments issued is the same as the effective date of ASC 842. Although early adoption is permitted, the Company plans to adopt the guidance on January 1, 2019. Topic 842 requires the recognition and measurement of leases at the beginning of the earliest comparative period presented in the financial statements, using a modified retrospective approach, with an option to apply the transition provisions of the new guidance at the adoption date without adjusting the comparative periods presented. The Company is evaluating the effect of adoption of the updated standard on its consolidated financial statements.

Adoption of ASC Topic 606, "Revenue from Contracts with Customers"

On January 1, 2018, the Company adopted Topic 606 using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under Topic 606, while prior period amounts are not restated and continue to be reported in accordance with accounting standards in effect for those periods.
Revenue Recognition
Infusion Revenues

The Company generates revenue principally through the provision of infusion services to provide clinical management services and the delivery of cost effective prescription medications. Prescription drugs are dispensed either through a pharmacy participating in the Company’s pharmacy network or a pharmacy owned by the Company. Fee-for-service agreements include pharmacy agreements, under which we dispense prescription medications through the Company’s pharmacy facilities.

The Company provides a variety of therapies to patients. For infusion-related therapies, the Company frequently provides multiple deliverables of drugs and related nursing services. After applying the criteria from Topic 606, the Company concluded that multiple performance obligations exist in its contracts with its customers. Revenue is allocated to each performance obligation based on relative standalone price, determined based on reimbursement rates established in the third party payor contracts. Drug revenue is recognized at the time the drug is shipped, and nursing revenue is recognized on the date of service.

Revenue Recognition

Topic 606 requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to be entitled to in exchange for those goods or services. Topic 606 requires application of a five-step model to determine when to recognize revenue and at what amount. The revenue standard applies to all contracts with customers and revenues are to be recognized when control of the promised goods or services is transferred to the Company’s patients in an amount that reflects consideration expected to be received in exchange for those goods or services.
Fair Value Measurement
The fair value hierarchy for disclosure of fair value measurements is as follows:
Level 1:  Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2:  Quoted prices, other than quoted prices included in Level 1, which are observable for the assets or liabilities, either directly or indirectly.
Level 3:  Inputs that are unobservable for the assets or liabilities.
Financial assets with carrying values approximating fair value include cash and cash equivalents and accounts receivable. Financial liabilities with carrying values approximating fair value include accounts payable and capital leases. The carrying value of these financial assets and liabilities approximates fair value due to their short maturities.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
BASIS OF PRESENTATION (Tables)
 9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Effect of Error Corrections
The following tables set forth the effect these corrections had on the Company’s unaudited consolidated statements of operations for the three and nine months ended ended September 30, 2017:
 
Three Months Ended 
 September 30, 2017
 
Nine Months Ended 
 September 30, 2017
 
Previously Reported
 
Corrections
 
Revised
 
Previously Reported
 
Corrections
 
Revised
 Net revenue
$
198,692

 
$
—

 
$
198,692

 
$
634,608

 
$
—

 
$
634,608

 Gross profit
67,176

 
(613
)
 
66,563

 
201,070

 
(2,022
)
 
199,048

 Total Operating Expenses
66,345

 
(144
)
 
66,201

 
221,128

 
(497
)
 
220,631

 Interest expense
13,175

 
185

 
13,360

 
38,635

 
14

 
38,649

 Loss from continuing operations, net of income taxes
(12,404
)
 
(654
)
 
(13,058
)
 
(60,090
)
 
(1,538
)
 
(61,628
)
 Income (loss) from discontinued operations, net of income taxes
(113
)
 
179

 
66

 
(1,053
)
 
447

 
(606
)
 Net loss
$
(12,517
)
 
$
(475
)
 
$
(12,992
)
 
$
(61,143
)
 
$
(1,091
)
 
$
(62,234
)
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Schedule of Accounts Receivable Aging
The following table sets forth the aging of our net accounts receivable (net of allowance for contractual adjustments, and prior to allowance for doubtful accounts), aged based on date of service and categorized based on the three primary overall types of accounts receivable characteristics (in thousands):
 
 
September 30, 2018
 
December 31, 2017
 
 
0 - 180 days
 
Over 180 days
 
Total
 
0 - 180 days
 
Over 180 days
 
Total
Government
 
$
12,555

 
$
3,028

 
$
15,583

 
$
20,602

 
$
10,082

 
$
30,684

Commercial
 
80,508

 
10,825

 
91,333

 
63,767

 
18,779

 
82,546

Patient
 
1,922

 
4,790

 
6,712

 
2,577

 
7,627

 
10,204

Gross accounts receivable
 
$
94,985

 
$
18,643

 
113,628

 
$
86,946

 
$
36,488

 
123,434

Allowance for doubtful accounts
 
 
 
 
 
—

 
 
 
 
 
(37,912
)
Net accounts receivable
 
 
 
 
 
$
113,628

 
 
 
 
 
$
85,522
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
REVENUE (Tables)
 9 Months Ended
Sep. 30, 2018
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue by Payor
The following table presents our revenues at amounts initially recognized for each associated payor class for the three and nine months ended September 30, 2018 (in millions). Sales and usage-based taxes are excluded from revenues.
 
 
Three Months Ended September 30, 2018
 
Nine Months Ended September 30, 2018
 Commercial
 
$
139,077

 
$
431,869

 Government
 
39,498

 
88,437

 Patient
 
2,387

 
5,029

 Total Revenue
 
$
180,962

 
$
525,335
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
LOSS PER SHARE (Tables)
 9 Months Ended
Sep. 30, 2018
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Loss Per Share
The following table sets forth the computation of basic and diluted loss per common share (in thousands, except for per share amounts):
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2018
 
2017
 
2018
 
2017
Numerator:
 
 
 
 
 
 
 
Loss from continuing operations, net of income taxes
$
(8,103
)
 
$
(13,058
)
 
$
(36,212
)
 
$
(61,629
)
Income (Loss) from discontinued operations, net of income taxes
(71
)
 
66

 
(118
)
 
(606
)
Net loss
$
(8,174
)
 
$
(12,992
)
 
$
(36,330
)
 
$
(62,235
)
Dividends on preferred stock
(2,861
)
 
(2,569
)
 
(8,272
)
 
(7,435
)
Loss attributable to common stockholders
$
(11,035
)
 
$
(15,561
)
 
$
(44,602
)
 
$
(69,670
)
 
 
 
 
 
 
 
 
Denominator - Basic and Diluted:
 

 
 

 
 

 
 

Weighted average common shares outstanding
127,528

 
127,488

 
127,893

 
122,519

 
 
 
 
 
 
 
 
Loss per Common Share:
 
 
 
 
 
 
 
Loss from continuing operations, basic and diluted
$
(0.09
)
 
$
(0.12
)
 
$
(0.35
)
 
$
(0.56
)
Loss from discontinued operations, basic and diluted
—

 
—

 
—

 
(0.01
)
Loss per common share, basic and diluted
$
(0.09
)
 
$
(0.12
)
 
$
(0.35
)
 
$
(0.57
)
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCKHOLDERS' DEFICIT (Tables)
 9 Months Ended
Sep. 30, 2018
Equity [Abstract]  
Carrying value and activity of Preferred Shares
The following table sets forth the activity recorded during the nine months ended September 30, 2018 related to the Series C Preferred Stock (in thousands):
Series C Preferred Stock carrying value at December 31, 2017
$
79,252

Dividends and discount accretion through September 30, 2018 1
7,973

Series C Preferred Stock carrying value September 30, 2018
$
87,225


1 Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.
The following table sets forth the activity recorded during the nine months ended September 30, 2018 related to the Series A Preferred Stock (in thousands):
Series A Preferred Stock carrying value at December 31, 2017
$
2,827

Dividends and discount accretion through September 30, 2018 1
299

Series A Preferred Stock carrying value September 30, 2018
$
3,126

1 Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES (Tables)
 9 Months Ended
Sep. 30, 2018
Restructuring and Related Activities [Abstract]  
Schedule of Restructuring, Acquisition, Integration, and Other Expenses, Net
Restructuring, acquisition, integration, and other expenses in the Unaudited Consolidated Statements of Operations for the three and nine months ended ended September 30, 2018 and 2017 consisted of the following (in thousands):
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2018
 
2017
 
2018
 
2017
Restructuring expense
$
833

 
$
3,791

 
$
4,666

 
$
10,881

Acquisition and integration expense
52

 
246

 
123

 
526

Total restructuring, acquisition, integration, and other expenses
$
885

 
$
4,037

 
$
4,789

 
$
11,407
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
DEBT (Tables)
 9 Months Ended
Sep. 30, 2018
Debt Disclosure [Abstract]  
Summary of Long-term Debt
As of September 30, 2018 and December 31, 2017, the Company’s debt consisted of the following (in thousands):
 
September 30,
 2018
 
December 31,
2017
First Lien Note Facility, net of unamortized discount
198,801

 
198,324

Second Lien Note Facility, net of unamortized discount
103,571

 
85,694

2021 Notes, net of unamortized discount
197,927

 
197,363

Capital leases
1,239

 
2,863

Less: Deferred financing costs
(2,692
)
 
(3,656
)
Total Debt
498,846

 
480,588

Less: Current portion of long-term debt
(2,076
)
 
(1,722
)
Long-term debt, net of current portion
$
496,770

 
$
478,866
Schedule of Carrying and Estimated Fair Values of Financial Instruments
The following details our financial instruments where the carrying value and the fair value differ (in thousands):
Financial Instrument
 
Carrying Value as of September 30, 2018
 
Markets for Identical Item (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
First Lien Note Facility
 
$
198,801

 
$
—

 
$
—

 
$
202,512

Second Lien Note Facility
 
103,571

 
—

 
—

 
117,219

2017 Warrants
 
21,724

 
—

 
21,724

 
—

2021 Notes
 
197,927

 
—

 
189,500

 
—

Total
 
$
522,023

 
$
—

 
$
211,224

 
$
319,731
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
INCOME TAXES (Tables)
 9 Months Ended
Sep. 30, 2018
Income Tax Disclosure [Abstract]  
Schedule of Federal and State Income Tax Provision (Benefit)
The Company’s federal and state income tax provision from continuing operations for the three months and nine months ended September 30, 2018 and 2017 is summarized in the following table (in thousands):
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2018
 
2017
 
2018
 
2017
Current
 
 
 
 
 
 
 
Federal
$
—

 
$
(925
)
 
$
—

 
$
(925
)
State
50

 
378

 
84

 
528

Total current
50

 
(547
)
 
84

 
(397
)
Deferred
 

 
 

 
 

 
 

Federal
—

 
515

 
—

 
1,523

State
52

 
92

 
107

 
271

Total deferred
52

 
607

 
107

 
1,794

Total income tax expense
$
102

 
$
60

 
$
191

 
$
1,397
Reconciliation of the Income Tax Rate
The Company’s reconciliation of the statutory rate from continuing operations to the effective income tax rate for the three months and nine months ended September 30, 2018 and 2017 is summarized as follows (in thousands):
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
2018
 
2017
 
2018
 
2017
Tax benefit at statutory rate
$
(1,680
)
 
$
(4,307
)
 
$
(7,564
)
 
$
(20,543
)
State tax expense, net of federal taxes
102

 
378

 
191

 
528

Alternative Minimum Tax receivable
—

 
(925
)
 
—

 
(925
)
Valuation allowance changes affecting income tax provision
1,261

 
4,876

 
7,163

 
22,194

Permanent items
419

 
38

 
401

 
143

Income tax expense
$
102

 
$
60

 
$
191

 
$
1,397
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
BASIS OF PRESENTATION (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
USD ($)
state
location
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
segment
state
location
Sep. 30, 2017
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Number of service locations | location 70   70  
Number of states in which the entity does business | state 27   27  
Number of operating segments | segment     1  
Error Corrections and Prior Period Adjustments Restatement [Line Items]        
Net revenue $ 180,962 $ 198,692 $ 525,335 $ 634,608
Gross profit 65,911 66,563 180,916 199,048
Loss from continuing operations, net of income taxes (8,103) (13,058) (36,212) (61,629)
Income (loss) from discontinued operations, net of income taxes (71) 66 (118) (606)
Net loss $ (8,174) (12,992) $ (36,330) (62,235)
Accounting For Suspense and Clearing Accounts        
Error Corrections and Prior Period Adjustments Restatement [Line Items]        
Net revenue   198,692   634,608
Gross profit   66,563   199,048
Total Operating Expenses   66,201   220,631
Interest expense   13,360   38,649
Loss from continuing operations, net of income taxes   (13,058)   (61,628)
Income (loss) from discontinued operations, net of income taxes   66   (606)
Net loss   (12,992)   (62,234)
Previously Reported | Accounting For Suspense and Clearing Accounts        
Error Corrections and Prior Period Adjustments Restatement [Line Items]        
Net revenue   198,692   634,608
Gross profit   67,176   201,070
Total Operating Expenses   66,345   221,128
Interest expense   13,175   38,635
Loss from continuing operations, net of income taxes   (12,404)   (60,090)
Income (loss) from discontinued operations, net of income taxes   (113)   (1,053)
Net loss   (12,517)   (61,143)
Corrections | Accounting For Suspense and Clearing Accounts        
Error Corrections and Prior Period Adjustments Restatement [Line Items]        
Net revenue   0   0
Gross profit   (613)   (2,022)
Total Operating Expenses   (144)   (497)
Interest expense   185   14
Loss from continuing operations, net of income taxes   (654)   (1,538)
Income (loss) from discontinued operations, net of income taxes   179   447
Net loss   $ (475)   $ (1,091)
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Accounting Policies [Abstract]    
Restricted cash $ 4,320 $ 4,950
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounts Receivable Aging (Details) - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross accounts receivable $ 113,628 $ 123,434
Allowance for doubtful accounts 0 (37,912)
Net accounts receivable 113,628 85,522
Government    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross accounts receivable 15,583 30,684
Commercial    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross accounts receivable 91,333 82,546
Patient    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross accounts receivable 6,712 10,204
Receivables 0 to 180 Days Past Due    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross accounts receivable 94,985 86,946
Receivables 0 to 180 Days Past Due | Government    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross accounts receivable 12,555 20,602
Receivables 0 to 180 Days Past Due | Commercial    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross accounts receivable 80,508 63,767
Receivables 0 to 180 Days Past Due | Patient    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross accounts receivable 1,922 2,577
Receivables Over 180 Days Past Due    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross accounts receivable 18,643 36,488
Receivables Over 180 Days Past Due | Government    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross accounts receivable 3,028 10,082
Receivables Over 180 Days Past Due | Commercial    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross accounts receivable 10,825 18,779
Receivables Over 180 Days Past Due | Patient    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Gross accounts receivable $ 4,790 $ 7,627
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
REVENUE (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Disaggregation of Revenue [Line Items]          
Total Revenue $ 180,962 $ 198,692 $ 525,335 $ 634,608  
Gross profit 65,911 66,563 180,916 199,048  
Bad debt expense 0 $ 6,488 0 $ 19,648  
Allowance for doubtful accounts 0   0   $ 37,912
Commercial          
Disaggregation of Revenue [Line Items]          
Total Revenue 139,077   431,869    
Government          
Disaggregation of Revenue [Line Items]          
Total Revenue 39,498   88,437    
Patient          
Disaggregation of Revenue [Line Items]          
Total Revenue 2,387   5,029    
Calculated under Revenue Guidance in Effect before Topic 606          
Disaggregation of Revenue [Line Items]          
Total Revenue 186,700   541,900    
Gross profit 71,600   197,500    
Bad debt expense 5,700   16,500    
Allowance for doubtful accounts $ 42,900   $ 42,900    
Revenue from Rights Concentration Risk | Sales Revenue, Net          
Disaggregation of Revenue [Line Items]          
Percentage of concentration risk     1.00%    
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
LOSS PER SHARE (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Earnings Per Share [Abstract]          
Common stock, par value (in dollars per share) $ 0.0001   $ 0.0001   $ 0.0001
Numerator:          
Loss from continuing operations, net of income taxes $ (8,103) $ (13,058) $ (36,212) $ (61,629)  
Income (loss) from discontinued operations, net of income taxes (71) 66 (118) (606)  
Net loss (8,174) (12,992) (36,330) (62,235)  
Dividends on preferred stock (2,861) (2,569) (8,272) (7,435)  
Loss attributable to common stockholders $ (11,035) $ (15,561) $ (44,602) $ (69,670)  
Denominator - Basic and Diluted:          
Weighted average number of common shares outstanding, basic and diluted (in shares) 127,528 127,488 127,893 122,519  
Loss per Common Share:          
Loss from continuing operations, basic and diluted (in dollars per share) $ (0.09) $ (0.12) $ (0.35) $ (0.56)  
Loss from discontinued operations, basic and diluted (in dollars per share) 0.00 0.00 0.00 (0.01)  
Loss per common share, basic and diluted (in dollars per share) (0.09) $ (0.12) (0.35) $ (0.57)  
Series A Preferred Stock          
Class of Stock [Line Items]          
Convertible preferred stock series, par value (in dollars per share) 0.0001   0.0001   0.0001
Series C Preferred Stock          
Class of Stock [Line Items]          
Convertible preferred stock series, par value (in dollars per share) $ 0.0001   $ 0.0001   $ 0.0001
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCKHOLDERS' DEFICIT - Carrying Value of Preferred Stock Narrative (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2018
Dec. 31, 2017
Series A Preferred Stock    
Class of Warrant or Right [Line Items]    
Dividend accrual rate 11.50%  
Accretion of dividends on preferred stock $ 200  
Discount accretion on preferred stock 100  
Convertible preferred stock series, liquidation preference $ 3,172 $ 2,916
Series C Preferred Stock    
Class of Warrant or Right [Line Items]    
Dividend accrual rate 11.50%  
Accretion of dividends on preferred stock $ 7,500  
Discount accretion on preferred stock 500  
Convertible preferred stock series, liquidation preference $ 92,038 $ 84,555
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCKHOLDERS' DEFICIT - Activity Related to Series A and C Preferred Stock (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2018
USD ($)
Series A Preferred Stock  
Increase (Decrease) in Temporary Equity [Roll Forward]  
Beginning Balance $ 2,827
Dividends and discount accretion through September 30, 2018 299
Ending Balance 3,126
Series C Preferred Stock  
Increase (Decrease) in Temporary Equity [Roll Forward]  
Beginning Balance 79,252
Dividends and discount accretion through September 30, 2018 7,973
Ending Balance $ 87,225
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCKHOLDERS' DEFICIT - 2017 Warrants (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Jun. 29, 2017
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Class of Warrant or Right [Line Items]          
Fair value adjustment   $ 1,605 $ 1,103 $ 1,228 $ 1,103
Common Stock | 2017 Warrants          
Class of Warrant or Right [Line Items]          
Warrant exercise threshold 4.99%        
Warrant holder outstanding common stock ownership limitation 19.99%        
Term of warrants 10 years        
Exercise price of warrants (in dollars per share) $ 2.00        
Warrants, fair value   $ 21,700   $ 21,700  
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Restructuring and Related Activities [Abstract]        
Restructuring expense $ 833 $ 3,791 $ 4,666 $ 10,881
Acquisition and integration expense 52 246 123 526
Total restructuring, acquisition, integration, and other expenses $ 885 $ 4,037 $ 4,789 $ 11,407
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
DEBT - Summary of Long-term Debt (Details) - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Debt Instrument [Line Items]    
Less: Deferred financing costs $ (2,692) $ (3,656)
Total Debt 498,846 480,588
Less: Current portion of long-term debt (2,076) (1,722)
Long-term debt, net of current portion 496,770 478,866
First Lien Note Facility, net of unamortized discount    
Debt Instrument [Line Items]    
Long-term debt 198,801 198,324
Second Lien Note Facility, net of unamortized discount    
Debt Instrument [Line Items]    
Long-term debt 103,571 85,694
2021 Notes    
Debt Instrument [Line Items]    
Long-term debt 197,927 197,363
Capital leases    
Debt Instrument [Line Items]    
Capital leases $ 1,239 $ 2,863
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
DEBT - Additional Information (Details) - USD ($)
 3 Months Ended 9 Months Ended
Jun. 29, 2017
Sep. 30, 2018
Sep. 30, 2018
Sep. 30, 2017
Jun. 21, 2018
Feb. 11, 2014
Debt Instrument [Line Items]            
Net proceeds from issuance of equity, net of issuance costs     $ 0 $ 20,822,000    
Paid-in-kind interest capitalized as principal on Second Lien Note Facility     3,800,000 $ 0    
Common Stock | 2017 Warrants            
Debt Instrument [Line Items]            
Warrant exercise threshold 4.99%          
Warrants classified within equity at fair value   $ 21,700,000 $ 21,700,000      
Private Placement | Common Stock            
Debt Instrument [Line Items]            
Net proceeds from issuance of equity, net of issuance costs $ 15,900,000          
Associated costs with private placement 200,000          
First Lien Notes | Senior Secured Debt            
Debt Instrument [Line Items]            
Face amount of debt instruments 200,000,000          
Amortization installment percentage of principal     0.625%      
Early repayment premium base rate     5.00%      
Principal prepayment limit     $ 50,000,000      
Default penalty interest rate increase     2.00%      
First Lien Notes | Senior Secured Debt | Base Rate            
Debt Instrument [Line Items]            
Basis spread on variable rate     6.00%      
First Lien Notes | Senior Secured Debt | LIBOR            
Debt Instrument [Line Items]            
Basis spread on variable rate     7.00%      
First Lien Notes | Senior Secured Debt | Prime Rate            
Debt Instrument [Line Items]            
Basis spread on variable rate     1.00%      
First Lien Notes | Senior Secured Debt | Redemption Period One            
Debt Instrument [Line Items]            
Early repayment premium rate     4.00%      
First Lien Notes | Senior Secured Debt | Redemption Period Two            
Debt Instrument [Line Items]            
Early repayment premium rate     2.00%      
First Lien Notes | Senior Secured Debt | Redemption Period Three            
Debt Instrument [Line Items]            
Early repayment premium rate     0.00%      
Second Lien Notes | Senior Secured Debt            
Debt Instrument [Line Items]            
Face amount of debt instruments $ 100,000,000 113,800,000.0 $ 113,800,000.0      
Early repayment premium base rate     5.00%      
Default penalty interest rate increase     2.00%      
Paid-in-kind interest capitalized as principal on Second Lien Note Facility   $ 3,800,000        
Second Lien Notes | Senior Secured Debt | Option One            
Debt Instrument [Line Items]            
Basis spread on variable rate     9.25%      
Second Lien Notes | Senior Secured Debt | Option Two            
Debt Instrument [Line Items]            
Basis spread on variable rate     11.25%      
Second Lien Notes | Senior Secured Debt | Option Three            
Debt Instrument [Line Items]            
Basis spread on variable rate     10.25%      
Second Lien Notes | Senior Secured Debt | Option Three, Half Cash            
Debt Instrument [Line Items]            
Basis spread on variable rate     4.625%      
Second Lien Notes | Senior Secured Debt | Option Three, Half Capitalized Interest            
Debt Instrument [Line Items]            
Basis spread on variable rate     5.625%      
Second Lien Notes | Senior Secured Debt | Redemption Period One            
Debt Instrument [Line Items]            
Early repayment premium rate     4.00%      
Second Lien Notes | Senior Secured Debt | Redemption Period Two            
Debt Instrument [Line Items]            
Early repayment premium rate     2.00%      
Second Lien Notes | Senior Secured Debt | Redemption Period Three            
Debt Instrument [Line Items]            
Early repayment premium rate     0.00%      
Second Lien Delayed Draw Notes | Senior Secured Debt            
Debt Instrument [Line Items]            
Face amount of debt instruments         $ 10,000,000  
Senior Unsecured 8.875% Notes            
Debt Instrument [Line Items]            
Face amount of debt instruments           $ 200,000,000.0
Stated rate on debt   8.875% 8.875%     8.875%
Debt discount           $ 5,000,000
Minimum | First Lien Notes | Senior Secured Debt | Base Rate            
Debt Instrument [Line Items]            
Basis spread on variable rate     0.50%      
Minimum | First Lien Notes | Senior Secured Debt | LIBOR            
Debt Instrument [Line Items]            
Basis spread on variable rate     1.00%      
Minimum | Second Lien Notes | Senior Secured Debt | Option One | LIBOR            
Debt Instrument [Line Items]            
Basis spread on variable rate     1.25%      
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
DEBT - Carrying and Estimated Fair Values of Financial Instruments (Details) - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total, carrying value $ 522,023  
First Lien Note Facility, net of unamortized discount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, carrying value 198,801 $ 198,324
Second Lien Note Facility, net of unamortized discount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, carrying value 103,571 85,694
2021 Notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, carrying value 197,927 $ 197,363
Markets for Identical Item (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrants, fair value 0  
Total, fair value 0  
Markets for Identical Item (Level 1) | First Lien Note Facility, net of unamortized discount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, fair value 0  
Markets for Identical Item (Level 1) | Second Lien Note Facility, net of unamortized discount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, fair value 0  
Markets for Identical Item (Level 1) | 2021 Notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, fair value 0  
Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrants, fair value 21,724  
Total, fair value 211,224  
Significant Other Observable Inputs (Level 2) | First Lien Note Facility, net of unamortized discount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, fair value 0  
Significant Other Observable Inputs (Level 2) | Second Lien Note Facility, net of unamortized discount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, fair value 0  
Significant Other Observable Inputs (Level 2) | 2021 Notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, fair value 189,500  
Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrants, fair value 0  
Total, fair value 319,731  
Significant Unobservable Inputs (Level 3) | First Lien Note Facility, net of unamortized discount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, fair value 202,512  
Significant Unobservable Inputs (Level 3) | Second Lien Note Facility, net of unamortized discount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, fair value 117,219  
Significant Unobservable Inputs (Level 3) | 2021 Notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt, fair value 0  
2017 Warrants | Common Stock    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Warrants, carrying value 21,724  
Warrants, fair value $ 21,700  
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONCENTRATION OF RISK (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2017
Customer Concentration Risk | United Healthcare    
Concentration Risk [Line Items]    
Percentage of concentration risk 18.10% 21.00%
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
INCOME TAXES - Schedule of Federal and State Income Tax Provision (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Income Tax Disclosure [Abstract]        
Federal $ 0 $ (925) $ 0 $ (925)
State 50 378 84 528
Total current 50 (547) 84 (397)
Federal 0 515 0 1,523
State 52 92 107 271
Total deferred 52 607 107 1,794
Total income tax expense $ 102 $ 60 $ 191 $ 1,397
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.10.0.1
INCOME TAXES - Reconciliation of the Income Tax Rate (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Income Tax Disclosure [Abstract]        
Tax benefit at statutory rate $ (1,680) $ (4,307) $ (7,564) $ (20,543)
State tax expense, net of federal taxes 102 378 191 528
Alternative Minimum Tax receivable 0 (925) 0 (925)
Valuation allowance changes affecting income tax provision 1,261 4,876 7,163 22,194
Permanent items 419 38 401 143
Total income tax expense $ 102 $ 60 $ 191 $ 1,397
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.10.0.1
INCOME TAXES - Additional Information (Details)
$ in Millions
Sep. 30, 2018
USD ($)
Operating Loss Carryforwards [Line Items]  
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration $ 37.1
Federal  
Operating Loss Carryforwards [Line Items]  
Net operating loss carryforwards 427.0
Net operating loss carryforwards subject to annual limitation 10.8
State  
Operating Loss Carryforwards [Line Items]  
Net operating loss carryforwards $ 467.1
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCK-BASED COMPENSATION (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
May 03, 2018
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Stock Options          
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]          
Share-based compensation expense (less than for ESPP)   $ 0.3 $ 0.1 $ 0.9 $ 0.8
Restricted Stock          
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]          
Share-based compensation expense (less than for ESPP)   0.8 0.4 1.8 0.6
Market Based Cash Awards          
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]          
Share-based compensation expense (less than for ESPP)   $ 0.1   $ 0.2 0.1
Employee Stock Purchase Plan          
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]          
Number of shares available for grant (in shares)   1,422,842   1,422,842  
Share-based compensation expense (less than for ESPP)   $ 0.1 $ 0.1 $ 0.1 $ 0.1
Purchase price of common stock, percent 85.00%        
Shares purchased on the open market for award (in shares)       827,158  
The 2018 Plan          
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]          
Number of shares authorized (in shares) 16,406,939        
Number of shares available for grant (in shares) 3,000,000 13,339,067   13,339,067  
EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 56 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 57 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 59 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 125 200 1 false 49 0 false 7 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.bioscrip.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.bioscrip.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.bioscrip.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.bioscrip.com/role/UnauditedCondensedConsolidatedStatementsOfOperations UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1003000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.bioscrip.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 2101100 - Disclosure - BASIS OF PRESENTATION Sheet http://www.bioscrip.com/role/BasisOfPresentation BASIS OF PRESENTATION Notes 6 false false R7.htm 2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.bioscrip.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 2103100 - Disclosure - REVENUE Sheet http://www.bioscrip.com/role/Revenue REVENUE Notes 8 false false R9.htm 2104100 - Disclosure - LOSS PER SHARE Sheet http://www.bioscrip.com/role/LossPerShare LOSS PER SHARE Notes 9 false false R10.htm 2105100 - Disclosure - STOCKHOLDERS' DEFICIT Sheet http://www.bioscrip.com/role/StockholdersDeficit STOCKHOLDERS' DEFICIT Notes 10 false false R11.htm 2106100 - Disclosure - RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES Sheet http://www.bioscrip.com/role/RestructuringAcquisitionIntergrationAndOtherExpenses RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES Notes 11 false false R12.htm 2107100 - Disclosure - DEBT Sheet http://www.bioscrip.com/role/Debt DEBT Notes 12 false false R13.htm 2108100 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.bioscrip.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 13 false false R14.htm 2109100 - Disclosure - CONCENTRATION OF RISK Sheet http://www.bioscrip.com/role/ConcentrationOfRisk CONCENTRATION OF RISK Notes 14 false false R15.htm 2110100 - Disclosure - INCOME TAXES Sheet http://www.bioscrip.com/role/IncomeTaxes INCOME TAXES Notes 15 false false R16.htm 2115100 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.bioscrip.com/role/StockBasedCompensation STOCK-BASED COMPENSATION Notes 16 false false R17.htm 2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.bioscrip.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 17 false false R18.htm 2301301 - Disclosure - BASIS OF PRESENTATION (Tables) Sheet http://www.bioscrip.com/role/BasisOfPresentationTables BASIS OF PRESENTATION (Tables) Tables http://www.bioscrip.com/role/BasisOfPresentation 18 false false R19.htm 2302302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.bioscrip.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.bioscrip.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 2303301 - Disclosure - REVENUE (Tables) Sheet http://www.bioscrip.com/role/RevenueTables REVENUE (Tables) Tables http://www.bioscrip.com/role/Revenue 20 false false R21.htm 2304301 - Disclosure - LOSS PER SHARE (Tables) Sheet http://www.bioscrip.com/role/LossPerShareTables LOSS PER SHARE (Tables) Tables http://www.bioscrip.com/role/LossPerShare 21 false false R22.htm 2305301 - Disclosure - STOCKHOLDERS' DEFICIT (Tables) Sheet http://www.bioscrip.com/role/StockholdersDeficitTables STOCKHOLDERS' DEFICIT (Tables) Tables http://www.bioscrip.com/role/StockholdersDeficit 22 false false R23.htm 2306301 - Disclosure - RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES (Tables) Sheet http://www.bioscrip.com/role/RestructuringAcquisitionIntergrationAndOtherExpensesTables RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES (Tables) Tables http://www.bioscrip.com/role/RestructuringAcquisitionIntergrationAndOtherExpenses 23 false false R24.htm 2307301 - Disclosure - DEBT (Tables) Sheet http://www.bioscrip.com/role/DebtTables DEBT (Tables) Tables http://www.bioscrip.com/role/Debt 24 false false R25.htm 2310301 - Disclosure - INCOME TAXES (Tables) Sheet http://www.bioscrip.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://www.bioscrip.com/role/IncomeTaxes 25 false false R26.htm 2401402 - Disclosure - BASIS OF PRESENTATION (Details) Sheet http://www.bioscrip.com/role/BasisOfPresentationDetails BASIS OF PRESENTATION (Details) Details http://www.bioscrip.com/role/BasisOfPresentationTables 26 false false R27.htm 2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) Sheet http://www.bioscrip.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) Details 27 false false R28.htm 2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounts Receivable Aging (Details) Sheet http://www.bioscrip.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableAgingDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounts Receivable Aging (Details) Details 28 false false R29.htm 2403402 - Disclosure - REVENUE (Details) Sheet http://www.bioscrip.com/role/RevenueDetails REVENUE (Details) Details http://www.bioscrip.com/role/RevenueTables 29 false false R30.htm 2404402 - Disclosure - LOSS PER SHARE (Details) Sheet http://www.bioscrip.com/role/LossPerShareDetails LOSS PER SHARE (Details) Details http://www.bioscrip.com/role/LossPerShareTables 30 false false R31.htm 2405402 - Disclosure - STOCKHOLDERS' DEFICIT - Carrying Value of Preferred Stock Narrative (Details) Sheet http://www.bioscrip.com/role/StockholdersDeficitCarryingValueOfPreferredStockNarrativeDetails STOCKHOLDERS' DEFICIT - Carrying Value of Preferred Stock Narrative (Details) Details 31 false false R32.htm 2405403 - Disclosure - STOCKHOLDERS' DEFICIT - Activity Related to Series A and C Preferred Stock (Details) Sheet http://www.bioscrip.com/role/StockholdersDeficitActivityRelatedToSeriesAndCPreferredStockDetails STOCKHOLDERS' DEFICIT - Activity Related to Series A and C Preferred Stock (Details) Details 32 false false R33.htm 2405404 - Disclosure - STOCKHOLDERS' DEFICIT - 2017 Warrants (Details) Sheet http://www.bioscrip.com/role/StockholdersDeficit2017WarrantsDetails STOCKHOLDERS' DEFICIT - 2017 Warrants (Details) Details 33 false false R34.htm 2406402 - Disclosure - RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES (Details) Sheet http://www.bioscrip.com/role/RestructuringAcquisitionIntergrationAndOtherExpensesDetails RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES (Details) Details http://www.bioscrip.com/role/RestructuringAcquisitionIntergrationAndOtherExpensesTables 34 false false R35.htm 2407402 - Disclosure - DEBT - Summary of Long-term Debt (Details) Sheet http://www.bioscrip.com/role/DebtSummaryOfLongTermDebtDetails DEBT - Summary of Long-term Debt (Details) Details 35 false false R36.htm 2407403 - Disclosure - DEBT - Additional Information (Details) Sheet http://www.bioscrip.com/role/DebtAdditionalInformationDetails DEBT - Additional Information (Details) Details 36 false false R37.htm 2407404 - Disclosure - DEBT - Carrying and Estimated Fair Values of Financial Instruments (Details) Sheet http://www.bioscrip.com/role/DebtCarryingAndEstimatedFairValuesOfFinancialInstrumentsDetails DEBT - Carrying and Estimated Fair Values of Financial Instruments (Details) Details 37 false false R38.htm 2409401 - Disclosure - CONCENTRATION OF RISK (Details) Sheet http://www.bioscrip.com/role/ConcentrationOfRiskDetails CONCENTRATION OF RISK (Details) Details http://www.bioscrip.com/role/ConcentrationOfRisk 38 false false R39.htm 2410402 - Disclosure - INCOME TAXES - Schedule of Federal and State Income Tax Provision (Details) Sheet http://www.bioscrip.com/role/IncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails INCOME TAXES - Schedule of Federal and State Income Tax Provision (Details) Details 39 false false R40.htm 2410403 - Disclosure - INCOME TAXES - Reconciliation of the Income Tax Rate (Details) Sheet http://www.bioscrip.com/role/IncomeTaxesReconciliationOfIncomeTaxRateDetails INCOME TAXES - Reconciliation of the Income Tax Rate (Details) Details 40 false false R41.htm 2410404 - Disclosure - INCOME TAXES - Additional Information (Details) Sheet http://www.bioscrip.com/role/IncomeTaxesAdditionalInformationDetails INCOME TAXES - Additional Information (Details) Details 41 false false R42.htm 2415401 - Disclosure - STOCK-BASED COMPENSATION (Details) Sheet http://www.bioscrip.com/role/StockBasedCompensationDetails STOCK-BASED COMPENSATION (Details) Details http://www.bioscrip.com/role/StockBasedCompensation 42 false false All Reports Book All Reports bios-20180930.xml bios-20180930.xsd bios-20180930_cal.xml bios-20180930_def.xml bios-20180930_lab.xml bios-20180930_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 61 0001628280-18-013693-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-18-013693-xbrl.zip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end

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�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